text
string | url
string | crawl_date
timestamp[ms] | label
int64 | id
string |
|---|---|---|---|---|
Minnesota Twins home opener postponed
Published: Apr. 6, 2022 at 7:19 AM CDT|Updated: moments ago
MINNEAPOLIS (KTTC) – Twins fans will have to wait one more day before opening day at Target Field. The Twins have postponed the 2022 opening day game to Friday because of the forecasted weather.
The Twins were scheduled to have it’s opening day game against the Seattle Mariners at 3:10 p.m. Thursday.
The ball club says in a news release that all of the opening day festivities and game will happen on Friday.
Game time on Friday will be at 3:10 p.m. against Seattle. Gates will open at 1 p.m.
Copyright 2022 KTTC. All rights reserved.
|
https://www.kttc.com/2022/04/06/minnesota-twins-home-opener-postponed/
| 2022-04-06T12:25:19
| 1
|
https://www.kttc.com/2022/04/06/minnesota-twins-home-opener-postponed/
|
Officer wounded, suspect dead after Minnesota shooting
Published: Apr. 6, 2022 at 6:25 AM CDT|Updated: 58 minutes ago
ROSEVILLE, Minn. (AP) --Authorities say a gunman is dead and a police officer is seriously wounded after a shooting in suburban Minneapolis.
Roseville officers responded to a report of shots fired Tuesday night. Police say the suspect shot at police and neighboring homes, striking an officer.
Police said early Wednesday that the officer was hospitalized for a serious gunshot wound. The suspect was also taken to a hospital, where police say the 53-year-old man was pronounced dead.
It wasn’t immediately clear whether the man was fatally wounded in the shooting, which is under investigation.
Copyright 2022 KTTC. All rights reserved.
|
https://www.kttc.com/2022/04/06/officer-wounded-suspect-dead-after-minnesota-shooting/
| 2022-04-06T12:25:19
| 0
|
https://www.kttc.com/2022/04/06/officer-wounded-suspect-dead-after-minnesota-shooting/
|
CAUGHT ON CAMERA: Ax-wielding man attacks drummer in California
CANYON CO., Calif. (KCAL/KCBS) - A shocking incident was caught on camera in California: A man says he was playing his drums along one of the trails in Canyon County when an ax-wielding man came out of nowhere.
In an instant, Andy Torres’ Saturday morning jam session turned violent.
The man struck the drumkit several times, frightening the 36-year-old musician.
“He just came up swinging already,” Torres said. “He didn’t announce himself or say get out of the way. Or, ‘Are you making the noise?’ No, he knew what he was going to do. I happened to just get out of the way.”
Torres says after the man nearly destroyed the drumkit, he threatened him again.
“It took everything in me not to want to launch at the guy, but I knew I couldn’t do that,” he said.
The attack was recorded on his GoPro camera.
It’s not shown in the video, but Torres says the man also pulled a gun on him.
As soon as he announced that he recorded the entire violent outburst on video, the man appears to change his attitude.
He turned and left, but not before Torres caught images of the man’s car and license plate.
Speaking at Todd Longshore Park near the scene of the attack, he says since the incident he’s been struggling emotionally.
“I get stuck thinking about that, and I have to pull myself out of it,” Torres said. “I know I will move ahead, because look I’m still here.”
Torres said he has been learning the drums for a while. He comes to the park at sunrise and sunset to play while wearing a mask as part of his persona.
Before the ax attack, no one had complained about the noise. He says this will not ruin his love for music, and he will find a way to fix the drums.
“It’s not destroyed. They’ll have to do better than that,” he said.
Torres says he’s filed a police report and turned over the video. He shared it in hopes someone turns the man in, since it’s a place a lot of parents bring their kids.
Copyright 2022 KCAL/KCBS via CNN Newsource. All rights reserved.
|
https://www.1011now.com/2022/04/06/caught-camera-ax-wielding-man-attacks-drummer-california/
| 2022-04-06T12:37:39
| 1
|
https://www.1011now.com/2022/04/06/caught-camera-ax-wielding-man-attacks-drummer-california/
|
Windy Wednesday
LINCOLN, Neb. (KOLN) - A strong low pressure system in the northern plains will be moving very slowly east over the next couple of days. This means it will be windy with cooler temperatures and the chance for a few showers. It won’t be quite as windy on Friday, but still cool and breezy. The weekend will be warmer with more sunshine.
High wind warning for most of central and western Nebraska today and Thursday. Wind gusts in the warning area will be between 50 and 60 mph. Wind advisory for parts of eastern Nebraska Today and Thursday. Wind gusts in this area will be between 45 and 50 mph.
Partly to mostly cloudy, windy and cooler Wednesday. Slight chance for a few sprinkles or light isolated showers this afternoon. High temperature in the Lincoln area will be in the mid 50s with a northwest wind 25 to 35 mph with gusts to around 50 mph.
Partly cloudy, windy and cool for Wednesday night. Lows in the mid 30s with a northwest wind 20 to 30 mph with gusts up to 45 mph.
Mostly cloudy, windy and colder on Thursday. A few sprinkles or flurries possible through out the day. Highs in the upper 40s with the northwest wind continuing 25 to 35 mph with gusts between 45 and 50 mph.
Friday will be cool with blustery conditions continuing. The weekend looks better with more sunshine on Saturday and seasonal temperatures. Sunday will be breezy and warmer with a small chance for rain.
Monday and Tuesday will be cooler with a chance of rain.
Copyright 2022 KOLN. All rights reserved.
|
https://www.1011now.com/2022/04/06/windy-wednesday/
| 2022-04-06T12:37:47
| 1
|
https://www.1011now.com/2022/04/06/windy-wednesday/
|
CAUGHT ON CAMERA: Ax-wielding man attacks drummer in California
CANYON CO., Calif. (KCAL/KCBS) - A shocking incident was caught on camera in California: A man says he was playing his drums along one of the trails in Canyon County when an ax-wielding man came out of nowhere.
In an instant, Andy Torres’ Saturday morning jam session turned violent.
The man struck the drumkit several times, frightening the 36-year-old musician.
“He just came up swinging already,” Torres said. “He didn’t announce himself or say get out of the way. Or, ‘Are you making the noise?’ No, he knew what he was going to do. I happened to just get out of the way.”
Torres says after the man nearly destroyed the drumkit, he threatened him again.
“It took everything in me not to want to launch at the guy, but I knew I couldn’t do that,” he said.
The attack was recorded on his GoPro camera.
It’s not shown in the video, but Torres says the man also pulled a gun on him.
As soon as he announced that he recorded the entire violent outburst on video, the man appears to change his attitude.
He turned and left, but not before Torres caught images of the man’s car and license plate.
Speaking at Todd Longshore Park near the scene of the attack, he says since the incident he’s been struggling emotionally.
“I get stuck thinking about that, and I have to pull myself out of it,” Torres said. “I know I will move ahead, because look I’m still here.”
Torres said he has been learning the drums for a while. He comes to the park at sunrise and sunset to play while wearing a mask as part of his persona.
Before the ax attack, no one had complained about the noise. He says this will not ruin his love for music, and he will find a way to fix the drums.
“It’s not destroyed. They’ll have to do better than that,” he said.
Torres says he’s filed a police report and turned over the video. He shared it in hopes someone turns the man in, since it’s a place a lot of parents bring their kids.
Copyright 2022 KCAL/KCBS via CNN Newsource. All rights reserved.
|
https://www.wistv.com/2022/04/06/caught-camera-ax-wielding-man-attacks-drummer-california/
| 2022-04-06T12:57:09
| 1
|
https://www.wistv.com/2022/04/06/caught-camera-ax-wielding-man-attacks-drummer-california/
|
New 1% for the Planet® Impact Fund at National Philanthropic Trust Open to Donors of All Sizes; unique collaboration among National Philanthropic Trust, 1% for the Planet and CapShift
BURLINGTON, Vt., April 6, 2022 /PRNewswire/ -- 1% for the Planet — the global network of individuals and businesses that has donated more than $350 million to support environmental nonprofits around the globe — today announced the launch of an innovative philanthropic fund providing environmentally focused investments and grants.
The new 1% for the Planet Impact Fund at National Philanthropic Trust ("Planet Impact Fund") is available to donors of all sizes with a commitment to the environment. Launching with a portfolio of public investments selected to drive climate impact, the fund will incorporate private investments when it reaches scale to drive even greater positive impact, going beyond the level of impact possible with a typical ESG portfolio. The public allocation will include mutual funds and exchange-traded funds and will target best-in-class managers investing in climate leaders and solutions. The private allocation will focus on high-impact, non-public investment opportunities that can drive meaningful climate mitigation and support climate change resiliency.
In addition, the Planet Impact Fund will annually disburse approximately 10% of all funds to vetted environmental nonprofits. This grantmaking will focus on a curated set of organizations that are advancing environmental justice and elevating the communities and ecosystems most impacted by threats to the environment.
Building on a Two-Decade Legacy
"For 20 years, 1% for the Planet has engaged businesses and individuals to donate one percent of annual sales or income to vetted environmental nonprofits driving positive environmental impacts," said Kate Williams, CEO. "The resulting collective contributions of hundreds of millions of dollars is truly making a global difference. And we can do so much more."
"That's why today we are excited to announce our partnership with National Philanthropic Trust and CapShift to launch the Planet Impact Fund, providing donors of all sizes a unique opportunity to optimize multiple levers of change that can generate positive outcomes for our planet and future generations."
The Planet Impact Fund is a collaboration among National Philanthropic Trust, 1% for the Planet and CapShift. National Philanthropic Trust, the largest national, independent public charity that manages donor-advised funds will serve as the Planet Impact Fund's sponsor and fiduciary.
"This collaboration with 1% for the Planet and CapShift furthers NPT's goal of offering ahead-of-the-curve options for donor-advised fund philanthropists," said Rene Paradis, Chief Operating Officer of National Philanthropic Trust. "NPT has the unique flexibility to provide engaged, visionary donors and organizations with customized options to address the issues that mean the most to them. With the Planet Impact Fund, most anyone can leverage decades of experience and research to effect positive environmental change."
Providing advisory services to the fund, including sourcing and vetting grantmaking opportunities, 1% for the Planet brings two decades of expertise in environmental philanthropy and a track record of innovation to inform a thoughtful, inclusive and future-oriented giving approach. CapShift provides investment advisory services to the fund, bringing deep knowledge of connecting capital to impact through investments.
Donor Options
Contributions to the Planet Impact Fund can be made in two ways.
First, donors at any level can contribute directly to the Planet Impact Fund. This tax-deductible donation will be fully allocated to best-in-class environmental impact investments and grants. Second, donors giving $25,000 or more also have the option to open their own donor-advised fund (DAF) on the Planet Impact Fund platform. Individual DAFs will be invested in the pre-selected environmental impact investments and DAF-holders may recommend grants to qualified charitable organizations at any time, provided their DAF has available liquidity.
For all donors, 1% for the Planet will provide annual impact reports about the investments. Donors to the Planet Impact Fund will additionally receive an impact report focused on granting to nonprofits.
Cash & Crypto
Donations can be made via credit card, wire or check. Cryptocurrencies and illiquid assets also are accepted. Initial annual net fees covering management, advisory and administration of the fund are estimated at 2.5% and are projected to decrease to below 2% per year as the fund reaches scale. Different fees may apply to DAFs on the Planet Impact Fund platform.
About 1% for the Planet
1% for the Planet is a global organization that exists to ensure our planet and future generations thrive. We inspire businesses and individuals to support environmental nonprofits through membership and everyday actions. We make environmental giving easy and effective through partnership advising, impact storytelling and third-party certification.
Started in 2002 by Yvon Chouinard, founder of Patagonia, and Craig Mathews, founder of Blue Ribbon Flies, our business members and individual members have given hundreds of millions of dollars to our approved nonprofit partners to date. Today, 1% for the Planet's global network consists of thousands of businesses, individuals and environmental nonprofits working toward a better future for all.
Look for our logo to purchase for the planet, learn more and join at onepercentfortheplanet.org.
About National Philanthropic Trust
Founded in 1996, National Philanthropic Trust (NPT) marked its 25th Anniversary in 2021 as the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $38.9 billion in charitable funding and has made more than 492,000 grants exceeding $17.5 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing solutions. More at NPTrust.org and NPTGivingPoint.org.
About CapShift
CapShift works with families and their trusted advisors and institutions to build impact investment portfolios which mobilize capital for social and environmental change. CapShift was founded by leaders in the impact investing, asset management and wealth advisory sectors, and has mobilized capital into dozens of high impact funds and enterprises providing solutions to global issues such as climate, health, racial justice and income inequality.
Media Contact
For 1% for the Planet
Matt Yemma
Peaks Strategies
909-633-9396
myemma@peaksstrategies.com
View original content:
SOURCE 1% for the Planet
|
https://www.wistv.com/prnewswire/2022/04/06/1-planet-launches-philanthropic-fund-drive-positive-change-environment/
| 2022-04-06T12:57:09
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/1-planet-launches-philanthropic-fund-drive-positive-change-environment/
|
One of Chicago's Best Experiential Designers, A.J. Tarzian, Collaborates with Company to Bring New Immersive Cannabis Educational Experience to Mission Dispensary South Chicago
PHOENIX, April 6, 2022 /PRNewswire/ - 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) ("4Front'' or the "Company"), a vertically integrated, multi-state cannabis operator and retailer, announced it will bring a new interactive art exhibition to Chicagoans ahead of 4/20, cannabis' cultural holiday. The Company collaborated with Anarchitype Productions Founder and Head Scenic Designer A.J. Tarzian to bring the Trail to 4/20, a one-of-a-kind immersive cannabis and "hidden learning experience" to Chicagoans at Mission Dispensary South Chicago.
Starting on Friday, April 8, 2022, the new immersive art exhibit designed by Tarzian – who has been behind-the-scenes for the last few years creating some of the most amazing interactive experiences in Chicago, including the local favorite, Emporium, known for its pop-ups – will open up to those 21 years and older at Mission Dispensary South Chicago, located at 8554 S Commercial Ave, Chicago. Attendees will be able to experience guided tours on Monday through Friday from 11:00 a.m. to 4:00 p.m. CT and self-guided tours from 4:00 p.m. to 8:00 p.m. CT.
This globetrotting art exhibit transports attendees through the "Caves of Mexico," the "Hindu Kush Mountains," to Hawaii, Thailand and then finally, to the Midwest to gain a deeper understanding of the cannabis plant, its origins and dissemination, genetic makeup and more. As guests travel the Trail to 4/20, they will learn about cannabis' amazing history, compounds in the plant like "cannabinoids," "terpenes" and "trichomes," and various cannabis strains and subcategories, including "indica," "sativa" and "landrace." Other highlights of the mesmeric trail include walking through a tunnel, over a bridge and uncovering objects such as rocks and mushrooms containing interesting factoids, which are strategically placed throughout the exhibit.
"Cannabis' history is deep, fascinating and has been part of cultures around the world for thousands of years," said 4Front CEO Leo Gontmakher. "We are thrilled to bring this hands-on, creative learning experience to the public. Working with A.J. – one of the country's best experiential designers and creative minds – has been a real honor. Ahead of 4/20, we are confident that this immersive collaboration will 'wow' everyone from the cannacurious to the connoisseurs, as well as history buffs, travel enthusiasts and plant lovers, and that participants will enjoy learning about the cannabis plant, its history and many uses in this fun, creative and interactive way. As we continue to be a resource for consumers, we look forward to hosting more educational events like this in the future."
"This new immersive experience at Mission Dispensary South Chicago is unlike any other in the country" said Founder and Head Scenic Designer of Anarchitype Productions A.J. Tarzian. "The exhibit will feature an adventurous pathway that guests can walk through and learn important facts about cannabis in celebration of cannabis' cultural holiday. I wanted to create something memorable, impactful and interactive, and I think the Trail to 4/20 is the perfect way to help break the stereotypes and misinformation surrounding cannabis. I look forward to people experiencing the exhibit and uncovering more about this incredible plant."
About 4Front Ventures Corp.
4Front Ventures Corp. ("4Front" of the "Company") (CSE: FFNT) (OTCQX: FFNTF) is a national, vertically integrated multi-state cannabis operator with operations in strategic medical and adult-use cannabis markets, including California, Illinois, Massachusetts, Michigan, and Washington. Since its founding in 2011, 4Front has built a strong reputation for its high standards and low-cost cultivation and production methodologies earned through a track record of success in facility design, cultivation, genetics, growing processes, manufacturing, purchasing, distribution, and retail. To date, 4Front has successfully brought to market more than 20 different cannabis brands and nearly 1,800 unique product lines, which are strategically distributed through its fully owned and operated Mission Dispensaries and retail outlets in its core markets. As the Company continues to drive value for its shareholders, its team is applying its decade of expertise in the sector across the cannabis industry value chain and ecosystem. For more information, visit https://4frontventures.com/.
View original content to download multimedia:
SOURCE 4Front Ventures Corp.
|
https://www.wistv.com/prnewswire/2022/04/06/4front-ventures-corp-brings-new-interactive-art-exhibition-chicagoans-ahead-420-cannabis-cultural-holiday/
| 2022-04-06T12:57:16
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/4front-ventures-corp-brings-new-interactive-art-exhibition-chicagoans-ahead-420-cannabis-cultural-holiday/
|
Pieter Abbeel's Groundbreaking Research Helped Shape Contemporary Robotics and Continues to Drive the Future of the Field
NEW YORK, April 6, 2022 /PRNewswire/ -- ACM, the Association for Computing Machinery, today named Pieter Abbeel the recipient of the 2021 ACM Prize in Computing for contributions to robot learning, including learning from demonstrations and deep reinforcement learning for robotic control. Abbeel pioneered teaching robots to learn from human demonstrations ("apprenticeship learning") and through their own trial and error ("reinforcement learning"), which have formed the foundation for the next generation of robotics. Abbeel is a Professor at the University of California, Berkeley and the Co-Founder, President and Chief Scientist at Covariant, an AI robotics company.
The ACM Prize in Computing recognizes early-to-mid-career computer scientists whose research contributions have fundamental impact and broad implications. The award carries a prize of $250,000, from an endowment provided by Infosys Ltd.
Early in his career, Abbeel developed new apprenticeship learning techniques to significantly improve robotic manipulation. As the field matured, researchers were able to program robots to perceive and manipulate rigid objects such as wooden blocks or spoons. However, programming robots to manipulate deformable objects, such as cloth, proved difficult because the way soft materials move when touched is unpredictable. Abbeel introduced new methods to enhance robot visual perception, physics-based tracking, control, and learning from demonstration. By combining these new methods, Abbeel developed a robot that was able to fold clothes such as towels and shirts ─ an improvement over existing technology that was considered an important milestone at the time.
Abbeel's contributions also include developing robots that can perform surgical suturing, detect objects, and plan their trajectories in uncertain situations. More recently, he has pioneered "few-shot imitation learning," where a robot is able to learn to perform a task from just one demonstration after having been pre-trained with a large set of demonstrations on related tasks.
Another especially promising area where Abbeel has made important contributions is in deep reinforcement learning for robotics. Reinforcement learning is an area of machine learning where an agent (e.g., a computer program) seeks to progress towards a reward (e.g., winning a game). While early reinforcement learning programs were effective, they could only perform simple tasks. The innovation of combining reinforcement learning with deep neural networks ushered in the new field of deep reinforcement learning, which can solve far more complex problems than computer programs developed with reinforcement learning alone.
Abbeel's key breakthrough contribution in this area was developing a deep reinforcement learning method called Trust Region Policy Optimization. This method stabilizes the reinforcement learning process, enabling robots to learn a range of simulated control skills. By sharing his results, posting video tutorials, and releasing open-source code from his lab, Abbeel helped build a community of researchers that has since pushed deep learning for robotics even further ─ with robots performing ever more complicated tasks.
Abbeel has also made several other pioneering contributions including: generalized advantage estimation, which enabled the first 3D robot locomotion learning; soft-actor critic, which is one of the most popular deep reinforcement learning algorithms to-date; domain randomization, which showcases how learning across appropriately randomized simulators can generalize surprisingly well to the real world; and hindsight experience replay, which has been instrumental for deep reinforcement learning in sparse-reward/goal-oriented environments.
"Teaching robots to learn could spur major advances across many industries ─ from surgery and manufacturing to shipping and automated driving," said ACM President Gabriele Kotsis. "Pieter Abbeel is a recognized leader among a new generation of researchers who are harnessing the latest machine learning techniques to revolutionize this field. Abbeel has made leapfrog research contributions, while also generously sharing his knowledge to build a community of colleagues working to take robots to an exciting new level of ability. His work exemplifies the intent of the ACM Prize in Computing to recognize outstanding work with 'depth, impact, and broad implications.'"
"Infosys is proud of our longstanding collaboration with ACM, and we are honored to recognize Pieter Abbeel for the 2021 ACM Prize in Computing," said Salil Parekh, Chief Executive Officer, Infosys. "The robotics field is poised for even greater advances, as innovative new ways are emerging to combine robotics with AI, and we believe researchers like Abbeel will be instrumental in creating the next great advances in this field."
Abbeel will be formally presented with the ACM Prize in Computing at the annual ACM Awards Banquet, which will be held this year on Saturday, June 11 at the Palace Hotel in San Francisco.
Biographical Background
Pieter Abbeel is a Professor of Computer Science and Electrical Engineering at the University of California, Berkeley and the Co-Founder, President and Chief Scientist at Covariant, an AI robotics company. Abbeel earned a B.S. in Electrical Engineering from Katholieke Universiteit Leuven, as well as M.S. and Ph.D. degrees in Computer Science from Stanford University.
Abbeel's honors include a Presidential Early Career Award for Scientists and Engineers, a National Science Foundation Early Career Development Program Award, and a Diane McEntyre Award for Excellence in Teaching. Additionally, Abbeel was named a Top Young Innovator Under 35 by the MIT Technology Review and received the Dick Volz Best U.S. Ph.D. Thesis in Robotics and Automation Award. He is a Fellow of IEEE.
About the ACM Prize in Computing
The ACM Prize in Computing recognizes an early to mid-career fundamental innovative contribution in computing that, through its depth, impact, and broad implications, exemplifies the greatest achievements in the discipline. The award carries a prize of $250,000. Financial support is provided by an endowment from Infosys Ltd. The ACM Prize in Computing was previously known as the ACM-Infosys Foundation Award in the Computing Sciences from 2007 through 2015. ACM Prize recipients are invited to participate in the Heidelberg Laureate Forum, an annual networking event that brings together young researchers from around the world with recipients of the ACM A.M. Turing Award, the Abel Prize, the Fields Medal, and the Nevanlinna Prize.
About ACM
ACM, the Association for Computing Machinery, is the world's largest educational and scientific computing society, uniting computing educators, researchers and professionals to inspire dialogue, share resources and address the field's challenges. ACM strengthens the computing profession's collective voice through strong leadership, promotion of the highest standards, and recognition of technical excellence. ACM supports the professional growth of its members by providing opportunities for life-long learning, career development, and professional networking.
About Infosys
Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With over three decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.
Contact:
Jim Ormond
212-626-0505
ormond@hq.acm.org
View original content to download multimedia:
SOURCE Association For Computing Machinery, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/acm-prize-computing-recognizes-pioneer-robot-learning/
| 2022-04-06T12:57:24
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/acm-prize-computing-recognizes-pioneer-robot-learning/
|
Flexible Bonusing Platform and Easy Integration with Acres' Cashless Wallet Drives Casino Player Engagement and Revenue
LAS VEGAS, April 6, 2022 /PRNewswire/ -- Acres Manufacturing Company ("Acres"), a leading casino loyalty and technology developer, today announced the launch of Precision Bonusing™, a bonusing platform compatible with any slot machine connected to the Acres Foundation™ ("Foundation") casino management system. Foundation's market-leading technology uniquely allows casino operators to make any slot machine immediately cashless and bonusing compatible.
Precision Bonusing is a suite of bonus applications that utilize the Foundation™ system to connect to any slot machine. Each bonus application is highly configurable, allowing casino operators to adjust the bonus pay table, trigger events and even the theme and appearance of the player-facing bonus sequence.
"Precision Bonusing allows casinos to easily integrate their own branded content into exciting bonuses on the casino floor," said Noah Acres of Acres Manufacturing. "Our new bonusing application transcends outdated bonusing experiences by providing a fully customizable menu of rules and trigger events. Importantly, while legacy bonusing products deploy the same themes across multiple casinos, Precision Bonusing empowers casinos to differentiate themselves by integrating their unique brand identity into on-the-floor casino bonusing."
Precision Bonusing will debut at the Indian Gaming Trade Show and Convention (commonly referred to as NIGA) April 19-22, 2022, in Anaheim, CA. At the show, Acres will be demonstrating a multi-level progressive, a wheel bonus, and a first-of-its-kind mobile bonus that pays cash and non-monetary prizes directly to an app-based cashless wallet. Casinos can also create their own bonuses or implement bonuses offered at the Foundation App Store by Acres or through third party developers.
Bonusing increases casino excitement by giving players a chance to win cash and prizes beyond the pay table offered by the slot machine. The concept was pioneered by Acres Gaming in the 1990s but has not meaningfully evolved since the company's sale in 2004. As a result, casinos today still rely on the limits of 25-year-old systems hardware that permeates land-based casinos. With the introduction of Foundation™ and Precision Bonusing™ casinos can now deliver the types of real-time, data-driven, personalized experiences that tech companies have used to fuel their rapid growth.
Noah Acres added, "The lack of technological innovation is a key reason casino revenue growth has not kept pace with other tech-driven industries. Precision Bonusing enables casinos to reveal and send cash and other prizes to the player's mobile device, which is the platform of choice for the modern consumer. With the average US adult spending over four hours per day on a smartphone, Precision Bonusing's ability to interface a live gaming session to a player's mobile device empowers casinos to influence players wherever they go."
About Acres Manufacturing Company
Acres Manufacturing Company (Acres) is a leading casino loyalty and technology expert and the creator of Foundation™, a modern, first-of-its-kind casino management system. Foundation provides casinos with real-time data from slot machines and a direct interface to the credit meter on any slot machine. The company was founded by John Acres, the inventor of casino systems technology. For more information on Acres and Foundation, visit acresmanufacturing.com.
Contact
Mike Vautrin
+17022830309
mike.vautrin@acresmanufacturing.com
View original content to download multimedia:
SOURCE Acres
|
https://www.wistv.com/prnewswire/2022/04/06/acres-launches-precision-bonusing-its-foundation-casino-management-system/
| 2022-04-06T12:57:31
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/acres-launches-precision-bonusing-its-foundation-casino-management-system/
|
PLYMOUTH, Mich., April 6, 2022 /PRNewswire/ -- Adient (NYSE: ADNT), a global leader in automotive seating, will host a call for financial analysts on May 5, 2022 at 8:30 a.m. (ET) to discuss its second quarter fiscal 2022 financial results. The call will be hosted by Adient's president and chief executive officer, Douglas Del Grosso, and executive vice president and chief financial officer, Jeff Stafeil.
A link to the live webcast of the call and presentation materials will be available on the Adient Investor Relations website (http://investors.adient.com). A replay will be available at the same site.
To participate by telephone, please dial 888-455-2945 (U.S.) or 773-799-3947 (international) 15 minutes prior to the start time of the call and ask to be connected to the Adient conference call. The conference passcode is ADIENT.
About Adient:
Adient (NYSE: ADNT) is a global leader in automotive seating. With approximately 75,000 employees in 33 countries, Adient operates 208 manufacturing/assembly plants worldwide. We produce and deliver automotive seating for all major OEMs. From complete seating systems to individual components, our expertise spans every step of the automotive seat-making process. Our integrated, in-house skills allow us to take our products from research and design to engineering and manufacturing — and into more than 20 million vehicles every year. For more information on Adient, please visit www.adient.com.
Contacts:
Media:
Mary Kay Dodero
+1 734.386.6253
Mary.Kay.Dodero@adient.com
Investors
Mark Oswald
+1 734.254.3372
Mark.A.Oswald@adient.com
View original content to download multimedia:
SOURCE Adient
|
https://www.wistv.com/prnewswire/2022/04/06/adient-discuss-q2-fiscal-2022-financial-results-may-5-2022/
| 2022-04-06T12:57:39
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/adient-discuss-q2-fiscal-2022-financial-results-may-5-2022/
|
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as follows:
Conference: 21st Annual Needham Virtual Healthcare Conference, April 11-14, 2022
Presentation Date/Time: Wednesday, April 13 at 9:30 a.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and CEO
Webcast: https://wsw.com/webcast/needham117/agle/2213747
To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.
View original content to download multimedia:
SOURCE Aeglea BioTherapeutics, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/aeglea-biotherapeutics-participate-needham-virtual-healthcare-conferences-april-2022/
| 2022-04-06T12:57:45
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/aeglea-biotherapeutics-participate-needham-virtual-healthcare-conferences-april-2022/
|
ARLINGTON, Va., April 6, 2022 /PRNewswire/ -- The AES Corporation (NYSE: AES) will host a conference call on Friday, May 6, 2022 at 10:00 a.m. Eastern Time (ET) to review its first quarter 2022 financial results.
The call will include prepared remarks and a question and answer session. It will be open to the media and the public in a listen-only mode by telephone and webcast. Interested parties may listen to the teleconference by dialing 1-844-200-6205 at least ten minutes before the start of the call. International callers should dial +1-929-526-1599. The Participant Access Code for this call is 606102. Internet access to the conference call and presentation materials will be available on the AES website at www.aes.com by selecting "Investors" and then "Presentations and Webcasts."
A webcast replay, as well as a replay in downloadable MP3 format, will be accessible at www.aes.com beginning shortly after the completion of the call.
About AES
The AES Corporation (NYSE: AES) is a Fortune 500 global energy company accelerating the future of energy. Together with our many stakeholders, we're improving lives by delivering the greener, smarter energy solutions the world needs. Our diverse workforce is committed to continuous innovation and operational excellence, while partnering with our customers on their strategic energy transitions and continuing to meet their energy needs today. For more information, visit www.aes.com.
Safe Harbor Disclosure
This news release contains forward-looking statements within the meaning of the Securities Act of 1933 and of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, those related to future earnings, growth and financial and operating performance. Forward-looking statements are not intended to be a guarantee of future results, but instead constitute AES' current expectations based on reasonable assumptions. Forecasted financial information is based on certain material assumptions. These assumptions include, but are not limited to, our expectations regarding the COVID-19 pandemic, accurate projections of future interest rates, commodity price and foreign currency pricing, continued normal levels of operating performance and electricity volume at our distribution companies and operational performance at our generation businesses consistent with historical levels, as well as the execution of PPAs, conversion of our backlog and growth investments at normalized investment levels and rates of return consistent with prior experience.
Actual results could differ materially from those projected in our forward-looking statements due to risks, uncertainties and other factors. Important factors that could affect actual results are discussed in AES' filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the risks discussed under Item 1A: "Risk Factors" and Item 7: "Management's Discussion & Analysis" in AES' Annual Report on Form 10-K and in subsequent reports filed with the SEC. Readers are encouraged to read AES' filings to learn more about the risk factors associated with AES' business. AES undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except where required by law.
Any Stockholder who desires a copy of the Company's 2021 Annual Report on Form 10-K filed February 28, 2022 with the SEC may obtain a copy (excluding Exhibits) without charge by addressing a request to the Office of the Corporate Secretary, The AES Corporation, 4300 Wilson Boulevard, Arlington, Virginia 22203. Exhibits also may be requested, but a charge equal to the reproduction cost thereof will be made. A copy of the Form 10-K may be obtained by visiting the Company's website at www.aes.com.
Website Disclosure
AES uses its website, including its quarterly updates, as channels of distribution of Company information. The information AES posts through these channels may be deemed material. Accordingly, investors should monitor our website, in addition to following AES' press releases, quarterly SEC filings and public conference calls and webcasts. In addition, you may automatically receive e-mail alerts and other information about AES when you enroll your e-mail address by visiting the "Subscribe to Alerts" page of AES' Investors website. The contents of AES' website, including its quarterly updates, are not, however, incorporated by reference into this release.
View original content to download multimedia:
SOURCE The AES Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/aes-announces-first-quarter-2022-financial-review-conference-call-be-held-friday-may-6-2022-1000-am-et/
| 2022-04-06T12:57:52
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/aes-announces-first-quarter-2022-financial-review-conference-call-be-held-friday-may-6-2022-1000-am-et/
|
Partnership Demonstrates Increasing Adoption of Tetra Data to Create Unrestricted Innovation
BOSTON, April 6, 2022 /PRNewswire/ -- TetraScience, the R&D Data Cloud company, announced today that Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, has joined the Tetra Partner Network (TPN) so that customers can create end-to-end data integrity and speed the delivery of drugs with improved quality and higher output.
"Aizon innovates how customers use data to achieve actionable insights within and across manufacturing sites," says Simon Meffan-Main, Ph.D., Vice President of Product for TPN. "We are delighted to partner with them to increase operational effectiveness from development through manufacturing using Tetra Data to create data liquidity and enable Aizon's advanced analytics."
Pharmaceutical manufacturers are increasingly adopting advanced technologies to integrate systems where data can be analyzed by algorithms and used for critical real-time business and operational efficiencies. However, moving scientific data from development into manufacturing and integrating data produced in heterogeneous formats for advanced analytics remains an obstacle.
Aizon uses advanced AI to provide deeper insights that inform better decision making in manufacturing across a range of applications, including predictive maintenance, bioreactor, digital twin, and GxP compliant data aggregation with contextualization. The Tetra R&D Data Cloud ingests raw scientific data from disparate sources and engineers it into the industry's only universally-adoptable format, Tetra Data, which is harmonized, compliant, liquid, and actionable, and can be used to accelerate scientific and operational outcomes across the pharma value chain.
"By partnering with TetraScience, we can use the data aggregation and engineering capabilities of the Tetra R&D Data Cloud so that we can help customers gain speed and insights into manufacturing processes in order to scale more quickly and with consistency," says John Vitalie, CEO of Aizon. "We are excited to partner with them on a joint effort to bring market-leading technology that is purpose-built for the industry to our customers, for real and impactful improvements on how to create value from manufacturing and GxP data."
"Every partner added to the Tetra Partner Network creates value for customers," says Patrick Grady, TetraScience Chairman and CEO. "As partners and customers continue to accelerate adoption of our open platform, the entire life sciences industry works in lockstep, eliminating data silos and delivering unrestricted scientific data innovation."
Read the Aizon blog: Digital Twins - Seeing Double with a Predictive Eye.
About TetraScience
TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D. For more information, please visit tetrascience.com.
About Aizon
Aizon is an AI software application and solution provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP-compliant manner, with end-to-end data integrity.
View original content to download multimedia:
SOURCE TETRASCIENCE
|
https://www.wistv.com/prnewswire/2022/04/06/aizon-partners-with-tetrascience-help-pharmaceutical-customers-increase-speed-efficiency-drug-manufacturing/
| 2022-04-06T12:58:01
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/aizon-partners-with-tetrascience-help-pharmaceutical-customers-increase-speed-efficiency-drug-manufacturing/
|
CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022 (SCM22), which will take place on demand and live in Boston on April 6 – 10, 2022.
Abstracts are available online in the SCM22 Abstract and ePoster Gallery: https://cme.kidney.org/spa/courses/resource/2022-spring-clinical-meetings/event/home/posters/browser
Akebia posters include:
- Real-World All-Cause Healthcare Costs Among Dialysis-Dependent Patients with Chronic Kidney Disease on Phosphate Binders (Poster #189)
- Real-World Adherence and Persistence on Phosphate Binders Among Dialysis-Dependent Patients with Chronic Kidney Disease (Poster #190)
- Hemodialysis Access Thrombotic Events in Patients with Dialysis-Dependent CKD Randomized to Vadadustat vs. Darbepoetin Alfa (Poster #280)
NKF SCM22 attendees can visit the Akebia booth (#915) or virtual booth in NKF's 2022 Spring Clinical Meeting Virtual Exhibit Hall: https://cme.kidney.org/spa/courses/resource/2022-spring-clinical-meetings/event/home/expo.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational new drug and is not approved by the U.S. Food and Drug Administration (FDA). On March 29, 2022, the FDA issued a complete response letter to Akebia's New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is currently under review by the European Medicines Agency for the treatment of anemia due to CKD in adults. In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:
SOURCE Akebia Therapeutics
|
https://www.wistv.com/prnewswire/2022/04/06/akebia-therapeutics-announces-poster-presentations-national-kidney-foundation-spring-clinical-meetings-2022/
| 2022-04-06T12:58:07
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/akebia-therapeutics-announces-poster-presentations-national-kidney-foundation-spring-clinical-meetings-2022/
|
Tracey James, RPh, assumes chief operating officer position to support future company strategy.
ORLANDO, Fla., April 6, 2022 /PRNewswire/ -- AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies in the country, recently announced its intent to rebrand. Effective June 24, 2022, AllianceRx Walgreens Prime will become AllianceRx Walgreens Pharmacy. Walgreens announced full ownership of AllianceRx Walgreens Prime in January, necessitating the name change.
"While our name is changing, we will be the same specialty and home delivery pharmacy our patients trust and depend on for life-saving medications," says Joel Wright, RPh, chief executive officer. "We will continue putting patients first in everything we do to provide hope and care for better tomorrows."
Wright says additional company changes include the promotion of senior vice president Tracey James, RPh, to chief operating officer. James, a licensed pharmacist who has been with the organization since its inception, will oversee pharmaceutical and payer relations, clinical and professional services, and Specialty360 therapy teams.
"Our Specialty360 therapy teams were developed to enable us to improve patient outcomes, reduce cost of care, and enhance the patient and provider experience," Wright says. "As the pharmacy industry evolves, the complexity of our patients' needs led us to change our operating model to support them with therapy-specific teams."
Specialty360 therapy team members will continue to specialize in therapies to better serve patients. New, dedicated therapy directors will work cross-functionally with pharmacy functions to oversee the delivery of patient care. Team members, including pharmacists, pharmacy technicians, nurses and dietitians, will be certified in specific diagnoses along with associated therapies. Those diagnoses include behavioral health, bone health, chronic inflammatory disease, endocrine, neurology, nursing and infusion-supporting therapies, oncology, organ/infectious disease, pulmonary and allergy, and reproductive health.
"We're evolving the organization to support a more personalized pharmacy experience with specific clinical expertise for our patients, based on their diagnoses," James says. "This new structure will allow our team members to meet our patients where they need us most and position the company for future growth."
AllianceRx Walgreens Prime (alliancerxwp.com) is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient's treatment journey with the medications they need every day. Formed in 2017, the company offers tools and resources for patients, providers and health plans to deliver the optimal health outcomes. The company is headquartered in Orlando, Florida, and its pharmacies are accredited by several national pharmacy accreditation services.
Media Contact
Adrienne Foley, APR
External communications manager
adrienne.foley1@alliancerxwp.com
View original content to download multimedia:
SOURCE AllianceRx Walgreens Prime
|
https://www.wistv.com/prnewswire/2022/04/06/alliancerx-walgreens-prime-become-alliancerx-walgreens-pharmacy/
| 2022-04-06T12:58:14
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/alliancerx-walgreens-prime-become-alliancerx-walgreens-pharmacy/
|
CALABASAS, Calif., April 6, 2022 /PRNewswire/ -- American Homes 4 Rent (NYSE: AMH) ("American Homes 4 Rent" or the "Company"), a leading provider of high-quality single-family homes for rent, issues an open letter to shareholders regarding its commitment to industry-leading Environmental, Social and Governance (ESG) practices.
Dear Fellow Shareholders,
At American Homes 4 Rent, we integrate sustainability into every aspect of our business, including our development program, and continually evaluate new opportunities to create more energy efficient and environmentally friendly communities and homes. Sustainability is a principle we take seriously to ensure we have a positive impact on our residents, team members and planet. With the support and oversight of the Nominating and Corporate Governance Committee of our Board, we are executing a multifaceted ESG strategy that is deliberate and aligned with our business goals.
As the leading national builder of purpose-built single-family rental homes, we design and construct new homes that embrace environmental sustainability practices. We build homes for long-term durability, to lower long-term maintenance costs, and conserve our natural resources.
Solar power plays a key role in our sustainability efforts. On March 28, 2022, we announced a landmark partnership with Elevation, a fully integrated residential energy solutions company. This partnership began with the integration of solar energy into our current and future community amenity centers and continues with the deployment of energy solutions into participating homes. To date, we have successfully integrated solar energy into amenity centers in two of our new home communities—The Ponds at Walden Woods in Tampa, Florida, and Creekside Ranch in New Braunfels, Texas—and have solar installation underway at Brentwood in Mooresville, North Carolina. In addition, we are evaluating dozens of other centers to determine the benefits of solar to those structures.
Solar energy is only one example of our many energy-saving programs and environmentally friendly policies. Some additional examples include:
- In 2020, we began a program to track RESNET Home Energy Rating System (HERS) scores for our newly built homes to demonstrate the energy efficiency and savings while living in our properties. In 2021, our newly constructed homes used nearly 40% less energy than a home built to the 2006 "reference home" standard and less than half of the energy of a typical home in this country. As we more broadly adopt utilization of solar energy across our portfolio, energy savings will only improve.
- Efficient and resource-saving initiatives are incorporated into our design, construction, and renovation processes, including energy efficient lighting, HVAC units and appliances.
- We recover or reuse/recycle refrigerant when servicing air conditioning units.
- We employ a third-party utilities administrator to monitor resident electricity and water usage.
American Homes 4 Rent is recognized as a leader in our industry for our ESG policies and sustainability commitments. In late 2021, American Homes 4 Rent was recognized as a Top ESG Regional Performer by Sustainalytics, a Great Place To Work®, and one of America's Most Responsible Companies 2022 by Newsweek and Statista. Additionally, in early 2022, American Homes 4 Rent was further named one of America's Most Trusted Companies 2022 by Newsweek and Statista, ranking third among its thirteen real estate industry peers on the list.
You may have seen a press release on April 4, 2022 from Land & Buildings Investment Management, LLC, a shareholder of American Homes 4 Rent, regarding our sustainability programs. This press release followed a call on March 29, 2022, with Craig Melcher of Land & Buildings, which was held at Land & Buildings' request.
During the meeting, we described in great detail the commitment of our Board and management team to acting in the best interests of the Company, our shareholders, the communities we serve and, in particular, the environment in which we live. Upon reading Land & Buildings' press release, we were disappointed to discover that Land & Buildings' principals had either misunderstood or mischaracterized our discussion.
Our Board and management team are aligned in their longstanding commitment to sustainability and will continue enhancing our policies and programs to create a more sustainable future for our planet, teams, residents, and communities.
Thank you for your investment and trust in us to oversee the long-term success and environmental sustainability of American Homes 4 Rent.
Sincerely,
Douglas N. Benham
Chairman of the Nominating and Corporate Governance Committee of the American Homes 4 Rent Board of Trustees
David P. Singelyn
Chief Executive Officer and Trustee of American Homes 4 Rent
About American Homes 4 Rent
American Homes 4 Rent (NYSE: AMH) is a leader in the single-family home rental industry and "American Homes 4 Rent" is a nationally recognized brand for rental homes, known for high-quality, good value and resident satisfaction. We are an internally managed Maryland real estate investment trust, or REIT, focused on acquiring, developing, renovating, leasing, and operating attractive, single-family homes as rental properties. As of December 31, 2021, we owned 57,024 single-family properties in selected submarkets in 22 states.
Additional information about American Homes 4 Rent is available on our website at www.americanhomes4rent.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that relate to beliefs, expectations or intentions and similar statements concerning matters that are not of historical fact and are generally accompanied by words such as "estimate," "project," "predict," "believe," "expect," "anticipate," "intend," "potential," "plan," "goal," "outlook," "guidance" or other words that convey the uncertainty of future events or outcomes. These forward-looking statements may include, but are not limited to, our expectations with respect to the success of our sustainability programs and ESG strategy, our belief that our efforts to integrate sustainability into our business will result in more energy efficient and environmentally friendly communities, our ability to identify new opportunities to advance our sustainability policies and the estimated timing of the integration of energy solutions into our current and future residences and amenity centers.
The Company has based these forward-looking statements on its current expectations and assumptions about future events. While the Company's management considers these expectations to be reasonable, they are inherently subject to risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control and could cause actual results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements to conform to actual results or changes in its expectations, unless required by applicable law.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the "Risk Factors" disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and in the Company's subsequent filings with the Securities and Exchange Commission (the "SEC").
Important Additional Information Regarding Proxy Solicitation
The Company has filed a definitive proxy statement (the "Proxy Statement") and form of proxy card with the SEC in connection with the solicitation of proxies for the Company's 2022 Annual Meeting of Shareholders. The Company and certain of its trustees, officers and regular employees will be participants in the solicitation of proxies from shareholders in respect of the 2022 Annual Meeting of Shareholders. Information regarding the Company's trustees and executive officers and their respective interests in the Company by security holdings or otherwise is set forth in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and shareholders can obtain a copy of the Proxy Statement and other relevant documents filed by the Company free of charge from the SEC's website at www.sec.gov and at the Company's website at www.americanhomes4rent.com under "Investor Relations."
Contacts:
American Homes 4 Rent
Megan Grabos
Media Relations
Phone: (805) 413-5088
Email: media@ah4r.com
American Homes 4 Rent
Nicholas Fromm
Investor Relations
Phone: (855) 794-2447
Email: investors@ah4r.com
View original content to download multimedia:
SOURCE American Homes 4 Rent
|
https://www.wistv.com/prnewswire/2022/04/06/american-homes-4-rent-issues-open-letter-shareholders-regarding-esg-sustainability-leadership/
| 2022-04-06T12:58:21
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/american-homes-4-rent-issues-open-letter-shareholders-regarding-esg-sustainability-leadership/
|
TEL AVIV, Israel, April 6, 2022 /PRNewswire/ -- A plane filled with Ukrainian Jewish refugees — sponsored by American Jewish Committee (AJC) and organized by Jewish Agency for Israel — has arrived in Israel from Budapest, Hungary.
"For Jews facing uncertain safety in their homes, Israel is a lifeline, a sanctuary, and a haven," said AJC CEO David Harris. "Whether they are still living in Ukraine or have fled the violent Russian invasion to neighboring countries, these Jews know they have a home in the State of Israel, where they can build their lives anew because of the warm welcome they receive."
AJC is the only advocacy organization to have sponsored two Jewish Agency for Israel flights for Ukrainian Jews to Israel, the earlier one originating in Warsaw, Poland.
Accompanying the 141 Ukrainian Jews on board were Curtis Lane, AJC Board of Trustees, New York; and Aldona Zawada and Barnabas Turai, staff members of AJC Central Europe. AJC Jerusalem Director Avital Leibovich was on hand at Ben Gurion Airport to greet the newest Ukrainian immigrants to Israel.
Funds for the AJC-chartered plane came from AJC's emergency #StandWithUkraine Fund. AJC has raised more than $2.1 million to date for organizations providing direct relief to Ukrainian refugees and humanitarian assistance to Ukraine. Twelve organizations have so far received #StandWithUrkaine grants. Additional grants will be announced soon.
View original content:
SOURCE American Jewish Committee
|
https://www.wistv.com/prnewswire/2022/04/06/american-jewish-committee-flies-141-ukrainian-jews-israel/
| 2022-04-06T12:58:27
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/american-jewish-committee-flies-141-ukrainian-jews-israel/
|
SAN JOSE, Calif., April 6, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at The 4th International Workshop on CAR-T (iwCAR-T) 2022 on Friday, April 29, 2022. Dr. Conejo-Garcia will be chairing a panel on breast and ovarian cancers and will discuss the use of Chimeric Endocrine Receptor T-cell (CER-T) technology for treating ovarian cancer, an approach he invented that is in development with Anixa. A Phase 1 clinical trial of the therapy based on this technology was recently activated at Moffitt Cancer Center.
During the presentation, titled, "Chimeric Endocrine Receptor (CER) T-cell technology for ovarian cancer," Dr. Conejo-Garcia will discuss the technology, which is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.
"I am excited to discuss our novel FSHR-mediated CAR-T technology at this event as part of the goal to share knowledge and research in CAR-T and immunotherapies," stated Dr. Conejo-Garcia. "Moffitt has been working in collaboration with Anixa to advance this program into human clinical studies, and we are thrilled to have recently activated the trial. We look forward to verifying results of this therapeutic approach in solid tumors. Importantly, if this therapeutic approach is successful this could enable a significant shift in the overall treatment paradigm for ovarian cancer."
Dr. José Conejo-Garcia and his research team developed the FSHR-mediated CAR-T technology when he was at the Wistar Institute where he contributed to report for the first time on the role of T-cell responses in the outcome of ovarian cancer patients. Anixa has an exclusive, world-wide license to this technology.
More information about the event can be found at: iwCAR-T.
Anixa is a clinical-stage biotechnology company with a number of programs addressing cancer and infectious disease. Anixa's portfolio of therapeutics includes a cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and, with partner MolGenie GmbH, a COVID-19 program focused on compounds targeting the Mpro enzyme of SARS-CoV-2, which is largely conserved across all recently identified variants like Delta and Omicron. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn and Facebook.
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contacts
Company Contact:
Mike Catelani
Chief Operating Officer and Chief Financial Officer
mcatelani@anixa.com
408-708-9808
Media:
Slavena Salve Nissan, M.D.
LifeSci Communications
snissan@lifescicomms.com
718-483-4440
Investors:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
646-751-4363
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/anixa-biosciences-ovarian-cancer-car-t-therapy-be-discussed-4th-international-workshop-car-t-2022/
| 2022-04-06T12:58:39
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/anixa-biosciences-ovarian-cancer-car-t-therapy-be-discussed-4th-international-workshop-car-t-2022/
|
Available Batch Capacity Now Doubled to Meet Growing Demands
TEDA TIANJIN, P.R. China, April 6, 2022 /PRNewswire/ -- Asymchem Laboratories (Tianjin) Co., Ltd., a leading CDMO serving the global pharmaceutical and biotech industry, announced the company has completed construction of a new building at its Dunhua, China, production site. The expansion will add nearly 500m³ of batch capacity to meet demands for upcoming commercialization projects. In addition, an API building expansion was completed at the company's Tianjin site, with an expected new batch capacity of 160m³.
"To meet the rapidly growing demand of Asymchem's clients and projects, we have accelerated the construction of several small molecule R&D and production sites across China. By the end of 2022, we plan to have added 1,700m³ of small molecule batch capacity in Dunhua, Tianjin and Yangtze River Delta, doubling existing batch capacity," says Chen Chaoyong, Executive Vice President of Manufacturing at Asymchem.
Additionally, Asymchem plans to continue to increase the application of continuous flow technology in all of its sites. This includes upgrading several current modules and buildings and adding continuous flow equipment in new facilities.
"With the completion of additional production sites, large-scale application of continuous flow technology, optimized capacity utilization, and consistent blockbuster commercial orders, we have sufficient space to undertake new customers and projects well into 2022 and beyond," said Dr. James Gage, Chief Scientific Officer at Asymchem.
About Asymchem
Founded in 1999, Asymchem (stock code: 002821.SZ/6821HKE) is a leading global integrated Contract Development and Manufacturing Organization (CDMO) providing innovative drug R&D and manufacturing. Asymchem is supported by 7000 employees based in PR China, US, and EU. Our mission is to be an essential player in the global pharmaceutical supply chain supporting drug development with innovative technological solutions in small molecule drug development and production.
View original content to download multimedia:
SOURCE Asymchem
|
https://www.wistv.com/prnewswire/2022/04/06/asymchem-completes-construction-two-new-production-sites/
| 2022-04-06T12:58:47
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/asymchem-completes-construction-two-new-production-sites/
|
Study Finds Consumer Spending in March up 11% Year-Over-Year, Suggesting Solid Economic Momentum
NEW YORK, April 6, 2022 /PRNewswire/ -- Bank of America launched the Bank of America Institute today with the release of its inaugural publication, Consumer Checkpoint, which provides a real-time and holistic view of U.S. consumers' spending and financial health.
Drawing on data and analyses from across the bank and the world, the Bank of America Institute is a new think tank that will provide timely and original perspectives on the economy, Environmental, Social and Governance (ESG) and global transformation.
"Through the Bank of America Institute, we can provide forward-looking thought leadership by leveraging our propriety data and harnessing the power of our extensive expertise," said Brian Moynihan, Chair of the Board and Chief Executive Officer. "Our Consumer Checkpoint is just one example of the insights we will uncover that provide a unique perspective on the health of the economy."
Throughout March, Bank of America credit and debit card spending was up 11% year-over-year, suggesting consumers continue to provide good momentum to the economy. Aggregated payment data also remains robust, pointing to broader growth in bigger-ticket services.
"Consumers are facing headwinds from higher energy and food prices, with gas prices up almost 50% from a year ago" said David Tinsley, senior economist for the Bank of America Institute. "But their balance sheets appear strong enough to weather the storm, provided it doesn't persist too long."
Bank of America spending data (card and payments) suggests that cash spending by U.S. households is exhibiting solid momentum. A number of tailwinds are supporting the consumer, such as the buoyant labor market, with near-record job openings and rising wages. The return to work following the omicron wave has also been a strong positive.
Still, the latest inflation figures, with the annual change in U.S. Consumer Price Index reaching 7.9% in February, represent a major headwind to the consumer. At the very least, high inflation means that every dollar spent by households goes less far in terms of the goods and services they want to buy.
Other key findings include:
- Travel and leisure spending rebounded since the ebbing of the omicron wave; throughout March, airline spending was 91% higher year-over-year while restaurant spending rose by 17%
- Lower-income consumers feel a greater squeeze; card spending by households making less than $50k/year was up 4% relative to the same period in 2021 and up 30.4% from 2019, whereas spending by upper-income households (>$125k/year) rose 11.8% year-over-year and 22.5% from the pre-pandemic level three years ago
- Higher gas prices are having a noticeable impact, with cardholders spending 41% more than the same period last year
- Pandemic savings are still providing cash buffers, as evidenced by lower-income consumers having elevated cash savings in deposit accounts relative to pre-pandemic levels
For the complete Consumer Checkpoint including methodology, please visit our website.
Bank of America
Bank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 67 million consumer and small business clients with approximately 4,200 retail financial centers, approximately 16,000 ATMs, and award-winning digital banking with more than 54 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and approximately 35 countries. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.
For more Bank of America news, including dividend announcements and other important information, register for email news alerts.
Reporters may contact:
Melissa Anchan, Bank of America
Phone: 1.646.532.9241
melissa.anchan@bofa.com
View original content to download multimedia:
SOURCE Bank of America Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/bank-america-institute-launches-with-monthly-consumer-checkpoint/
| 2022-04-06T12:58:54
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/bank-america-institute-launches-with-monthly-consumer-checkpoint/
|
The 2022 report illustrates how employer benefit plan design and employee decisions are shifting by analyzing enrollments from 361 large employers and more than 4.7 million employees across the last five years.
CHARLESTON, S.C., April 6, 2022 /PRNewswire/ -- Benefitfocus, Inc. (NASDAQ: BNFT), an industry-leading cloud-based benefits administration technology company that simplifies benefits administration for employers, health plans and brokers, today announced the release of its fifth annual State of Employee BenefitsTM report. As employers continue to manage the complexity of the evolving workforce, the report uncovers how employer benefit packages have shifted to meet a more diverse set of needs with the goal of attracting and retaining talent. At the same time, employee enrollment data shows a shift in how employees are prioritizing financial security.
"In its second consecutive year analyzing pandemic era benefit trends, The State of Employee Benefits reveals how employers are responding to new challenges and evolving workforce dynamics," said Matt Levin, CEO of Benefitfocus. "As employers continue to diversify their benefit offerings to attract and retain talent, improve outcomes, and manage health care costs, effectively administering these benefits, communicating their value, and engaging employees in these programs becomes increasingly critical."
Interesting findings from the report include:
- Employers are persistent about diversifying health benefits packages, increasing flexibility and placing a greater emphasis on voluntary benefit options across a variety of categories. 77 percent of employers now offer an average of five health plan options between HDHP and PPOs, and nearly two thirds now offer both an HSA and FSA. Further, as employers look to diversify offerings to attract and retain talent amid "The Great Resignation," HR professionals identified preferred voluntary benefits, including:
- Employers continue to limit cost-sharing. After nearly two years of weighing the impacts of COVID-19 on health care costs and employee turnover, employers limited out-of-pocket cost increases to two percent or less on average. Employers also picked up the five percent premium increase for individual PPOs.
- Employees are prioritizing financial security, driving a shift in enrollment across PPOs and HDHPs, and an increase in adoption of voluntary benefits.
"The report's findings demonstrate how HR and benefits have evolved to an entirely new level over the past year," said Tina Provancal, Chief Product and Strategy Officer at Benefitfocus. "Increasingly complex benefit programs combined with growing expectations of today's workforce are reinforcing the need for employers to partner with a technology provider that prioritizes the employee experience and the need to increase engagement in benefit programs by delivering exceptional support while leveraging data to drive smarter, more cost-effective benefit decisions."
The State of Employee Benefits 2022 was compiled by aggregating and analyzing enrollment transactions of 361 large employers (+1,000 employees) within the Benefitfocus customer base, representing more than 4.7 million employees in total. This year's report also includes insights and perspectives based on sponsored surveys. Click here to access and download the full report.
Connect with Benefitfocus
Like Benefitfocus on Facebook
Follow @benefitfocus on Twitter
Follow Benefitfocus on LinkedIn
Follow Benefitfocus on Instagram
About Benefitfocus
Benefitfocus (NASDAQ: BNFT) is a cloud-based benefits administration technology company committed to helping our customers, and the people they serve, get the most out of their health care and benefit programs. Through exceptional service and innovative SaaS solutions, we aim to be the safest set of hands for our customers helping to simplify the complexity of benefits administration while delivering an experience that engages people and unlocks the potential for better health and improved outcomes. Our mission is simple: to improve lives with benefits.
View original content to download multimedia:
SOURCE Benefitfocus, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/benefitfocus-2022-state-employee-benefits-report-reveals-employers-persistence-meeting-employee-needs-by-diversifying-benefit-offerings/
| 2022-04-06T12:59:02
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/benefitfocus-2022-state-employee-benefits-report-reveals-employers-persistence-meeting-employee-needs-by-diversifying-benefit-offerings/
|
HORSHAM, Pa. , April 6, 2022 /PRNewswire/ -- Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings and coating equipment for medical devices, announced its expansion into the design, development and delivery of hydrophilic dip coating equipment. Biocoat's new equipment line is called EMERSE and offers companies who require an in-house dip coating system to coat their medical devices and complete the production process.
The addition of coating equipment now positions Biocoat as one of the only companies that can offer a complete, full-service solution for medical devices that require a hydrophilic coating. The EMERSE hydrophilic dip coating system is specifically designed and manufactured to meet the rigorous requirements that are encountered when coating products in the medical device, pharmaceutical, biotechnology and life science industries. Biocoat's coating systems will be available in either Thermal heat or Ultraviolet (UV) cure systems and is available in two models, the semi-automated Compact system, that offers an annual production of ~25,000 units per year per shift and the One Touch automated system that can coat ~75,000-100,000 units per year per shift.
"The addition of coating equipment fulfills our strategic vision of making Biocoat the premier full-service coatings company to partner with for medical device companies." said Jim Moran, President, and CEO, Biocoat. "Our coating systems will be automated and fully compatible for use on either our industry leading HYDAK® coatings or any other coatings in the market. Our aim is to work closely with our customers to provide the highest level of service available, while ensuring that we deliver the equipment on-time and on-budget, every time."
About Biocoat, Inc.
Biocoat, Inc. is a full-service coatings provider specializing in supplying lubricious hydrophilic coatings custom engineered to meet specific clinical parameters for medical devices to original equipment manufacturers, start-up companies, and contract manufacturers. Biocoat also provides coating services and equipment to aspiring medical device companies that require assistance with manufacturing.
To learn more about Biocoat visit www.biocoat.com, or connect on LinkedIn and Twitter.
View original content to download multimedia:
SOURCE Biocoat, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/biocoat-inc-launches-coating-equipment-business-unit-completes-full-service-hydrophilic-coating-offering/
| 2022-04-06T12:59:09
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/biocoat-inc-launches-coating-equipment-business-unit-completes-full-service-hydrophilic-coating-offering/
|
BEIJING, April 6, 2022 /PRNewswire/ -- Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No. YH003005) of YH003 (anti-CD40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) and pembrolizumab (anti-PD-1 mAb) in Australia.
The study is an open-label, dose-escalation study designed to evaluate the safety, tolerability and efficacy of YH003 in combination with YH001 and pembrolizumab in patients with advanced solid tumors. Pharmacokinetics and immunogenicity of YH003 will also be evaluated.
"Previous phase I clinical trials of YH003/Toripalimab (anti-PD-1 mAb) combination therapy and YH001/Toripalimab combination therapy indicate desirable safety profiles and preliminary efficacy for both products," said Dr. Yuelei Shen, Chairman and CEO of Biocytogen and Eucure Biopharma. "The combination of CTLA-4, PD-1 and CD40 mAbs is based on their different but complementary biological mechanisms; we hope that the three-drug combination study can further strengthen the antitumor efficacy to benefit patients."
About YH003
YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 mAb drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor models in Biocytogen's humanized CD40 mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.
About YH001
YH001 is an anti-CTLA-4 monoclonal antibody. CTLA-4 is a key target for tumor immunotherapies, due to the potential to enhance the immune response to tumor cells and promote removal of regulatory T cells (Treg) from the tumor microenvironment. Blocking the inhibitory signals from both CTLA-4 and PD-1 to enhance the anti-tumor responses is considered a promising tumor immunotherapy, as they control the different types of T cells.
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen's R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II MRCT and two in phase I.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that streamlines the research and development of antibody drugs using innovative technologies, including RenMabTM and RenLiteTM mice for fully human antibody production, high-throughput antibody screening platforms, in vivo drug efficacy screening capabilities and strong clinical development ability. Biocytogen is undertaking a large-scale project to develop antibody drugs in collaboration with global partners for more than 1000 druggable targets, known as Project Integrum. With the implementation of Project Integrum, Biocytogen has entered ongoing collaborations with dozens of partners worldwide and has established a pipeline of 12 core products, with 2 products in phase II MRCT and 2 products in phase I trials. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.
Media Contact:
jframe@biocytogen.com
View original content to download multimedia:
SOURCE Biocytogen
|
https://www.wistv.com/prnewswire/2022/04/06/biocytogen-subsidiary-eucure-biopharma-completes-first-patient-dosing-phase-i-clinical-trial-yh003-anti-cd40-mab-triple-combination-therapy/
| 2022-04-06T12:59:17
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/biocytogen-subsidiary-eucure-biopharma-completes-first-patient-dosing-phase-i-clinical-trial-yh003-anti-cd40-mab-triple-combination-therapy/
|
Latest enhancements automate incident response, security, and development to keep costs low, data safe, and productivity high
HOUSTON, April 6, 2022 /PRNewswire/ -- BMC, a global leader in software solutions for the Autonomous Digital Enterprise, today announced new capabilities and integrations across its BMC AMI (Automated Mainframe Intelligence) and BMC Compuware portfolios. These innovations dramatically increase developer productivity, predict service impacts, and help prevent attackers from compromising mainframe environments.
"Organizations are looking to treat the mainframe like any other computing platform with the same needs to innovate and be more efficient and secure," said Katie Norton, Senior Research Analyst, DevOps at IDC. "That requires selecting the right tools that truly optimize performance and costs while keeping developer productivity high. Using modern mainframe development tools, threat detection, and response, along with automation, helps businesses connect the mainframe to their broader transformation initiatives like DevOps, AppSec, SecOps, and AIOps."
Increased Developer Productivity and Delivery Speed
Through the new BMC Compuware ISPW Git integration, mainframe development teams have the flexibility to fully adopt Git or use the ISPW feature-branching sandbox for a fully controlled and isolated environment to create and change code. With a simple right-click, Git users take full advantage of the ISPW mainframe build, test, and deploy capabilities in their CI/CD pipeline. According to Forrester, leveraging modern mainframe development tools increases developer productivity by 175% and deployment frequency by 600% without compromising quality1.
Using Veracode integration with BMC Compuware Topaz Workbench, organizations can now discover security risks in mainframe applications early in the development lifecycle. The modern integrated development environment (IDE) of the BMC Compuware Topaz Workbench solution edits and debugs code, followed by the Veracode IDE Scan that identifies vulnerabilities in the code written. The Veracode integration allows developers to shift left and scan code for security defects early in the development lifecycle, where it is easier and less costly to fix.
Zero Trust Security and Ransomware Protection
An industry-first for mainframe environments, the BMC AMI Enterprise Connector for Illumio product allows customers to achieve a successful Zero Trust implementation by serving as a two-way translator between Illumio's Zero Trust segmentation and the mainframe. In addition, the BMC AMI Command Center for Security system surfaces malicious performance activity for incident responders, reducing operating costs with the ability to automate password resets and offload security monitoring workloads to reduce usage charges. These innovations allow organizations to improve their security posture by preventing compromise at multiple layers to protect against damaging ransomware attacks.
Enabling Uninterrupted Service
By combining predictive analysis and actionable details into a single interface, the BMC AMI Ops solution now assures operations teams of uninterrupted service by helping them respond to potential problems before they occur. The solution uses artificial intelligence (AI) ready out-of-the-box to begin surfacing the root cause of an issue through an intuitive interface that presents data in a prioritized, at-a-glance view for fast remediation. Smart card and certificate support provide an added level of security without additional complexity.
BMC also recently announced day one support of the latest IBM® Db2® and IBM® z16™ release, working with IBM so that the entire portfolios of the BMC AMI and BMC Compuware mainframe solutions are compatible with both Db2 13 and IBM z16.
"BMC is committed to delivering modern mainframe solutions that empower developers and help enterprises succeed amidst change," said John McKenny, senior vice president and general manager, Intelligent Z Optimization and Transformation at BMC. "With our 30th quarterly release, we are helping organizations increase their velocity, quality, and efficiency to outperform the industry with new capabilities across our BMC AMI and BMC Compuware portfolios."
Additional Resources
- Learn what's new in BMC's mainframe solutions
- Discover choice and flexibility when choosing Git for the mainframe
- Discover what it takes to be an Autonomous Digital Enterprise
¹ "The Total Economic Impact(TM) Of BMC Compuware and ISPW And Topaz," a commissioned study conducted by Forrester Consulting on behalf of BMC.
About BMC
From core to cloud to edge, BMC delivers the software and services that enable over 10,000 global customers, including 84% of the Forbes Global 100, to thrive in their ongoing evolution to an Autonomous Digital Enterprise.
BMC, BMC Software, the BMC logo, and other BMC marks are the exclusive properties of BMC Software, Inc. and are registered or may be registered with the U.S. Patent and Trademark Office or in other countries.
©Copyright 2022 BMC Software, Inc.
Db2 and IBM are trademarks or registered trademarks of International Business Machines Corporation in the United States, other countries, or both.
BMC—Run and Reinvent
www.bmc.com
Editorial contact:
Sheila Watson
BMC
ExtComms@bmc.com
View original content to download multimedia:
SOURCE BMC Software, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/bmc-delivers-new-innovations-dramatically-increase-mainframe-developer-productivity-deployment-frequency/
| 2022-04-06T12:59:24
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/bmc-delivers-new-innovations-dramatically-increase-mainframe-developer-productivity-deployment-frequency/
|
REITERATES FULL YEAR REVENUE GUIDANCE OF $55-$60 MILLION
ANDOVER, Mass., April 6, 2022 /PRNewswire/ -- Byrna Technologies Inc. (NASDAQ: BYRN) ("Byrna", "the Company", "we" or "us") today announced financial results for its fiscal first quarter (Q1 FY22) ended February 28, 2022.
First Quarter 2022 Financial Highlights and Updates
- Revenues decreased (10.3%) to $8.0 million from $8.9 million in last year's first quarter, however;
- Order backlog as of February 28, 2022 was $2.2 million with $1.6 million of international orders were held pending exports permits;
- Orders received during Q1 FY22 rose 45.6% to $8.9 million from $6.1 million in last year's first quarter (Q1 FY21);
- Gross profit for the quarter decreased by (2.7%) to $4.6 million from $4.7 million in last year's first quarter, however;
- Gross profit margin improved at 57.8% compared to 53.3% in last year's first quarter
- 296,168 shares of common stock repurchased for $2.7 million during Q1 FY 22. First $10 million tranche completed in March with 1,050,249 shares repurchased.
First Quarter 2022 Results Overview
While revenues for Q1 FY22 decreased (10.3%) to $8.0 million in from $8.9 million in Q1 FY21, orders received during the quarter increased substantially, up 45.6% to $8.9 million in Q1 FY22 from $6.1 million in Q1 FY21. Sales for Q1 FY22 were lower than expected due to the large order backlog that did not ship by month-end. In addition to $1.6 million of international orders that were held pending export permits, part of the backlog was comprised of the Sportsman's Warehouse order, which shipped in March.
Lower sales volume caused only a slight decrease in gross profit which declined to $4.6 million, or 57.8% of reported net revenue, in Q1 FY22 as compared to gross profit of $4.7 million, or 53.3% of net revenue, in Q1 FY21. The improvement in gross margin as a percentage of sales was helped by improved operating efficiencies at the factories despite the lower production volumes. These improvements were partially offset by higher inbound freight costs which we believed peaked during this last quarter. We expect to see continued improvements in gross margins due to both increased production volumes and reduced per unit freight costs.
Operating expenses were $8.0 million in Q1 FY22 as compared to $5.2 million in Q1 FY21 and $8.8 million in the fourth quarter of fiscal year 2021 (Q4 FY21). The increase in comparison with Q1 FY21 is due to several aspects of corporate growth that drove up structural costs (primarily payroll related and non-cash compensation), regulatory and insurance costs as well as increased investment in discretionary marketing costs.
Net loss in Q1 FY22 was $(3.2) million, or $(0.14) per share, compared to a net loss of $(0.3) million, or $(0.02) per share, in Q1 FY21, due primarily to the higher operating expenses outlined above.
Excluding non-cash incentive and stock-based compensation and one-time severance costs, non-GAAP adjusted net loss1 for Q1 FY22 was $(1.8) million or $(0.07) per share compared to non-GAAP adjusted net income of $0.2 million or $0.02 per share in Q1 FY21.
Financial Position as of February 28, 2022:
- Total cash and cash equivalents of $44.7 million, compared to total cash and cash equivalents of $56.3 million, including restricted cash of $0.1 million at November 30, 2021
- Total assets of $70.5 million, compared to $75.3 million at November 30, 2021
- No current or long-term debt
Commentary:
Bryan Ganz, CEO of Byrna, commented "While the first quarter of 2022 was challenging in many respects, we are very pleased with the continued improvements we are seeing in production, order flow and gross profit margin."
Like many companies, during Q1 FY22, Byrna had to deal with supply chain disruptions and logistics issues that resulted in a persistent shortage of critical components. As a result, our primary manufacturing facility in Fort Wayne Indiana was in production only 36 days during the first quarter. With limited components, total production for the quarter was just shy of 19,000 units (versus a production plan of 30,000 units). This resulted in many products showing "out-of-stock" throughout the quarter.
We are pleased to report that we expect the supply chain disruptions that we were grappling with in Q1 are a thing of the past. During the month of March, Byrna produced over 14,000 launchers (a quarterly pace of 42,000 units). Currently we are not "out-of-stock" on any SD launcher nor are we "out-of-stock" on any of our ammo offerings. We also have enough components on hand to build another 20,000+ launchers not taking into account any additional shipments from our suppliers. We plan to run at these elevated levels of production as we rebuild our finished goods inventory so that we can handle any unplanned spike in sales (such as we have experienced over the last two years due to both civil unrest and celebrity endorsements).
On the sales side, while the industry is seeing a reversion to mean in 2022 with sales of all classes of self-defense products (from guns to pepper spray) showing significant declines from prior year, Byrna continues to see strong growth in organic order flow. In 2020 and 2021 (the "pandemic" years), guns sales (which are a proxy for our industry) averaged 20.3 million units per year versus an average of just 13.5 million units in the prior two years (2018 and 2019). This year guns sales appear to be trending back to pre-pandemic levels. Based on the FBI's National Instant Background Check (NIICS), which track with gun sales, gun purchases are down 34.0% in the first quarter of 2022 (running at the same level as 2019).
By contrast, for Q1 FY22, Byrna's orders are up 45.6% in comparison with Q1 FY21 (despite the fact that last year's numbers included the "January 6th Insurrection" period which saw a spike in demand for all self-defense products). This trend continued in March with orders on Byrna.com up 86% over March of last year, even though the Byrna product line is now also offered on Amazon.com.
Amazon sales are also showing steady growth. While there is no year-over-year comparison (as Byrna products were not offered on Amazon in Q1 FY2021) over the last several months, we have seen continuous improvement in sales on Amazon.com. Average daily sales in January of this year were $7,569. In February this climbed to $8,596. By March, average daily sales were $10,033 (with the second half of the month clocking in at $12,090). Amazon has now increased Byrna's allocated "shelf-space" to more than 18,000 units and while we have not yet filled this space, we expect to do so in the next several weeks. We believe that as we fill this space, we will see continued steady growth in Amazon sales. Based on observed trends in demand and the new product development pipeline we reiterate our full year revenue guidance of $55 - $60 million.
Finally, margins were up nicely in Q1, coming in at 57.8% compared to 53.3% in Q1 FY21 and 51.1% in Q4 FY21 (where margins were hurt by Black Friday specials). We were very pleased with this significant margin improvement as Q1 FY22 margins were negatively impacted by both the low production volumes and very high inbound freight. As production levels improve and as we reduce inbound freight through better packaging and by shifting some shipments to ocean freight from airfreight, we expect to see gross profit margins steadily improve throughout the year.
While operating costs were up $2.9 million year-over-year, from $5.2 million to $8.0 million, they were down $0.8 million quarter-over-quarter coming in at $8.0 million in Q1 FY22 versus $8.8 million in Q4 FY21. This indicates a leveling off in Byrna's operating expense budget. Eliminating non-cash items, operating expenses for Q1 FY22 were $6.45 million and should remain reasonably constant at this level for the remainder of FY 22 with the only increases coming from one-time charges and additional variable operating expenses such as credit card fees, Amazon fees and outbound freight which will all increase as sales increase.
The year-over-year increase stems from Byrna's investment in growing the business. Advertising and marketing spend was up $1.1 million year-over-year as Byrna significantly increased its advertising budget to build brand awareness and drive consumers to Byrna's website. This resulted in sessions for the quarter growing from 852,000 in Q1 FY21 to 1.6 million in Q1 FY22. Additionally, people costs were up $0.8 million as Byrna added the staff in the areas of IT, R&D, Supply Chain, Accounting and Sales & Marketing to be able to continue to grow the business. Travel was also up by $0.1 million as Byrna's employees hit the road after two years of quarantine. Finally, Byrna's topline growth and its uplisting to Nasdaq added $0.5 million to Byrna's public company costs in the areas of D&O insurance and franchise taxes.
With improvements across the board in production, sales and margins, coupled with a flat operating expense budget, Byrna expects positive adjusted EBITDA1 in Q3 of FY22.
Conference Call
Byrna Technologies will host a conference call later this morning at 9:00 am ET to review these results. To listen to the call live, dial (201) 689-8354 or (877) 709-8150 and ask for the Byrna Technologies call. The question-and-answer portion of the call will be open to industry research analysts. To listen to a simultaneous webcast of the call, please visit ir.byrna.com ten minutes prior to the start of the call and click on the Investors section to download and install any necessary audio software. If you are unable to listen live, the conference call webcast will be archived on Byrna Technologies' website for thirty days.
About Byrna Technologies Inc.
Byrna is a technology company, specializing in the development, manufacture, and sale of innovative non-lethal personal security solutions. For more information on the Company, please visit the corporate website here https://byrna.com/ or the Company's investor relations site here ir.byrna.com. The Company is the manufacturer of the Byrna® SD personal security device, a state-of-the-art handheld CO2 powered launcher designed to provide a non-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company's e-commerce store www.byrna.com.
Forward Looking Information
This news release contains "forward-looking statements" within the meaning of the securities laws. All statements contained in this news release, other than statements of current and historical fact, are forward-looking. Often, but not always, forward-looking statements can be identified by the use of words such as "plans," "expects," "intends," "anticipates," and "believes" and statements that certain actions, events or results "may," "could," "would," "should," "might," "occur," or "be achieved," or "will be taken." Forward-looking statements include descriptions of currently occurring matters which may continue in the future. Forward-looking statements in this news release include but are not limited to the Company's statements related to supply chain disruptions and shipments from suppliers, our ability to handle unplanned increases in sales, seasonal trends in sales, growth in Amazon sales and our ability to fill "shelf-space", our ability to reduce freight costs and shift from air freight to ocean freight, our gross profit margins and future profitability, and our operating expenses and the components thereof. Forward-looking statements are not, and cannot be, a guarantee of future results or events. Forward-looking statements are based on, among other things, opinions, assumptions, estimates, and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies, and other factors that may cause actual results and events to be materially different from those expressed or implied.
Any number of risk factors could affect our actual results and cause them to differ materially from those expressed or implied by the forward-looking statements in this news release, including, but not limited to, disappointing market responses to current or future products or services; prolonged, new, or exacerbated disruption of our supply chain; the further or prolonged disruption of new product development; production or distribution or delays in entry or penetration of sales channels due to inventory constraints, competitive factors, pandemic-related factors, civil unrest, increased shipping costs or freight interruptions; prototype, parts and material shortages, particularly of parts sourced from limited or sole source providers; reduced air freight capacity,; determinations by third party controlled distribution channels, including Amazon, not to carry or reduce inventory of our products; potential cancellations of existing or future orders including as a result of any fulfillment delays, introduction of competing products, negative publicity, or other factor; ransomware attack or data breach, product design defects or recalls; litigation, enforcement proceedings or other regulatory or legal developments; changes in consumer or political sentiment affecting product demand; regulatory factors including the impact of commerce and trade laws and regulations; import-export related matters or sanctions or embargos that could affect the Company's supply chain or markets; delays in planned operations related to licensing, registration or permit requirements; and future restrictions on the Company's cash resources, increased costs and other events that could potentially reduce demand for the Company's products or result in order cancellations. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive; accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, ("Risk Factors") in our most recent Form 10-K, should understand it is impossible to predict or identify all such factors or risks, should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking information. The Company assumes no obligation to update or revise any forward-looking information, except as required by applicable law.
Non-GAAP Financial Metrics
In addition to providing financial measurements based on generally accepted accounting principles in the United States (GAAP), we provide the following additional financial metrics that are not prepared in accordance with GAAP (non-GAAP): adjusted EBITDA, non-GAAP net loss, and non-GAAP net loss per share. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. We believe that these non-GAAP financial measures help us to identify underlying trends in our business that could otherwise be masked by the effect of certain expenses that we exclude in the calculations of the non-GAAP financial measures.
Accordingly, we believe that these non-GAAP financial measures reflect our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business and provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.
These non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. There are limitations in the use of non-GAAP measures, because they do not include all the expenses that must be included under GAAP and because they involve the exercise of judgment concerning exclusions of items from the comparable non-GAAP financial measure. In addition, other companies may use other non-GAAP measures to evaluate their performance, or may calculate non-GAAP measures differently, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.
Adjusted EBITDA
Adjusted EBITDA is defined as net (loss) income as reported in our condensed consolidated statements of operations and comprehensive (loss) income excluding the impact of (i) depreciation and amortization; (ii) income tax provision (benefit); (iii) interest income (expense); (iv) stock-based compensation expense; and (v) other expenses. Our Adjusted EBITDA measure eliminates potential differences in performance caused by variations in capital structures (affecting finance costs), tax positions, the cost and age of tangible assets (affecting relative depreciation expense) and the extent to which intangible assets are identifiable (affecting relative amortization expense). We also exclude certain one-time and non-cash costs. Reconciliation of Adjusted EBITDA to comprehensive net (loss) income, the most directly comparable GAAP measure, is as follows (in thousands):
Non-GAAP net income (loss) and non-GAAP net income (loss) per share
Non-GAAP net loss is defined as net (loss) income as reported in our condensed consolidated statements of operations and comprehensive (loss) income excluding the impact of (i) stock-based compensation expense and (ii) other expenses. Our non-GAAP net loss measure eliminates potential differences in performance caused by certain non-cash and one-time costs. We also provide non-GAAP net loss per share by dividing non-GAAP net loss by the average basic shares outstanding for the period. Reconciliation of Non-GAAP comprehensive (loss) income to Comprehensive net (loss) income, the most directly comparable GAAP measure, is as follows (in thousands):
1 See non-GAAP financial measures at the end of this press release for a reconciliation and a discussion of non-GAAP financial measures.
View original content to download multimedia:
SOURCE Byrna Technologies Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/byrna-technologies-reports-first-quarter-2022-financial-results/
| 2022-04-06T12:59:31
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/byrna-technologies-reports-first-quarter-2022-financial-results/
|
VANCOUVER, BC, April 6, 2022 /PRNewswire/ - Capella Minerals Ltd. (TSXV: CMIL) (OTCQB: CMILF) (FRA: N7D2) (the "Company" or "Capella") is pleased to announce that it has signed an Exploration and Exploitation Agreement ("EEA") with Hessjøgruva AS for the acquisition of a 100% interest in the advanced exploration-stage Hessjøgruva Copper-Zinc-Cobalt ("Cu-Zn-Co") project in central Norway. The Hessjøgruva project is located approximately 20km SW of the Company's 100%-owned Kjøli Cu-Zn-Co project (Figure 1) and has a current mineral inventory (non-Canadian National Instrument NI 43-101 compliant mineral resource) of 3MT @ 1.7% Cu + 1.4% Zn1,2 (or 2.2% Cu equivalent3) based on a total of 12,139m / 68 holes of historical diamond drilling.
The Hessjøgruva project provides Capella with a potential near-term development asset which complements the Company's ongoing exploration activities at the adjacent Kjøli project. Both Hessjøgruva AS and local government / communities will benefit directly from the successful advancement and development of the Hessjøgruva project, with copper and cobalt also being key metals required for zero-carbon energy transmission and for battery/energy storage.
Highlights
- Capella to acquire a 100% interest in the advanced-stage Hessjøgruva Cu-Zn-Co project.
- Hessjøgruva's current mineral inventory (non-Canadian National Instrument NI 43-101 compliant mineral resource) is 3MT @ 1.7% Cu + 1.4% Zn1,2 (or 2.2% Cu equivalent3), based on 12,139m / 68 holes of diamond drilling completed by previous operators in the 1970's. Historical assaying was focused principally on copper and zinc (but not cobalt).
- The Cu-Zn-Co mineralization at Hessjøgruva is massive-sulfide ("VMS")-type, identical to the mineralization type being targeted at Kjøli. The Hessjøgruva mineralization occurs primarily in three lenses (A-C, with Lens A hosting most of the high-grade mineralization; Figures 2-4), all of which extend from surface to >400m vertically below surface and all remain open down-dip. Mineralization is dominated by chalcopyrite, pyrite/pyrrhotite, and sphalerite, with Cu content observed to increase with depth in the deposit.
- The average thickness of the highest-grade Lens A is approximately 10m1, with the thickest and highest-grade intercept reported from the historical drilling being 14.5m @ 4.35% Cu + 1.3% Zn (or 4.8% Cu equivalent2) (approximate true thickness) from 455.5m to 470m downhole in DDH-312. This Cu-Zn-Co mineralization remains open down dip.
- As part of a due-diligence process, the Company completed a systematic resampling program of the Hessjøgruva drill core stored at the NGU storage facility in Løkken. A total of 113 quarter core samples were taken for analysis and confirmed: i) the reliability of copper and zinc grades reported from historical drilling, and ii) the existence of elevated cobalt concentrations (ranging from below detection limit to 0.1% Co) within the re-assayed core intervals.
- The combined Hessjøgruva and Kjøli projects provide Capella with both a potential near-term development project as well as significant exploration upside within the past producing Røros Mining District of central Norway.
Eric Roth, Capella's President and CEO, commented: "The acquisition of the advanced-stage Hessjøgruva copper-zinc-cobalt project provides Capella with a potential near-term growth platform in the broader Kjøli district. The advancement of Hessjøgruva will also bring significant tangible benefits to both Hessjøgruva AS and local communities / government, all of which have been strongly supportive of our exploration activities at Kjøli. Our partnership with Hessjøgruva AS will also provide Capella with significant local knowledge and operating "know how"'.
Our strict compliance to ESG (Environmental, Social and Governance) principles will also ensure that we continue to work with net zero-carbon emission standards and with maximum respect towards both local communities and the environment.
We expect our first priority to be the completion of an NI 43-101 compliant mineral resource for the project, which is expected to also lead to further infill and step-out drilling. Subsequently, we expect to initiate some of the development-related studies (such as metallurgical testwork) that a scoping-level mining study would require. I look forward to keeping all stakeholders updated as the Hessjøgruva project moves forward."
2022 and Beyond Work Program at Hessjøgruva
The Company's expected work plans for the Hessjøgruva project commencing immediately are:
i) The completion of a Canadian National Instrument 43-101 ("NI 43-101") compliant Mineral Resource Estimate ("MRE"). In addition to producing a formal MRE, this study would identify those areas where infill drilling is required (in order to potentially upgrade the category of the existing mineral inventory) in addition to determining where step-out drilling would have the highest probability of extending known mineralization.
ii) Subsequent to the completion of the MRE and further recommended drilling, Capella would initiate a Preliminary Economic Assessment in order to evaluate potential mining, mineral processing, and infrastructure requirements of the project.
Terms of the Hessjøgruva Acquisition
Capella may acquire a 100% interest in the Hessjøgruva Cu-Zn-Co project in return for:
i) Capella managing and funding exploration / development activities on the project.
ii) Capella paying Hessjøgruva AS a one-time amount of Euro 500,000 upon completion of a positive Bankable Feasibility Study.
iii) Capella providing Hessjøgruva AS with a 2.5% Net Smelter Royalty ("NSR") on all future metal production from the project, retaining an option to buy-back 0.5% of this NSR at any time prior to the commencement of commercial production for Euro 1,000,000.
iv) Capella to cover the cost of annual property payments and basic administration costs.
Quality Assurance / Quality Control (QA/QC)
Capella utilizes industry-standard exploration sampling methodologies and techniques. All soil, stream, and rock (including drill core) samples are collected under the supervision of the Company's geologists and in accordance with best industry practices. Drill core samples taken as part of the Hessjøgruva due diligence were quarter core and were cut from half core stored at the NGU's covered core storage facility at Løkken. All samples were sent to ALS Laboratory's ("ALS") sample preparation facility in Malå, Sweden (ALS code PREP-31Y), and subsequently dispatched to ALS's analytical facilities in Loughrea, Ireland, for multi-element geochemical analysis (ALS codes ME-MS61 and PGM-ICP23). All geochemical assays are subject to quality assurance / quality control programs using a combination of internationally recognized standards, duplicates, and blanks, as provided by both ALS and the Company.
Disclosure Relating to Historical Estimate
In accordance with Section 2.4 of National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"), an issuer may disclose an historical estimate, using the original terminology, if the disclosure identifies the following:
Source and date of the historical estimate, including any existing technical reports
- · Information relating to this historical estimate is summarized from a 2007 technical report prepared for the Geological Survey of Norway ("NGU") by Terje Bjerkgård ("Report 2007.023: The Hersjø ore deposit, evaluation of ore potential").
Relevance and reliability of the historical estimate:
- · The historical estimate for Hessjøgruva was derived from drilling undertaken by three mining companies - Røros Kobberverk AS, AS Sydvaranger, and Killingdal Grubelskap AS - up until 1977. Whilst Capella does not consider the historical estimate to have been completed in accordance with current NI 43-101 standards, it is considered relevant to reporting on the project.
Key assumptions, parameters and methods used to prepare the historical estimate:
- Original (pre-1977) technical reports relating to the calculation of the historical estimate and outlining the assumptions / parameters used have not been sighted by Capella.
Resource category used:
- As the historical estimate is not believed to have been completed in accordance with current NI 43-101 standards, Capella utilizes the terminology "mineral inventory" rather than either mineral resources or mineral reserves to classify the known mineralization.
More recent estimates or data available to the issuer:
- No more recent estimates are currently available to the issuer. A study completed during 2016 (Geometric and Qualimetric Modeling of the Hessjø deposit; Nørsett, S.J.; NTNU M.Sc. Thesis) confirmed most aspects of the geometry of the Cu-Zn-Co mineralization and distribution of Cu-Zn-Co grades as utilized in the historical estimate.
Work needed to be done to upgrade or verify the historical estimate as current mineral resources or mineral reserves:
- An independent Qualified Person ("QP") has not yet done sufficient work to review the historical data and historical estimate to determine what further work would be required to prepare a technical report in accordance with NI 43-101. Capella is in the process of engaging a QP with suitable experience in the deposit style being evaluated in order to prepare a technical report in accordance with NI 43-101.
Capella is not treating the historical estimate as current mineral resources or reserves. At this time, a Qualified Person has not done sufficient work on behalf of Capella to classify this historical estimate as current mineral resources or reserves. Investors should not rely on the historical estimate as a current mineral resource estimate until it has been verified and supported in a technical report in accordance with NI 43-101.
Qualified Persons and Disclosure Statement
The technical information in this news release relating to the Hessjøgruva copper project has been prepared in accordance with Canadian regulatory requirements set out in NI 43-101, and approved by Eric Roth, the Company's President & CEO, a Director, and a Qualified Person under NI 43-101. Mr. Roth holds a Ph.D. in Economic Geology from the University of Western Australia, is a Fellow of the Australian Institute of Mining and Metallurgy (AusIMM) and is a Fellow of the Society of Economic Geologists (SEG). Mr. Roth has 30 years of experience in international minerals exploration and mining project evaluation.
On Behalf of the Board of Capella Minerals Ltd.
"Eric Roth"
___________________________
Eric Roth, Ph.D., FAusIMM
President & CEO
About Capella Minerals Ltd
Capella is engaged in the acquisition, exploration, and development of quality mineral resource properties in favourable jurisdictions with a focus on high-grade gold and copper(-zinc-cobalt) deposits. The Company also holds 1,000,000 common shares (on a post-consolidation basis) in Prospector Metals Corp. (formally Ethos Gold Corp.), providing Capella shareholders with indirect exposure to exploration success at both the Savant Lake JV Project and elsewhere within Prospector's extensive Canadian project portfolio.
The Company's copper(-zinc-cobalt) focus is currently on the discovery of high-grade VMS-type deposits within 100%-owned, district-scale land positions around the past-producing Løkken, Kjøli, and now Hessjøgruva copper mines in central Norway. The Company's precious metals focus is on the discovery of high-grade gold deposits on its recently acquired Finnish properties (Katajavaara, Aakenus), the 100%-owned Southern Gold Line Project in Sweden, and its active Canadian Joint Ventures with Prospector Metals Corp (TSXV: PPP) at Savant Lake (Ontario) and Yamana Gold Inc. at Domain (Manitoba). The Company also retains a residual interest (subject to an option to purchase agreement with Austral Gold Ltd) in the Sierra Blanca gold-silver divestiture in Santa Cruz, Argentina.
Cautionary Notes and Forward-looking Statements
This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding the future results of operations, performance and achievements of Capella, including the timing, completion of and results from the exploration and drill programs described in this release. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by Capella in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading "Risks and Uncertainties" in Capella's most recently filed MD&A. Capella does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking information.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:
SOURCE Capella Minerals Limited
|
https://www.wistv.com/prnewswire/2022/04/06/capella-acquires-advanced-stage-hessjgruva-copper-zinc-cobalt-project-kjli-district-norway/
| 2022-04-06T12:59:37
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/capella-acquires-advanced-stage-hessjgruva-copper-zinc-cobalt-project-kjli-district-norway/
|
The leader in early clinical development expands ADME suite to meet ongoing demand.
LINCOLN, Neb., April 6, 2022 /PRNewswire/ -- Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced that it has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services to meet continuously increasing demand to conduct these studies. This investment includes expanding laboratory space, adding new capabilities as well as a dedicated customer service team.
Celerion has invested in new state-of-the-art equipment and laboratory space to perform on-site scintillation counting allowing for radioactivity recovery results to be delivered in real-time. This service ensures high total recovery of radioactive dose while providing for efficient clinical study conduct. What's more, this investment has also enabled Celerion to double capacity of lab throughput.
In addition to running human ADME studies, Celerion offers innovative metabolite identification and profiling. Celerion is one of the few laboratories using the newest and most advanced High Resolution Mass Spectrometry (HR-MS) Metabolite Profiling and Identification instrumentation and technologies to identify major metabolites, important metabolites (MIST), and unique metabolites.
"With over 100 radiolabeled studies and 800 participants dosed, our experience in ADME studies ensures clients' studies run efficiently and effectively from initial planning through to the final report," said Phil Bach, Celerion's Vice President of Global Clinical Research. "Additionally, our clinical and bioanalytical services are located within the same facility, enabling faster access to quality data and savings in time and cost."
Celerion has dedicated pharmacy staff consisting of Pharm D's and registered technicians with over 40 years of Phase I experience. We have an authorized nuclear pharmacist to run all ADME studies and assign a lead pharmacist to each new study. The pharmacist will be involved with the study from start-up to close out and available for any consultation needed. All pharmacy staff are cross-trained on all protocols and all pharmacy functions. "From compounding formulation through data received our dedicated operational team along with a nuclear pharmacist and lab director work to provide a one stop shop for all of your ADME needs", Bach added.
Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience, and scientific excellence that gives its clients the confidence to make fast, accurate decisions about their drug development path.
For over fifty years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic, and pharmacodynamic studies in highly controlled clinical environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies, as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. In addition, Celerion offers data management, biostatistics, clinical monitoring, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends and people in need around the world. For more information, please visit www.celerion.com.
CONTACT:
Michelle Maklas-Baker
Associate Director, Global Marketing
+1 732-306-7804
michelle.maklasbaker@celerion.com
View original content to download multimedia:
SOURCE Celerion
|
https://www.wistv.com/prnewswire/2022/04/06/celerion-announces-investment-adme-suite-services/
| 2022-04-06T12:59:44
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/celerion-announces-investment-adme-suite-services/
|
MANASSAS, Va., April 6, 2022 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of six new wastewater-based epidemiology centers of excellence. The new centers add to the nine existing centers of excellence previously announced in November 2021 and to the wastewater testing program in metro-Atlanta that is being run by Emory University, all supported by an $8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative.
These sixteen sites encompass non-profit, university, public health, and commercial testing labs located in fourteen states, including Arizona, California, Connecticut, Illinois, Georgia, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, New York, Texas, West Virginia, and Wisconsin and are providing wastewater testing services to forty states.
The centers are regularly monitoring wastewater from a wide range of sources, including from wastewater treatment plants to provide information on overall virus trends in a county or city; from sewersheds to support decision-making for public health resource allocation at a neighborhood level; and from building-level locations like college dorms, skilled nursing facilities, correctional facilities, K-12 schools, summer camps, and airports.
Each center was selected based on its ability to utilize the expanded capacity to extend services into underserved and underprivileged communities and is expected to share results with local and state public health authorities, as well as to submit data to the CDC National Wastewater Surveillance System (NWSS).
Each center of excellence received the materials and on-site training to implement an automated Nanotrap® particle protocol, which enables same-day delivery of wastewater testing results for over 100 samples per day. Extracted nucleic acids from this automated protocol are compatible with multiple nucleic acid detection methods, including reverse transcription-quantitative polymerase chain reaction (RT-qPCR), reverse transcription-droplet digital PCR (RT-ddPCR), and genomic sequencing.
"The wastewater testing capacity that this NIH-funded program has established nationwide is proving critical for monitoring the rise of new SARS-CoV-2 variants," said Ben Lepene, Chief Technology Officer at Ceres Nanosciences. "I'm also very excited by the data we are seeing that demonstrate that the same method can be used to enable wastewater monitoring of a much wider range of infectious disease, including other viruses, bacteria, and parasites."
Full details are available at https://www.ceresnano.com/press-release-coe16
Press Contact:
Ross M. Dunlap
Ceres Nanosciences, Inc
1.800.615.0418 ext. 202
rdunlap@ceresnano.com
www.ceresnano.com
View original content to download multimedia:
SOURCE Ceres Nanosciences, Inc
|
https://www.wistv.com/prnewswire/2022/04/06/ceres-nanosciences-establishes-sixteen-wastewater-based-epidemiology-centers-excellence-under-nih-radx-initiative/
| 2022-04-06T12:59:51
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/ceres-nanosciences-establishes-sixteen-wastewater-based-epidemiology-centers-excellence-under-nih-radx-initiative/
|
Virtual conference for investment and wealth professionals set to welcome more than 3,000 delegates
NEW YORK, April 6, 2022 /PRNewswire/ -- CFA Institute, the global association of investment professionals, today announced the agenda for its flagship conference, Alpha Summit GLOBAL, set to take place between 17 and 19 May 2022. Registration is now open.
A fully virtual three-day event, Alpha Summit GLOBAL will address the industry's biggest challenges and trends. Calling on investment leaders and practitioners to "think beyond the horizon," Alpha Summit GLOBAL will deliver engagement with renowned industry leaders, investors, academics, entrepreneurs, and best-selling authors through five key themes:
- Opportunities and Responsibilities with Sustainable Investing: including ESG Standards and how finance can directly help society through investment. Sessions include:
- Excelling in a Post-Pandemic World: compelling the investment industry to build back better and smarter through beneficial systems and behaviors that can prepare the world for long-run risks. Sessions include:
- Harnessing the Benefits of Innovation and Technology: unlocking disruptive technologies to digitally transform internal processes, analytical skills, and customer experiences. Sessions include:
- The Future of Capital Markets Today: preparing investors to face the macro risks and uncertainties and continual market evolution and applying the skills required to help shape a better future for society through investment. Sessions include:
- Advancements for the Investment Management Professional: elevating and expanding knowledge and skills through organizational systems, technologies, and relationships to optimize the client experience. Sessions include:
Barbara Pettit, CFA, Managing Director, Professional Learning at CFA Institute, comments:
"Investment professionals are seeking high-quality continuous learning to ensure they remain ready to lead and support clients through the many acute and significant challenges facing investors. Our Alpha Summit will connect industry leaders, investors, analysts, advisors, and wealth managers with the content they need. I encourage all investment professionals to mark their calendars and register for this once-a-year global event."
Alpha Summit GLOBAL is sponsored by PGIM, the global asset management business of Prudential Financial Inc.
To register to attend Alpha Summit GLOBAL, or to view the full agenda, please visit here.
#AlphaSummit
For more information, contact PR@CFAInstitute.org
Alpha Summit is a three-part global and regional conference series for investment professionals hosted by CFA Institute. Alpha Summit GLOBAL is the third in the series, with delegate access available through Basic (free to register) and Premium package options. Early registration pricing is available for delegates enrolling before 19 April 2022. Delegates are eligible to earn up to 12 Professional Learning (PL) credits, including 2.25 Standards, Ethics, and Regulation credits. PL Credits for CFA Institute members and CFA charterholders registering through their online CFA Institute login will be automatically applied. APAC and EMEA Alpha Summit content, recorded in February 2022, is available on-demand here.
CFA Institute is the global association of investment professionals that sets the standard for professional excellence and credentials. The organization is a champion of ethical behavior in investment markets and a respected source of knowledge in the global financial community. Our aim is to create an environment where investors' interests come first, markets function at their best, and economies grow. There are more than 180,000 CFA® charterholders worldwide in more than 160 markets. CFA Institute has nine offices worldwide and there are 160 local societies. For more information, visit www.cfainstitute.org or follow us on LinkedIn and Twitter at @CFAInstitute.
View original content:
SOURCE CFA Institute
|
https://www.wistv.com/prnewswire/2022/04/06/cfa-institute-announces-agenda-flagship-alpha-summit-global/
| 2022-04-06T12:59:58
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/cfa-institute-announces-agenda-flagship-alpha-summit-global/
|
Company continues to drive global patient enrollment in pivotal study of Berubicin
HOUSTON, April 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and from the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
"Access to patients is the lifeblood of any clinical study and this approval, in the second most populous country in Europe, provides just that for our Berubicin trial. We have said time and again that our number one priority is the advancement of this potentially pivotal study. This is evidenced by our continuous dedication to driving enrollment and bringing global clinical sites on line. We are grateful to the French Competent Authority and Ethics Committee and their positive feedback on what we believe is an incredibly important clinical program. Across the globe there is an urgent need for GBM treatment options. We will continue to press on in our efforts to advance Berubicin through the clinic and importantly, to patients and their families. I am proud of the progress our team has made to-date and believe there are additional clinical sites to join those that have already been added to this globlal potentially pivotal study," commented John Climaco, CEO of CNS Pharmaceuticals.
Dr. Carole Gourmelon, MD, Institut de Cancérologie de l'Ouest, St Herblain, added, "GBM is a devastating disease with significant unmet need. I have been encouraged by the data Berubicin has demonstrated to date and look forward to further evaluating its potential to provide benefit to patients. Now with the necessary approvals received, I look forward to joining the Company's efforts to progress Berubicin through the clinic."
Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The potentially pivotal global trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line therapy. Approximately 243 patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive Berubicin or lomustine for the evaluation of Overall Survival, the primary endpoint of the study. Overall Survival is a rigorous endpoint that the U.S. Food and Drug Administration (FDA) has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm.
A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.
The FDA recently granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with the FDA to expedite the development and review process. As previously announced, the Company also received Orphan Drug Designation from the FDA which may provide seven years of marketing exclusivity upon approval of an NDA.
For more information about the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069.
About Berubicin
Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company's cash runway to extend until Q1 2022 and the timing of patient dosing to commence. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:
SOURCE CNS Pharmaceuticals, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/cns-pharmaceuticals-receives-approval-france-ethics-committee-competent-authority-potentially-pivotal-study-berubicin-treatment-glioblastoma-multiforme-gbm/
| 2022-04-06T13:00:05
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/cns-pharmaceuticals-receives-approval-france-ethics-committee-competent-authority-potentially-pivotal-study-berubicin-treatment-glioblastoma-multiforme-gbm/
|
DALLAS, April 6, 2022 /PRNewswire/ -- Consilium Staffing, a premier locum tenens healthcare staffing firm bringing doctors and advanced practitioners to facilities nationwide, announced that it has tapped John Moberly to lead the firm's anesthesia practice area as Divisional Vice President of Anesthesia.
In this role, Moberly will be responsible for developing key strategic initiatives related to the procurement and recruitment of Anesthesiologists and Certified Registered Nurse Anesthesiologists (CRNAs), along with expanding the reach of the Anesthesia Division to serve more communities that are in need of anesthesia-related services.
The impetus for Moberly's move is based partly on the skyrocketing demand for locum tenens providers, and in particular, locums Anesthesiologists and CRNAs. As elective surgeries and procedures open back up after being sidelined during the height of the COVID-19 pandemic, hospitals and healthcare facilities are striving to book patients and catch up. As a result, anesthesia providers continue to be at the forefront of locum tenens demand for Consilium Staffing — and the overall locums industry.
Prior to this role, Moberly was Vice President of Recruiting, where he was responsible for hiring, developing, and training recruiters. Moberly was also a company Vice President for 10 years. Before co-founding Consilium Staffing in 2010, Moberly co-founded Med Travelers and grew the company to $41 million in just nine years. He began his locum tenens recruiting career before that working at StaffCare.
"John is an industry veteran, consummate professional, and an all-around great person to work with," said Matthew Baade, Executive Vice President of Consilium. "His leadership and ability to mentor will help us better address the growing demand in the anesthesia practice area for locum tenens providers."
ABOUT CONSILIUM STAFFING
Consilium Staffing is a premier locum tenens company offering temporary healthcare providers to medical facilities nationwide. For more information, please visit Consilium Staffing and follow us on LinkedIn, Facebook, Twitter, and Instagram.
Media contact:
Katy Morehouse
214-272-6935
kmorehouse@consiliumstaffing.com
View original content to download multimedia:
SOURCE Consilium Staffing
|
https://www.wistv.com/prnewswire/2022/04/06/consilium-staffing-names-john-moberly-new-divisional-vice-president-anesthesia/
| 2022-04-06T13:00:11
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/consilium-staffing-names-john-moberly-new-divisional-vice-president-anesthesia/
|
NEW YORK, April 6, 2022 /PRNewswire/ -- On April 1, 2022, Credit Suisse declared a Coupon Amount for the Credit Suisse S&P MLP Index ETN (the "ETN").
Press Contact
Andre Rosenblatt, Credit Suisse, andre.rosenblatt@credit-suisse.com
Credit Suisse ETNs
Telephone +1 800 320 1225, ETN.Desk@credit–suisse.com
The ETNs may not be suitable for all investors and should be purchased only by knowledgeable investors who understand the potential consequences of investing in the ETNs. The ETNs are subject to the credit risk of Credit Suisse. You may receive less, and possibly significantly less, than the principal amount of your investment at maturity or upon repurchase or sale. Investors will not have any partnership interests or other rights in the MLPs included in the index. Coupon Amounts on the ETNs will vary and could be zero. An investment in the ETNs involves significant risks. For further information regarding risks, please see the section entitled "Risk Factors" in the applicable pricing supplement.
Credit Suisse is one of the world's leading financial services providers. Our strategy builds on Credit Suisse's core strengths: its position as a leading wealth manager, its specialist investment banking capabilities and its strong presence in our home market of Switzerland. We seek to follow a balanced approach to wealth management, aiming to capitalize on both the large pool of wealth within mature markets as well as the significant growth in wealth in Asia Pacific and other emerging markets, while also serving key developed markets with an emphasis on Switzerland. Credit Suisse employs approximately 50,110 people. The registered shares (CSGN) of Credit Suisse Group AG, are listed in Switzerland and, in the form of American Depositary Shares (CS), in New York. Further information about Credit Suisse can be found at www.credit-suisse.com.
Disclaimer
This document was produced by and the opinions expressed are those of Credit Suisse as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of Credit Suisse to any person to buy or sell any security. Any reference to past performance is not necessarily a guide to the future. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but Credit Suisse does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof.
Credit Suisse has filed a registration statement (including a prospectus) with the Securities and Exchange Commission, or SEC, for the offering to which this press release relates. Before you invest, you should read the applicable Pricing Supplement, the Prospectus Supplement dated June 18, 2020, and the Prospectus dated June 18, 2020 that Credit Suisse has filed with the SEC for more complete information about Credit Suisse and this offering. You may obtain these documents without cost by visiting EDGAR on the SEC website at www.sec.gov or clicking the hyperlink below:
Pricing Supplement dated November 9, 2020:
https://www.sec.gov/Archives/edgar/data/1053092/000089109220012081/e11689-424b2.htm
Alternatively, Credit Suisse, Credit Suisse Securities (USA) LLC or any agent or any dealer participating in this offering will arrange to send you the applicable pricing supplement, prospectus supplement and prospectus if you so request by calling 1-800-320-1225.
This document was produced by and the opinions expressed are those of Credit Suisse as of the date of writing and are subject to change.
Copyright © 2022, CREDIT SUISSE GROUP AG and/or its affiliates. All rights reserved.
View original content to download multimedia:
SOURCE Credit Suisse AG
|
https://www.wistv.com/prnewswire/2022/04/06/credit-suisse-announces-coupon-amount-its-credit-suisse-sampp-mlp-index-etn-ticker-symbol-mlpo/
| 2022-04-06T13:00:18
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/credit-suisse-announces-coupon-amount-its-credit-suisse-sampp-mlp-index-etn-ticker-symbol-mlpo/
|
NEW YORK, April 6, 2022 /PRNewswire/ -- On April 1, 2022, Credit Suisse announced expected coupon payments for the following ETNs:
Press Contact
Andre Rosenblatt, Credit Suisse, andre.rosenblatt@credit-suisse.com
Credit Suisse ETNs
Telephone +1 800 320 1225, ETN.Desk@credit-suisse.com
The ETNs may not be suitable for all investors and should be purchased only by knowledgeable investors who understand the potential consequences of investing in the ETNs. The ETNs are subject to the credit risk of Credit Suisse. You may receive less, and possibly significantly less, than the principal amount of your investment at maturity or upon repurchase or sale. Coupon payments on the ETNs will vary and could be zero. There is no actual portfolio of assets in which any investor in the ETNs has any ownership or other interest. Investors in the ETNs do not have voting rights, distribution rights or other rights with respect to the assets included in the tracked indices. An investment in the ETNs involves significant risks. For further information regarding risks, please see the section entitled "Risk Factors" in the applicable pricing supplement.
Credit Suisse
Credit Suisse is one of the world's leading financial services providers. Our strategy builds on Credit Suisse's core strengths: its position as a leading wealth manager, its specialist investment banking capabilities and its strong presence in our home market of Switzerland. We seek to follow a balanced approach to wealth management, aiming to capitalize on both the large pool of wealth within mature markets as well as the significant growth in wealth in Asia Pacific and other emerging markets, while also serving key developed markets with an emphasis on Switzerland. Credit Suisse employs approximately 50,110 people. The registered shares (CSGN) of Credit Suisse Group AG, are listed in Switzerland and, in the form of American Depositary Shares (CS), in New York. Further information about Credit Suisse can be found at www.credit-suisse.com.
Disclaimer
This document was produced by and the opinions expressed are those of Credit Suisse as of the date of writing and are subject to change. It has been prepared solely for information purposes and for the use of the recipient. It does not constitute an offer or an invitation by or on behalf of Credit Suisse to any person to buy or sell any security. Any reference to past performance is not necessarily a guide to the future. The information and analysis contained in this publication have been compiled or arrived at from sources believed to be reliable but Credit Suisse does not make any representation as to their accuracy or completeness and does not accept liability for any loss arising from the use hereof.
Credit Suisse has filed a registration statement (including a prospectus) with the Securities and Exchange Commission, or SEC, for the offering to which this press release relates. Before you invest, you should read the applicable Pricing Supplement, the Prospectus Supplement dated June 18, 2020 and the Prospectus dated June 18, 2020 that Credit Suisse has filed with the SEC for more complete information about Credit Suisse and this offering. You may obtain these documents without cost by visiting EDGAR on the SEC website at www.sec.gov or clicking the hyperlinks below:
USOI:
Pricing Supplement dated March 23, 2022, including the Prospectus Supplement dated June 18, 2020, and Prospectus dated June 18, 2020:
https://notes.credit-suisse.com/api/DocFile/GetProspectus/USOI
GLDI:
Pricing Supplement dated May 24, 2021, including the Prospectus Supplement dated June 18, 2020, and Prospectus dated June 18, 2020:
https://notes.credit-suisse.com/api/DocFile/GetProspectus/GLDI
SLVO:
Pricing Supplement dated June 24, 2021, including the Prospectus Supplement dated June 18, 2020, and Prospectus dated June 18, 2020:
https://notes.credit-suisse.com/api/DocFile/GetProspectus/SLVO
Alternatively, Credit Suisse, Credit Suisse Securities (USA) LLC or any agent or any dealer participating in this offering will arrange to send you the applicable pricing supplement, prospectus supplement and prospectus if you so request by calling 1-800-320-1225.
This document was produced by and the opinions expressed are those of Credit Suisse as of the date of writing and are subject to change.
X-Links® is a registered trademark of Credit Suisse Securities (USA) LLC.
Copyright © 2022, CREDIT SUISSE GROUP AG and/or its affiliates. All rights reserved.
View original content to download multimedia:
SOURCE Credit Suisse AG
|
https://www.wistv.com/prnewswire/2022/04/06/credit-suisse-announces-coupon-payments-expected-coupon-payments-credit-suisse-x-links-exchange-traded-notes-etns/
| 2022-04-06T13:00:27
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/credit-suisse-announces-coupon-payments-expected-coupon-payments-credit-suisse-x-links-exchange-traded-notes-etns/
|
WAKEFIELD, Mass., April 6, 2022 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the first quarter ended March 31, 2022 after market close on May 9, 2022.
Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company's operational and financial highlights.
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until May 16, 2022 and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 (Canada) or +1-412-317-0088 (International) and entering replay pin number: 3727058
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 23 states with 128 dispensaries, 26 cultivation sites, and employs over 5,600 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Curaleaf IR Twitter Account: https://twitter.com/Curaleaf_IR
Investor Toolkit: https://ir.curaleaf.com/investor-toolkit
Investor Relations Website: https://ir.curaleaf.com/
Investor Contact:
Curaleaf Holdings, Inc.
IR@curaleaf.com
Media Contact:
Tracy Brady, VP Corporate Communications
media@curaleaf.com
View original content:
SOURCE Curaleaf Holdings, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/curaleaf-report-first-quarter-2022-financial-operational-results/
| 2022-04-06T13:00:37
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/curaleaf-report-first-quarter-2022-financial-operational-results/
|
From April 15 – 18, Planet Fitness Invites Members and Non-Members Alike to Reset and Unwind from Tax Season Stress at All Clubs Nationwide
HAMPTON, N.H. , April 6, 2022 /PRNewswire/ -- Planet Fitness, one of the largest and fastest-growing franchisors and operators of fitness centers with more members than any other fitness brand, invites everyone – whether a member of the Judgement Free Zone® or not – to de-stress and relax this tax season with a free workout and HydroMassage® at any of its more than 2,200 locations nationwide. The limited-time offer* is available from April 15 – 18. Beginning April 15, visit PlanetFitness.com/Hydro for a coupon to redeem in-club. Find the nearest club here.
HydroMassage, currently a benefit to all Planet Fitness Black Card® members, provides a convenient way to enjoy the relaxing benefits of a massage, typically enjoyed either pre-workout to loosen tight muscles or post-workout as a cool-down. Travelling jets move up and down the body with wave-like streams of heated water, allowing users to select the exact points where they would like to concentrate the massage, select the desired massage pressure, adjust the speed and even hold the massage in any given area.
"Tax season is a stressful time of year, and Planet Fitness is here to help everyone relax, unwind and feel good with a free workout and HydroMassage," said Jeremy Tucker, chief marketing officer at Planet Fitness. "Exercise can help lift your mood, reduce the risk of anxiety and depression and improve sleep – so put yourself first this tax season and experience all that the Judgement Free Zone has to offer."
Planet Fitness' top priority continues to be keeping its members and employees safe, and is the first fitness brand to receive the WELL Health-Safety Rating for Facility Operations and Management by the International WELL Building Institute (IWBI). The rating recognizes Planet Fitness' leadership in adopting the leading framework to ensure a safer and healthier environment for its employees and members across all of its more than 2,200 facilities.
Enhanced COVID-19 safety and sanitization protocols at its well-ventilated and spacious clubs include:
- Touchless check-in via the free Planet Fitness App
- A Crowd Meter on the Planet Fitness App that allows members to check club capacity in real-time before even leaving the house
- Increased sanitization to continually clean and sanitize high-touch areas, with cleaning stations available for member use
- Mask policies in accordance with local guidelines
Planet Fitness offers extremely low prices and a variety of benefits, including a hassle-free environment, brand name cardio and strength equipment, fully equipped locker rooms, flat screen televisions and much more. The free Planet Fitness App, available to members and non-members alike, puts more than 1,000 exercises right in your pocket with routines for all levels and interests.
To locate the nearest Planet Fitness club and treat yourself to a free workout and HydroMassage from April 15 – 18, please visit PlanetFitness.com/Local-Clubs.
*Offer applies to anyone ages 18+, valid ID required
About Planet Fitness
Founded in 1992 in Dover, NH, Planet Fitness is one of the largest and fastest-growing franchisors and operators of fitness centers in the United States by number of members and locations. As of December 31, 2021, Planet Fitness had 15.2 million members and 2,254 stores in 50 states, the District of Columbia, Puerto Rico, Canada, Panama, Mexico and Australia. The Company's mission is to enhance people's lives by providing a high-quality fitness experience in a welcoming, non-intimidating environment, which we call the Judgement Free Zone®. More than 90% of Planet Fitness stores are owned and operated by independent business men and women.
View original content to download multimedia:
SOURCE Planet Fitness, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/de-stress-this-tax-season-with-free-workout-hydromassage-planet-fitness/
| 2022-04-06T13:00:48
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/de-stress-this-tax-season-with-free-workout-hydromassage-planet-fitness/
|
VANCOUVER, BC, April 6, 2022 /PRNewswire/ - Deep-South Resources Inc. ("Deep-South") (TSXV: DSM) and its affiliate Koryx Copper BV (together, the "Companies") announce the appointment of King & Spalding LLP as international legal counsel. The mandate of King & Spalding is to review the Companies' options under international law in relation to the Namibian government's handling of the Haib Copper Exploration and Prospecting License and the government's refusal to renew the License.
King & Spalding is an international law firm with 1,200 lawyers in 22 countries. The firm specializes in international dispute resolution. King & Spalding's international arbitration practice is consistently ranked among the top arbitration practices in the world. In 2022, the firm's practice is again ranked number one in Global Arbitration Review's "GAR 30" guide to the world's leading international arbitration practices. Global Arbitration Review has praised King & Spalding's track record in obtaining strong results for its clients. Further information is available on: https://www.kslaw.com
Deep-South Resources is a mineral exploration and development company. Deep-South's growth strategy is to focus on the exploration and development of quality assets in significant mineralized trends and in proximity to infrastructure in stable countries. In using and assessing environmentally friendly technologies in the development of its copper project, Deep-South embraces the green revolution.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information contained in this news release which are not statements of historical facts may be "forward-looking information" for the purposes of Canadian securities laws. Such forward-looking information involves risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward looking information. The words "believe", "expect", "anticipate", "contemplate", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule", "understand" and similar expressions identify forward-looking information. These forward-looking statements relate to, among other things: the Minister's refusal to renew the Company's Licence, the Company's intention to contest the Minister's decision before the Courts of Namibia and the outcome of such proceedings.
Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable by Deep-South, are inherently subject to significant technical, political, business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking information. Factors and assumptions that could cause actual results or events to differ materially from current expectations include, among other things: political risks associated with the Company's operations in Namibia; the failure of the Namibian Government to comply with its continuing obligations under the Act to allow for the renewal of the Licence; the impact of changes in, or to the more aggressive enforcement of, laws, regulations and government practices; the inability of the Company and its subsidiaries to enforce their legal rights in certain circumstances. For additional risk factors, please see the Company's most recently filed Management Discussions & Analysis available on SEDAR at www.sedar.com.
There can be no assurances that forward-looking information and statements will prove to be accurate, as many factors and future events, both known and unknown could cause actual results, performance or achievements to vary or differ materially from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements contained herein or incorporated by reference. Accordingly, all such factors should be considered carefully when making decisions with respect to Deep-South, and prospective investors should not place undue reliance on forward looking information. Forward-looking information in this news release is made as at the date hereof. The Company assumes no obligation to update or revise forward-looking information to reflect changes in assumptions, changes in circumstances or any other events affecting such forward-looking information, except as required by applicable law.
View original content to download multimedia:
SOURCE Deep-South Resources Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/deep-south-appoints-king-amp-spalding-international-legal-counsel/
| 2022-04-06T13:00:54
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/deep-south-appoints-king-amp-spalding-international-legal-counsel/
|
AL-KHOBAR, Saudi Arabia, April 6, 2022 /PRNewswire/ -- In recent decades, the interdisciplinary field of futuristic or futures studies has emerged to empower people to expansively envision the future and bring about positive change here in the present. A pivotal event in modern human history that has altered both the course of futuristic studies and revealed the field's value is the COVID-19 pandemic. Societal shutdowns and transformations worldwide in response to the pandemic have demonstrated the need for forward thinking, as well as changed how people interact and learn remotely across borders with newfound ease and open-mindedness.
Just before the pandemic struck, Prince Mohammad Bin Fahd University (PMU) founded the Prince Mohammad Bin Fahd Center for Futuristic Studies (PMFCFS) in 2019 at the university's Al-Khobar campus. With this center, PMU aims to be a pioneer in futures studies not only in its home nation of Saudi Arabia, but also in the broader Middle East and North Africa (MENA) region and worldwide. As the world adapts to the swift change ushered in by the pandemic, PMFCFS is helping shape the education of the next generation of leaders, enhancing the understanding of futures studies, and ultimately delivering the field's benefits to humankind.
"The Prince Mohammad Bin Fahd Center for Futuristic Studies is a world-class institute with a mission to research, identify, and spread the best and most sustainable policy solutions worldwide through futures studies," said Dr. Issa Al Ansari, President of PMU. "We firmly believe peaceful prosperity can be equitably achieved for all people in all places on our shared planet. The coordinated global response to the COVID-19 pandemic has reinforced this view."
In alignment with PMU's mission and vision, PMFCFS aims to position itself among the leading academic institutions in the Middle East as a research-led center. Examples of PMU's global collaboration include the establishment of the first United Nations Educational, Scientific and Cultural Organization (UNESCO) Chair in the Gulf Region at PMU in December 2021. In October 2021, PMU partnered with World Futures Studies Federation (WFSF) in convening the WFSF 24th World Conference, an international event held in Berlin, Germany.
Many other agreements are in place, including a memorandum of understanding (MOU) with Teach the Future, a non-profit futures literacy organization based in Sacramento, California, United States; an MOU with the Association of Professional Futurists (APF) located in Seattle, Washington, United States; and an MOU with the Future Foresight Foundation (FFF) in Abu Dhabi, United Arab Emirates.
Video - https://www.youtube.com/watch?v=wzKDKPJ39IA
Photo - https://mma.prnewswire.com/media/1779612/PMU_Center_Futuristic_Studies.jpg
Logo - https://mma.prnewswire.com/media/1393618/PMU_Logo.jpg
Contact:
Ankit S Bhosale
(+966 13) 849 9346
abhosale@pmu.edu.sa
View original content to download multimedia:
SOURCE Prince Mohammad Bin Fahd University
|
https://www.wistv.com/prnewswire/2022/04/06/delivering-benefits-future-studies-prince-mohammad-bin-fahd-university-pmu/
| 2022-04-06T13:01:03
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/delivering-benefits-future-studies-prince-mohammad-bin-fahd-university-pmu/
|
The Deloitte VMware Distributed Cloud practice will help transform business IT via enhanced capabilities for automation, edge computing, IoT and AI/ML
For the third consecutive year, Deloitte recognized by VMware with 2022 Partner Achievement Award
NEW YORK and PALO ALTO, Calif., April 6, 2022 /PRNewswire/ -- Today, Deloitte and VMware Inc. (NYSE: VMW) announced the creation of the Deloitte VMware Distributed Cloud (DVDC) practice to help clients transform their businesses and the industries they serve by more effectively implementing and utilizing distributed cloud architectures. The Deloitte and VMware alliance, and now the strategic DVDC practice, will help clients more effectively and efficiently implement distributed cloud architectures, including public, private and the edge, to deliver impactful transformations and address unique industry considerations. This launch is the direct result of close alignment and collaboration between Deloitte and VMware, which now sees Deloitte recognized with a VMware Partner Achievement award for the third consecutive year.
The strategic DVDC practice area within Deloitte will provide advanced software engineering and multi-cloud services capabilities to clients to accelerate product velocity, enabled across distributed cloud environments. Deloitte and VMware will help clients pivot to modern software engineering by enhancing developer experience and enabling tools and services to deliver more efficient and effective development and delivery of products and applications. Deloitte's industry cloud solutions bring together pertinent client experience from similar work, leading practices and methods for assured outcomes, pre-integrated ecosystems of software, reference architecture, business transformation elements, and delivery accelerators. VMware Cross-Cloud™ services, particularly VMware Tanzu, will provide a modern cloud-native apps platform in an ecosystem strategy that enables Deloitte to deliver apps to production faster and more securely across industries such as retail, public sector, health care, financial services and automotive.
"The Deloitte VMware Distributed Cloud practice will focus on transforming our client's technology to become an innovation enabler. A leading provider of multi-cloud services, the DVDC practice leverages VMware's innovative multi-cloud infrastructure, management and migration technologies; and Tanzu modern application capabilities with Deloitte's extensive software engineering and digital transformation capabilities to guide organizations through their journey," said Ranjit Bawa, principal and U.S. cloud leader, Deloitte Consulting LLP. "I am extremely proud of how we have scaled this practice area which allows us to deliver modern application and hence business outcomes across on-premises, edge and public cloud."
"VMware and Deloitte have a proven track record of helping clients achieve faster, more predictable outcomes, realize faster time to value on new products and services, and deliver innovation-driven differentiation in the most highly competitive industries around the world," said Zia Yusuf, senior vice president of strategic ecosystem and industry solutions, VMware. "As exemplified by being a multi-year VMware Partner Achievement award winner, it's clear that VMware and Deloitte are fully aligned on our commitment to delivering outcomes as a service to our mutual clients."
For more information about the Deloitte and VMware alliance, visit here. For more information about Deloitte's Hybrid Cloud Practice, go here.
About VMware
VMware is a leading provider of multi-cloud services for all apps, enabling digital innovation with enterprise control. As a trusted foundation to accelerate innovation, VMware software gives businesses the flexibility and choice they need to build the future. Headquartered in Palo Alto, California, VMware is committed to building a better future through the company's 2030 Agenda. For more information, please visit www.vmware.com/company.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's more than 345,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms. VMware and VMware Cross-Cloud are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
VMware, VMware Cross-Cloud, and Tanzu are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
View original content to download multimedia:
SOURCE Deloitte
|
https://www.wistv.com/prnewswire/2022/04/06/deloitte-vmware-collaborate-launch-strategic-distributed-cloud-practice/
| 2022-04-06T13:01:10
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/deloitte-vmware-collaborate-launch-strategic-distributed-cloud-practice/
|
STOCKHOLM, April 6, 2022 /PRNewswire/ -- Devyser´s annual report 2021 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year covers the period from 1 January to 31 December 2020.
The information was submitted for publication, through the agency of the contact persons below, on April 6, 2022 at 14:00 CET.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About Devyser Diagnostics AB (publ)
Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for complex DNA testing within hereditary diseases, oncology, and transplantation. The products are used to guide targeted cancer therapies, to enable a wide array of genetic tests, as well as in post-transplant follow-up. Devyser's product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.
Devyser's shares are listed on Nasdaq First North Growth Market (ticker: DVYSR). The company's certified adviser is Redeye AB, e-mail certifiedadviser@redeye.se and telephone number +46 8 121 576 90. For more information, please visit www.devyser.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Devyser Diagnostics AB
|
https://www.wistv.com/prnewswire/2022/04/06/devyser-publishes-annual-report-2021/
| 2022-04-06T13:01:17
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/devyser-publishes-annual-report-2021/
|
AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC) derived extracellular vesicle (EV) platform technology, announces topline results from its first-in-human, multicenter, Phase II double-blind, placebo-controlled, randomized clinical trial, EXIT COVID-19, today which used the EV product ExoFlo to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS).
"Overall, ExoFlo demonstrated a robust safety and efficacy profile that warrants further clinical investigation with a pivotal Phase III study. In addition to an unequaled reduction in 60-day mortality rate of 37.6% in comparison to placebo, no reportable adverse events were observed," said Dr. Vikram Sengupta, Chief Medical Officer. "ExoFlo also substantially outperformed placebo with respect to time to discharge and ventilator free days. Additionally, subgroup analysis revealed a larger mortality benefit among patients who were severely hypoxic at randomization," he said.
"With the recent emergence of the BA.2 variant, healthcare providers across the US are preparing for another wave of hospitalizations caused by COVID-19 related ARDS. Under the present standard of care, the mortality rate still exceeds thousands of lives per week and ARDS due to COVID-19 remains a leading cause of death in the US. There is still a profound unmet need for a novel therapeutic to address this problem, and we believe that ExoFlo is the solution," said Dr. Sascha Sengupta, Associate Chief Medical Officer.
ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation.
Physicians can learn more and may request information on becoming a study site at http://www.clinicaltrials.gov. For more information on Direct Biologics and regenerative medicine, visit: https://directbiologics.com.
About Direct Biologics
Direct Biologics, LLC, is headquartered in Austin, Texas, with an R&D facility located at the University of California, and an Operations and Order Fulfillment Center located in San Antonio, Texas. Direct Biologics is a market-leading innovator and cGMP manufacturer of regenerative medical products, including a robust extracellular vesicle based biologic platform technology. Direct Biologics' management team holds extensive collective experience in biologics research, development, and commercialization, making it the leader in the evolving space of next generation biologics. Direct Biologics is dedicated to pursuing additional clinical applications of ExoFlo through the FDA's investigational new drug application process. For more information visit https://directbiologics.com.
View original content to download multimedia:
SOURCE Direct Biologics
|
https://www.wistv.com/prnewswire/2022/04/06/direct-biologics-reveals-successful-outcomes-exit-covid-19-phase-ii-clinical-trial/
| 2022-04-06T13:01:23
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/direct-biologics-reveals-successful-outcomes-exit-covid-19-phase-ii-clinical-trial/
|
Local businesses share experiences to shed light on how the internet accounts for 432K jobs and contributes $152B to state GDP in New York
NEW YORK, April 6, 2022 /PRNewswire/ -- After a recent economic study finds direct links between the internet ecosystem and economic growth in New York, New York-based businesses join the national coalition, Internet for Growth, to help tell their individual stories of how they and their businesses have benefited from the internet.
The Economic Impact of the Market-Making Internet, a study released every four years by the Interactive Advertising Bureau (IAB), finds that the internet contributed $152.4 billion to the state's GDP in 2020, and accounts for approximately 432,000 jobs in the Empire State.
The growth in New York State's internet jobs has been remarkable, going from 150,000 in 2012 to just under 432,000 in 2020—a growth rate of 187 percent.
Recently, the IAB helped launched a national coalition, Internet for Growth, to help capture the stories of the millions of creators, entrepreneurs, and small businesses that rely on the ad-supported internet so that as policy makers consider regulations, they have a full understanding of how the internet is being used to help grow and transform our economy. Internet for Growth has more than 300 small business members including several based in New York, including Schneps Media and Myra.
"This type of growth shows how critical the internet really is to the economy in New York State and for businesses of every size and sector," said Josh Schneps, CEO and co-publisher of Schneps Media.
"That's why I've joined the Internet for Growth coalition. I want policymakers to understand how critical the internet has been to my business and how important it is to every part of our state's economy."
According to the study, 15 New York Congressional districts have at least 10,000 internet-dependent jobs. In three of New York's Congressional districts, internet-related jobs employ at least six percent of the population.
This dramatic job growth can be attributed to a number of factors, including the internet's ability to improve and refine advertising and marketing approaches, particularly for small businesses.
"The internet lowers cost to entry for all businesses, but it provides a significant benefit to small businesses," said Greg Laptevsky, Founder and CEO of Myro. "Small businesses and the self-employed created 38 percent of internet jobs—a larger percentage than medium (28%) or large firms (34%). This clearly shows how the internet democratizes business creation, allowing the smallest of firms to compete."
Nationally, the study finds that the internet economy grew seven times faster than the overall total US economy, creating more than 7 million jobs in the last four years.
About Internet for Growth
Internet for Growth, an initiative of the Interactive Advertising Bureau, supports the transformative role the advertising-supported internet plays in empowering America's small businesses, helping entrepreneurs bring their ideas to life. Supported by a diverse community of over 700 IAB members including marketers, agencies, publishers, platforms, and ad tech providers, as well as hundreds of small businesses and creators, we highlight the benefits the internet delivers to local economies, expanding opportunities for innovators to reach markets far beyond their neighborhoods. Our work ensures people understand the limitless opportunity the internet provides for creativity and commerce, fair competition, and connecting with consumers on mutually shared values and interests, no matter the background or geography.
Contact: Lauren Corcoran-Doolin, lcorcorandoolin@gmail.com
View original content:
SOURCE Internet for Growth
|
https://www.wistv.com/prnewswire/2022/04/06/economic-study-prompts-small-businesses-join-coalition-showcase-vital-role-internet-new-york-economy/
| 2022-04-06T13:01:30
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/economic-study-prompts-small-businesses-join-coalition-showcase-vital-role-internet-new-york-economy/
|
Doubling down on its mission to get more money in the hands of women, 90% of Ellevest's Series B investors are women and underrepresented investors, contributing 68% of total funds
NEW YORK, April 6, 2022 /PRNewswire/ -- Ellevest, the financial company built by women for women, today announced a $53M Series B funding round. The round was co-led by BMO and Contour Venture Partners. It included investments from several new women-led investors, including Halogen Ventures, Cleo Capital, New York Ventures of Empire State Development, Stardust Equity, The Venture Collective, and Envestnet, as well as the LGBTQIA+ investment syndicate Gaingels.
Returning institutional investors include Melinda French Gates' Pivotal Ventures, Astia Venture Fund, Khosla, Morningstar, AME Cloud Ventures, Salesforce Ventures, PayPal Ventures, and Allianz Life Insurance Company of North America, as well as individuals like Elaine Wynn.
Ellevest is the first financial company built by women to achieve this level of success, having grown to $1.44B total AUM as of 12/31/21. Ellevest was also named the #1 mission-driven investing offering by Bankrate.*
Ellevest will use the capital to deepen its offerings, providing personalized coaching, product solutions, and community to help women reach their money goals and furthering Ellevest's mission to get more money in the hands of women.
"Ellevest was built by women, for women. It is also funded by women, with 360 women and underrepresented investors participating in this funding round. This group recognizes that women have been disproportionately losing financial ground, and that's bad news for all of us. Ellevest has a key role to play in addressing this issue: to help women — and their families — rewrite their financial narratives and thrive," said Sallie Krawcheck, co-founder and CEO of Ellevest.
"Wonderful things happen when women support women in business. That's why we are proud to stand behind a company that is focused on giving women the tools they need to thrive financially," said Sarah Kunst, managing director at Cleo Capital.**
"There is a massive need for financial products that serve women," said Caroline Lewis, managing partner of Rogue Women's Fund. "Ellevest truly lives by its values, creating space for women and diverse-led firms to be part of its growth story. It's an honor to be one of those firms."**
BMO stands out among the large banks, with a board of directors that includes 50% women in independent board positions and a leadership team that is 40% women.
"Our investment in Ellevest is grounded in the same values that guide us at BMO," said Shannon Kennedy, global president at BMO Family Office. "As a bank, we are committed to growing the good in business and life, supporting women entrepreneurs, and championing gender equality in the workplace and beyond. Investing in Ellevest, a company focused on equity and inclusion, has only furthered that mission, and we're looking forward to supporting their journey."**
Moelis & Company LLC and Cooley LLP advised Ellevest.
To learn more about Ellevest, please visit www.ellevest.com.
About Ellevest
Ellevest is a financial company built by women, for women, providing solutions for all stages of women's financial lives to help them build wealth. Ellevest's offerings include digital investing tools, banking services, professional career and money coaching, and learning resources, as well as private wealth management for high net worth clients who want a personalized financial strategy that may include impact investing. Named best mission-oriented investing service by Bankrate,* Ellevest has built an online community of more than 3 million women working toward financial equality. To learn more, visit ellevest.com. See ellvst.co/series-b-annotated-release for disclosures.
*As of January 4, 2022, rating based on research and data collected by Bankrate between Oct. 4 and Nov. 30, 2021. Bankrate and Ellevest are not affiliated with one another and have no formal relationship. Bankrate is not compensated by Ellevest and Bankrate's opinions are their own.
**Endorsements provided by the individuals referenced above are presented with their permission and based on their equity investments in Ellevest, Inc. as of April 2022. The individuals presented may also be clients of Ellevest and were not compensated in connection with their statements; however, a conflict of interest exists because investors benefit from the success of their investment in Ellevest. The above content is provided for general informational purposes only. A testimonial or endorsement is not a guarantee of successful results.
View original content to download multimedia:
SOURCE Ellevest
|
https://www.wistv.com/prnewswire/2022/04/06/ellevest-raises-53m-series-b-funding-round-backed-by-powerful-roster-women-investors/
| 2022-04-06T13:01:37
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/ellevest-raises-53m-series-b-funding-round-backed-by-powerful-roster-women-investors/
|
SEATTLE, April 6, 2022 /PRNewswire/ -- While Spring Break has yet to wrap for some states, many U.S. travelers are already planning their summer vacations. According to Expedia® data, searches for summer getaways have steadily increased over the last month, with many top destinations seeing double-digit increases week-over-week in March. Destinations seeing a recent spike in interest for June to August travel include Singapore (+60%), Houston (+55%), Bali (+35%) and Washington, D.C. (+35%), indicating travelers are researching getaways both near and far.
With summer vacation FOMO taking hold, Expedia offers a look at the season's trending destinations and tips for helping travelers get more out of their summer trips, including how to score the season's cheapest fares.
"People are ready to make their summer vacations happen no matter what," said Christie Hudson, senior public relations manager for Expedia. "With many travel restrictions easing over the past month, travelers have been inspired to dust off their bucket lists and get a jumpstart on planning. Prices are already reflecting that pent-up demand, so timing is going to be key for getting the best deal."
Summer hotspots
These are some of the trending destinations travelers are eyeing for summer getaways, based on recent spikes in flight searches1:
- Beach bliss: Bali (+35%), Maldives (+25%), Santorini (+20%), Los Angeles (+20%), Bar Harbor (+20%)
- U.S. city breaks: Chicago (+40%), Houston (+55%), Washington, D.C. (+35%), Austin (+30%), New York City (+30%)
- Adventures abroad: Singapore (+60%), Stockholm (+35%), Ontario (+35%), Berlin (+30%), Dubai (+20%)
National and state parks and other outdoor destinations are expected to remain popular this summer as top road-trip destinations, including Mount Rushmore, Banff and Yellowstone National Park.
Best times to travel this summer2
- August is the cheapest month to fly, with average ticket prices (ATPs) nearly 10% lower compared to July and 5% cheaper than June.
- The most expensive day to fly is July 1st, the Friday prior to the July 4th holiday, when average ticket prices are 25% higher than average for summer months.
- Between June and August, the highest ATPs are generally found on Fridays and the cheapest tend to occur on Tuesdays.
Where to fly under $350 roundtrip2
These are a few of the cities where average ticket prices are below $350 for the summer months:
- Fort Lauderdale
- Toronto
- Tampa
- San Antonio
- Houston
- Austin
- Providence
- Myrtle Beach
- Kelowna
- Nashville
- New Orleans
- Charleston
Expert tips for booking this summer's getaway
- Book early and book smart: As with demand, prices will likely increase as the months go by, making last-minute deals harder to find. Travelers should lock in plans early by using "free cancellation" filters on Expedia and choosing flights with waived change fees. While it may be tempting to save a few dollars by choosing restrictive basic economy or saver fares, selecting flexible options will not only save travelers money in the long run but also ensure peace of mind as plans can change.
- Be flexible with dates: When viable, travelers should remain flexible with their travel dates. For instance, choosing a weekday over a weekend or avoiding traveling over the holidays can yield savings. Use fare calendars and create price alerts to track pricing and snag a deal.
- Bundle to save: More likely than not, travelers will need airfare, hotel and sometimes a rental car for a single trip. Booking them together – also known as bundling – on Expedia can save travelers hundreds of dollars.
- Get more with membership: The easiest way to save is by signing up for a free Expedia Rewards account, unlocking access to member pricing of 10% off or more on thousands of hotels. Additionally, members collect points to save on future travel and earn exclusive perks and benefits at top-rated properties around the world.
1Summer hotspots are destinations that saw spikes in flight searches during March for travel between June 1 – August 31, 2022. Search growth compares the first week of March to the last week of March.
2Best time to travel and where to go under $350 roundtrip based on average ticket prices booked through March 28, 2022 for travel between June 1 – August 31, 2022. List is arranged by price, lowest to highest, ranging from $275 – $345.
About Expedia:
Expedia® is one of the world's leading full-service travel brands, with a mission of helping travelers get the most out of every trip they take by providing everything they need all in one place, ensuring they are getting the most out of every trip they take, and above all else, feel supported every step of the way.
Our commitment to insights matched with our unprecedented scale allows us to understand our travelers better than anyone else, delivering exactly what they need, when they need it. Our personalized experiences backed by incredible technology, enables us to deliver the widest selection of product offerings across accommodations, transportation, activities and experiences, that help you get the most out of your journey.
Use our mobile app or visit expedia.com to plan your journey with us.
© 2022 Expedia, Inc., an Expedia Group company. All rights reserved. Expedia and the Airplane logo are trademarks of Expedia, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners. CST# 2029030-50.
Notes to Editor:
Traveler wellbeing is our priority. Expedia understands how the global impact of the coronavirus pandemic continues to affect travelers everywhere, as well as the importance of abiding by government restrictions and practicing social distancing. Travelers can visit the Expedia COVID-19 travel resource page for information to make informed travel decisions.
View original content to download multimedia:
SOURCE Expedia.com
|
https://www.wistv.com/prnewswire/2022/04/06/expedia-releases-summer-travel-cheat-sheet-revealing-cheapest-times-fly/
| 2022-04-06T13:01:44
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/expedia-releases-summer-travel-cheat-sheet-revealing-cheapest-times-fly/
|
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1
PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood vessels, the lymphatic system and other tissues2,3
Approval based on real-world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction in the size of PROS lesions and improvement of PROS-related signs and symptoms
Novartis to offer robust patient support program that includes assistance to access medication, financial resources for eligible patients and continued education
EAST HANOVER, N.J., April 6, 2022 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.1 Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.2,3 In accordance with the Accelerated Approval Program, continued approval may be contingent upon verification and description of clinical benefit from confirmatory evidence.
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9015251-fda-approves-novartis-vijoice-as-treatment-for-pros
"Today's approval of the first treatment for PROS offers hope for a better quality of life to patients and families affected by these rare conditions," said Kristen Davis, Executive Director of CLOVES Syndrome Community. "PROS conditions can be debilitating and disabling and can result in disruptions to everyday activities. Until today, often the only treatment options for patients were surgical or interventional radiology procedures."
PROS conditions can affect quality of life and pose a range of physical, emotional and social challenges for patients and their families, ranging from functional impacts and developmental delays to chronic pain, mobility issues, and feelings of isolation.3-6 PROS management can be challenging, requiring collaboration from a multidisciplinary team, and patients and physicians have only had access to interventions focused on symptom management.6,7
"I am proud of this outstanding achievement for the PROS community. The EPIK-P1 study results build on our earlier pre-clinical findings and demonstrate the efficacy of Vijoice for select PROS conditions, effectively reducing PROS growths," said Guillaume Canaud, MD, PhD, Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, Inserm (INEM Institute Necker Enfants Malades – Centre for Molecular Medicine). "This is a significant advancement in therapy for PROS with the potential to positively change the treatment trajectory and outcomes for patients."
FDA approval was based on real-world evidence from EPIK-P1, a retrospective chart review study that showed patients treated with Vijoice experienced reduced target lesion volume and improvement in PROS-related symptoms and manifestations. The primary endpoint analysis conducted at week 24 showed 27% of patients (10/37) achieved a confirmed response to treatment, defined as 20% or greater reduction in the sum of PROS target lesion volume. Nearly three in four patients with imaging at baseline and week 24 (74%, 23/31) showed some reduction in target lesion volume, with a mean reduction of 13.7%, and no patients experienced disease progression at time of primary analysis. Additionally, at week 24, investigators observed patient improvements in pain (90%, 20/22), fatigue (76%, 32/42), vascular malformation (79%, 30/38), limb asymmetry (69%, 20/29), and disseminated intravascular coagulation (55%, 16/29). These improvements were observed in subsets of patients across the study population (n=57) who reported symptoms at baseline and at week 24.1,2
"The approval of Vijoice marks a turning point for patients who, until now, have not had an approved therapy to specifically address their disease," said Victor Bulto, President, Novartis Innovative Medicines US. "We are grateful to the physicians, patients and families who participated in the EPIK-P1 trial. We are continuing to invest in studies to advance the scientific understanding of PROS conditions and to understand the full potential of Vijoice."
In EPIK-P1, the most common adverse events (AEs) of any grade were diarrhea (16%), stomatitis (16%), and hyperglycemia (12%). The most common grade 3/4 AE was cellulitis (4%); one adult case was considered treatment-related.1
Novartis is committed to providing patients with access to medicines, as well as resources and support to address a range of needs. The Novartis Oncology Patient Support Program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. Patients or providers can call 800-282-7630 or visit Patient.NovartisOncology.com or HCP.Novartis.com/Access to learn more about eligibility and to enroll.
About PIK3CA-Related Overgrowth Spectrum (PROS)
The PROS classification was proposed by researchers and parent representatives of patient-family support and advocacy organizations at a National Institutes of Health workshop in 2013 to unite a group of rare overgrowth conditions caused by PIK3CA mutations.4,6 Specific conditions associated with PROS include KTS, CLOVES syndrome, ILM, MCAP/M–CM, HME, HHML, FIL, FAVA, macrodactyly, muscular HH, FAO, CLAPO syndrome and epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis.4,6 The estimated prevalence of PROS conditions is approximately 14 people per million.3
About Vijoice
Vijoice® (alpelisib) is a kinase inhibitor that treats rare overgrowth conditions caused by the effects of PIK3CA mutations in adults and children with PIK3CA-Related Overgrowth Spectrum (PROS). Vijoice works by inhibiting the PI3K pathway, predominantly the PI3K-alpha isoform.1 Vijoice is the first FDA-approved treatment for PROS conditions. Vijoice is not approved for use outside the United States.
FDA approval of Vijoice is based primarily on real-world evidence from the EPIK-P1 study. To further understand the long-term efficacy and safety of alpelisib in PROS, Novartis is conducting additional clinical trials. EPIK-P2 is a prospective Phase II multi-center study with a randomized, double-blind, upfront 16-week placebo-controlled period, and extension period to evaluate the safety, the efficacy and pharmacokinetics of alpelisib to treat pediatrics and adults with PROS. EPIK-P3 is a Phase II study to assess long-term safety and efficacy of alpelisib in people with PROS who participated in EPIK-P1.
Important Safety Information
Indication
VIJOICE® (alpelisib) tablets is a prescription medicine used to treat adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Important Safety Information
Patients should not take VIJOICE if they have had a severe allergic reaction to alpelisib or are allergic to any of the ingredients in VIJOICE.
VIJOICE may cause serious side effects. VIJOICE can cause severe allergic reactions. Patients should tell their health care provider or get medical help right away if they have trouble breathing, flushing, rash, fever, or fast heart rate during treatment with VIJOICE. VIJOICE can cause severe skin reactions. Patients should tell their health care provider or get medical help right away if they get a severe rash or a rash that keeps getting worse; reddened skin; flu-like symptoms; blistering of the lips, eyes, or mouth; blisters on the skin or peeling skin, with or without a fever. VIJOICE can cause high blood sugar levels (hyperglycemia). Hyperglycemia is common with VIJOICE and can be severe. Health care providers will monitor blood sugar levels before patients start, and during treatment with, VIJOICE. Health care providers may monitor blood sugar levels more often if patients have a history of type 2 diabetes. Patients should tell their health care provider right away if they develop symptoms of hyperglycemia or its complications, including excessive thirst, dry mouth, urinating more often than usual or having a higher amount of urine than normal, increased appetite with weight loss, confusion, nausea, vomiting, fruity odor on breath, difficulty breathing, or dry or flushed skin. VIJOICE can cause lung problems (pneumonitis). Patients should tell their health care provider right away if they develop new or worsening symptoms of lung problems, including shortness of breath or trouble breathing, cough, or chest pain. Diarrhea is common with VIJOICE and can be severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney injury. Patients who develop diarrhea during treatment with VIJOICE should tell their health care provider right away.
Before taking VIJOICE, patients should tell their health care provider if they have a history of diabetes; skin rash; redness of skin; blistering of the lips, eyes, or mouth; peeling skin; are pregnant, or plan to become pregnant, because VIJOICE can harm their unborn baby. Females who can become pregnant should use effective birth control during treatment with VIJOICE and for 1 week after the last dose. Do not breastfeed during treatment with VIJOICE and for 1 week after the last dose. Males with female partners who can become pregnant should use condoms and effective birth control during treatment with VIJOICE and for 1 week after the last dose.
Patients should tell their health care provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIJOICE and other medicines may affect each other and cause side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine.
The most common side effects of VIJOICE are diarrhea, mouth sores (stomatitis), and hyperglycemia.
Please see full Prescribing Information for VIJOICE, available at VIJOICE.com.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs nearly 15,000 people in the United States. For more information, please visit https://www.novartis.us.
Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library.
For questions about the site or required registration, please contact media.relations@novartis.com.
References
- Vijoice: Prescribing Information. East Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation; April 2022.
- Canaud G, et al. EPIK-P1: Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib as Part of a Compassionate Use Programme. Presented at the 2021 ESMO Congress; September 17-21, 2021.
- Data on file. Novartis Pharmaceuticals Corp; 2020.
- Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164A(7):1713-1733.
- Parker VER, Keppler-Noreuil KM, Faivre L, et al. Genet Med. 2019;21(5):1189-1198.
- Mirzaa G, Conway R, Graham JM Jr, Dobyns WB. PIK3CA-related segmental overgrowth. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2019.
- Hughes M, Hao M and Luu M. PIK3CA vascular overgrowth syndromes: an update. Current Opinion in Pediatrics. 2020;32(4):539-546.
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
E-mail: investor.relations@novartis.com
View original content:
SOURCE Novartis Pharmaceuticals Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/fda-approves-novartis-vijoice-alpelisib-first-only-treatment-select-patients-with-pik3ca-related-overgrowth-spectrum-pros/
| 2022-04-06T13:01:51
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/fda-approves-novartis-vijoice-alpelisib-first-only-treatment-select-patients-with-pik3ca-related-overgrowth-spectrum-pros/
|
CORNELIUS, N.C., April 6, 2022 /PRNewswire/ -- Financial Independence Group, LLC (FIG), a leading financial services conglomerate and a staple of the Cornelius, North Carolina community since 1998, will build a modern and elegant building and corporate campus that will be an exciting new community landmark on Westmoreland Road in Cornelius. The company will be moving from its current Cornelius headquarters near the corner of West Catawba Avenue and Jetton Road to a 5 acre site located at 8715 Westmoreland Rd. The new campus will be home to Financial Independence Group and three of its affiliate companies; Alphastar Capital Management, Barnabas Capital, and Independent Property and Casualty Group.
Community development has always held an important place in the hearts of FIG's co-founders Bill and Ericka Cain and Co-CEOs Brian Williams, Jim Cooper and Mike Mullan. This core belief of FIG has only strengthened over time as the company and its affiliates experiences sustained and remarkable growth. Because of this, it made sense to chart a new path forward that promotes an exciting workplace environment for the future of the company and its team members.
FIG is grateful to the Town of Cornelius and Mecklenburg County for their support in keeping the company in the community. Mecklenburg County and the Town of Cornelius are supporting the company's $22.3M investment through a Business Investment Program grant. The project will result in the creation of 20 additional jobs in Cornelius over the next 5 years.
As FIG along with three other of its affiliate companies write the next chapter in the company's history, they look forward to the new campus and continuing their community outreach efforts in the Cornelius area. Construction on the facility is expected to break ground in late 2022 or early 2023 and is scheduled to be completed by November 2023.
For media inquiries, please contact FIG Co-CEO Brian Williams at (800) 527-1155 or Brian.Williams@FIGMarketing.com.
About Financial Independence Group, LLC
FIG is a financial services conglomerate and national leader in the independent marketing organization (IMO) and field marketing organization (FMO) industry. Privately held and independently owned, FIG's fixed insurance solutions help the independent, licensed financial professional guide their retail investment clients to an optimal retirement plan. FIG has provided solutions for over 45 years, specializing in guaranteed income, asset protection, and multi-generational planning. Over 3,000 professionals across the US access more than 70 top-rated carriers to design fixed index annuity, fixed annuity, life insurance, care planning, and disability income solutions to best fit the interests of their clients. For more information, please visit www.FIGMarketing.com.
CONTACT
Brian Williams
(800) 527-1155
Brian.Williams@FIGMarketing.com
View original content to download multimedia:
SOURCE Financial Independence Group
|
https://www.wistv.com/prnewswire/2022/04/06/financial-independence-group-set-build-new-corporate-headquarters-cornelius-nc/
| 2022-04-06T13:01:57
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/financial-independence-group-set-build-new-corporate-headquarters-cornelius-nc/
|
VILNIUS, Lithuania, April 6, 2022 /PRNewswire/ -- 2021 was a record year for the fintech sector in Lithuania: the number of employees and revenues smashed previously set records, and 265 fintech companies are already calling Lithuania home (FinTech in Lithuania '22 map by Rockit). An in-depth analysis is published with The Fintech Landscape in Lithuania 2021-2022.
Lithuania ranks 1st in the EU, with a total of 147 licensed fintechs, when it comes to licensed entities (payment institution, electronic money institution and special banking license holders). Second ranking France has 90 licensed entities, Germany - 86, and Netherlands have 84.
The growth in the number of companies is complemented by a growth in revenue and employees. This serves as proof that Lithuania attracts active fintech companies with tangible value and is not considered for licensing only.
Increased number of employees and revenues
In 2021, the fintech sector had 5,900 employees in Lithuania, which is a 48% increase compared to 2020.
"Fintech companies have proven, time and time again, that Lithuania is a stable partner for business growth. By establishing such core competencies as compliance, customer onboarding and support, product development, business development, and sales here, the majority of international fintechs trust Lithuania with essential functions of their business," says the Head of Technology Team at Invest Lithuania, Gintarė Bačiulienė.
With well-established brands expanding and newcomers choosing Lithuania, fintechs have generated more than 500 million EUR in revenue in 2021. That shows an increase of over 25% compared to 2020.
Ecosystem diversifies
Payments remain the primary function for Lithuania-based fintechs (31%), but the market is getting more diverse: 18% of companies are working in financial software, 11% in lending, 10% in savings and investments, and 10% in digital banking.
"This is only a start: the Bank of Lithuania aims to develop the country's potential for fintech solutions for capital markets, with an emphasis on Crowdfunding, Wealthtech, and Green Finance sectors," said Bačiulienė.
Risk management and solid partnerships
Lithuania established an AML Centre of Excellence in 2021 and ranks 9th globally among the lowest risk jurisdiction (AML Basel Index). More than 10,200 specialists are qualified to work in AML/CTF, compliance or risk management related fields, and 86% of the surveyed fintechs claim they hired specialists with such qualifications last year.
Fintechs have become an active and responsive part of the Lithuanian society. Following the war, Lithuania-based fintechs partnered up with business and NGOs to deliver support for Ukraine. Partnerships create sustainable bonds and help companies diversify the offering of their products. 77% of companies reported they have at least one fintech partner. Partnerships are also thriving outside of the private sector, as Lithuania ranks 1st for university-business cooperation in Central and Eastern Europe.
Head of Rockit, Lina Žemaitytė Kirkman, notes that fintech ecosystem brings financial inclusion: "While it can take a longer time for more traditional players to become more inclusive, fintechs' agility allows them to lead the way, which is very much needed in today's context."
Logo - https://mma.prnewswire.com/media/1780184/Invest_Lithuania_Logo.jpg
View original content to download multimedia:
SOURCE Invest Lithuania
|
https://www.wistv.com/prnewswire/2022/04/06/fintech-lithuania-resilient-focused-quality/
| 2022-04-06T13:02:04
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/fintech-lithuania-resilient-focused-quality/
|
MIAMI, April 6, 2022 /PRNewswire/ -- CEO Coaching International, the leading executive coaching firm for growth-focused CEOs and entrepreneurs globally, is pleased to announce Mateo Romano as its newest Partner and Coach.
Romano is a high-impact, global entrepreneurial consumer products industry leader with 25+ years of experience at top brands including Mattel, Moose Toys, and Tyco Toys. He is known to be a future-focused turnaround specialist with a long-term strategic vision and an exceptional driver of business growth, revenues, and profitability at companies across the globe. Romano has held various executive roles throughout North America, South America, and Europe.
As Mattel's VP of Global Commercial Marketing, Romano developed the SKU optimization process, captured international input during the development process to ensure 80% global alignment on Key Drivers, developed a line architecture dashboard to keep track of the SKUs developed, and created the process to develop e-commerce ready product.
"Mateo makes an excellent addition to our team of world-class CEO coaches," said Mark Moses, CEO and Founding Partner at CEO Coaching International. "As an innovative turnaround specialist, he will be able to guide clients to transform and grow businesses and Make BIG Happen."
"I am proud to be joining this elite group of business coaches in their mission to Make BIG Happen," Romano said. "CEO Coaching International combines a proven methodology and resources with my experience as a business leader driving growth and results around the world, to help clients grow their business, develop their people, and achieve breakthrough results. I'm highly motivated to help others achieve their goals."
Some of Romano's other achievements include leading the restructuring of a top global brand's European subsidiaries into a $1B regional organization, turning around a stagnant sales trend in Spain and delivering 7% growth for three years in a row, and expanding the target market for core brands in Mexico by developing products and targeting adults.
Romano attended Universidad Tecnológica de México. He has been a member of YPO (now YPO Gold) and is a Global Advisory Board Member at Virtual Advisory Board (VAB). He also served as the Co-Chairman of Toy Industries of Europe (TIE). He is fluent in Spanish and English.
Romano resides in Redondo Beach, CA with his wife and three kids and enjoys riding bicycle, running, and kayaking.
To schedule a complimentary introduction call with Mateo Romano or another one of the CEO Coaching International coaches, visit: ceocoachinginternational.com/coach/mateo-romano/
About CEO Coaching International
CEO Coaching International works with CEOs and their leadership teams to achieve extraordinary results quarter after quarter, year after year. Known globally for its success in coaching growth-focused entrepreneurs to meaningful exits, CEO Coaching International has coached more than 1,000 CEOs and entrepreneurs in more than 60 countries and 45 industries. The coaches at CEO Coaching International are former CEOs, presidents, or executives who have made BIG happen. The firm's coaches have led double-digit sales and profit growth in businesses ranging in size from startups to over $10 billion, and many are founders that have led their companies through successful eight, nine, and ten-figure exits. Companies working with CEO Coaching International for two years or more have experienced an average EBITDA CAGR of 67.8% during their time as a client, nearly four times the U.S. average and a revenue CAGR of 25.5%, more than twice the U.S. average. For more information, please visit: https://www.ceocoachinginternational.com.
View original content to download multimedia:
SOURCE CEO Coaching International
|
https://www.wistv.com/prnewswire/2022/04/06/former-mattel-global-vice-president-joins-ceo-coaching-international/
| 2022-04-06T13:02:11
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/former-mattel-global-vice-president-joins-ceo-coaching-international/
|
Foxit also Introduces Powerful New APIs and Increased Compliance to Foxit eSign
FREMONT, Calif., April 6, 2022 /PRNewswire/ -- Foxit, a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase their productivity and do more with documents, today announced the launch of the Foxit eSign iOS mobile app, allowing users to prepare, send, sign and manage documents from anywhere. Foxit has also announced the inclusion of powerful new APIs for developers and with improved compliance for Foxit eSign.
Foxit's eSign iOS mobile app is an exciting new extension to the recently launched Foxit eSign solution. Users will now be able to prepare documents, create their templates, assign recipients, and send for signing with just a few taps on their mobile device while on the go. The new solution also comes with an offline mode that allows users to get documents signed where the internet is not available, and sync completed documents once connected again. Users leveraging the app will have tamper-proof and legally signed documents that can be used for practically any function.
Key features and functions of the new Foxit eSign iOS app include:
- Intuitive and parallel workflow-based interface that fluidly guides you from template creation to sending and storing for a more streamlined and efficient experience
- Reduced customer onboarding times with an easy-to-use design and step-by-step signing walkthrough
- Easily guide recipients when you're not there in person by establishing signer roles, pre-filling information, and marking required fields on documents
- Establish ordered signing and keep things moving by arranging signer sequences for multiple signatories
- Upload documents in almost any file format and convert to PDF in a snap, including DOC, DOCX, XLSX, XLS, PPT, PPTX, CSV, TXT, RTF, and PNG
- Prepare your documents for signing quickly and easily by dragging and dropping signature fields, date fields, data entry fields, and advanced field options, such as hyperlinks and accept/decline options
- Simplify the sending process by generating a unique signing link in one click to email clients, allowing them to sign on any device connected to the internet
The New Foxit eSign app can be easily and quickly downloaded to your preferred iOS device (iPad, iPhone, iPod Touch) right from the convenience of the Apple Store.
Increased Compliance
Foxit has also announced it has met or exceeded industry compliance requirements as HIPAA, FERPA, FINRA, 21 CFR Part 11, CCPA, and more, all through its mobile iOS signing solution. In addition, Foxit eSign utilizes features, such as knowledge-based authentication (KBA), to ensure compliance more easily with IRS forms, 21 CFR Part 11 documentation, banking documents, and more. Foxit eSign also ensures accurate and valid documents through identity verification options, such as two-factor (2FA) and multi-factor authentication (MFA), allowing users to establish and prove signer identities throughout the mobile signing process.
Foxit eSign is compliant with the Electronic Identification, Authentication, and Trust Services (eIDAS) as set forth by EU regulations for transactions in the European Single Market. For European customers, Foxit eSign services are also hosted in the AWS EU data centers located in Frankfurt, Germany and maintain complete GDPR compliance with SSAE16 facilities that are SOC 2 Type 2 compliant and PCI compliant.
Improved APIs
A great deal of focus was put on making Foxit eSign an intuitive and powerful tool for developers. New additions to Foxit eSign's eSignature API make it a purpose-built and enterprise-ready solution capable of streamlining productivity, adding important functionality, and reducing costs. The solution has made it easy for developers to save time and reduce the effort of everyday tasks such as gathering important paperwork and agreements from employees. Instead of manually communicating with and gathering documents from each employee, eSignature APIs are able to automate the signing process in seconds.
By using Foxit's eSignature API, businesses can both transform their workflows and seamlessly meet the needs of their customers in vital ways. Organizations can now allow users to pre-fill information about the document prior to sending, sign directly within the business website or application, download extensive Excel reports with advanced filters, just to name a few. Leveraging webhooks, Foxit eSign applications can automatically sync customer data in-application with any relevant information present in the signature. With all of these upgrades to Foxit eSign APIs, the solution is taking the ability to sign a PDF to the next level by placing customized and comprehensive signing power into the hands of businesses and their customers.
To learn more about Foxit eSign, the please visit: https://www.foxit.com/esign-pdf/
About Foxit
Foxit is a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase their productivity and do more with documents. Foxit addresses the needs of three distinct market segments. For End-User Productivity, Foxit delivers easy to use desktop software, mobile apps, and cloud services to make knowledge workers more productive. Foxit's Developer Solutions enable developers to incorporate powerful PDF technology into their applications. For Enterprise Automation, Foxit provides server software for large scale PDF document management and data capture.
Foxit has over 650 million users and has sold to over 425,000 customers, ranging from SMBs to global enterprises, located in more than 200 countries. The company has offices all over the world, including locations in the US, Asia, Europe, and Australia. For more information, please visit https://foxit.com.
View original content:
SOURCE Foxit Software
|
https://www.wistv.com/prnewswire/2022/04/06/foxit-esign-gets-mobile-treatment-with-launch-new-ios-mobile-app/
| 2022-04-06T13:02:18
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/foxit-esign-gets-mobile-treatment-with-launch-new-ios-mobile-app/
|
SAN ANTONIO, April 6, 2022 /PRNewswire/ -- GemCap provided a $4.0 million facility consisting of a working capital revolver, an equipment term loan, and a mortgage for a munitions manufacturer which wholesales and retails its inventory. "This is a high-growth, high-demand industry and we're happy to assist our client's growth," says Richard Ellis, Co-President. "GemCap continues to focus on assisting small and mid-sized businesses across a diverse range of industries"
GemCap, an innovative lending firm, provides senior-secured, commercial asset-based loans and accounts receivable factoring facilities to low and middle market businesses within the United States & Canada, as well as in-transit inventories en route to the United States. Loans range from $1 million to $10 million, and factoring facilities can be as little as $100,000. Collateral groups include: inventories (consumer & industrial), receivables, equipment, real estate and intellectual property.
For inquiries to GemCap, please reach either David Ellis or Richard Ellis at ellis@gemcapsolutions.com.
www.gemcapsolutions.com
9901 I.H. 10 West, Suite 800, San Antonio, TX 78230
View original content:
SOURCE GemCap
|
https://www.wistv.com/prnewswire/2022/04/06/gemcap-funds-40-million-facility-munitions-manufacturer/
| 2022-04-06T13:02:24
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/gemcap-funds-40-million-facility-munitions-manufacturer/
|
- This award is presented to the engineering team responsible for the highest-rated new entry into the market for the 2021 model year
- The award, based on consumer evaluations of Initial Quality and Appeal, is for the vehicle introduced for the 2021 model year that is furthest ahead of its direct competitors
DETROIT, April 6, 2022 /PRNewswire/ -- Today, the Genesis GV80 SUV received the J.D. Power Engineering Award for Highest-Rated All-New Vehicle. This award is presented to the team responsible for engineering the highest-rated new entry into the market for the 2021 Model Year. The award, based on consumer evaluations of Initial Quality and Appeal, is for the vehicle introduced for the 2021 Model Year that is furthest ahead of its direct competitors.
"Genesis is committed to designing and engineering world class-products for consumers around the globe," said Claudia Marquez, chief operating officer of Genesis Motor North America. " We are pleased to receive this recognition from J.D. Power. With its refined performance, bold design, leading technologies, and exceptional comfort, it is no surprise that GV80 continues to be a favorite of our customers and industry observers alike."
This award combines the results of the J.D. Power Initial Quality Study (IQS) which measures new-vehicle quality by the number of problems experienced per 100 vehicles (PP100) as reported by consumers during the first 90 days of ownership; and the J.D. Power Automotive Performance, Execution and Layout (APEAL) Study, which measures new-vehicle owners' overall satisfaction with their vehicles within the first 90 days of ownership. The IQS score and the APEAL score of every new vehicle is calculated and compared to the average for vehicles in each segment ("Premium Upper Middle SUV" for GV80). The two studies carry equal weight. The award is given to the vehicle that is furthest ahead of its segment average on the combined score and is presented to the vehicle introduced for the 2021 model year that is furthest ahead of its segment average for the combined score.
Genesis Motor North America
At Genesis, we put the customer at the core of everything we do. Genesis is a global automotive brand that delivers the highest standards of performance, design, safety, and innovation while looking towards a more sustainable future. Genesis designs customer experiences that go beyond products, embodying audacious, forward-thinking, and distinctly Korean characteristics within its unique Athletic Elegance design identity. With a growing range of award-winning models — including the 2022 MotorTrend SUV of the Year, GV70, along with G70, G80, G90, GV60, and GV80 — Genesis aims to lead the age of electrification by focusing on a dual electrification strategy involving fuel-cell and battery EVs, starting with its Electrified G80 and GV60 electric models. Genesis has stated its commitment to becoming a 100% zero emission vehicle brand by 2030 and to pursuing carbon neutrality by 2035.
Please visit our media site for the latest news at www.genesisnewsusa.com.
View original content to download multimedia:
SOURCE Genesis Motor America
|
https://www.wistv.com/prnewswire/2022/04/06/genesis-gv80-receives-jd-power-engineering-award-highest-rated-all-new-vehicle/
| 2022-04-06T13:02:31
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/genesis-gv80-receives-jd-power-engineering-award-highest-rated-all-new-vehicle/
|
New study finds low treatment satisfaction, poor control of symptoms, high psychosocial burden and shortcomings in patient centered care for eczema patients worldwide.
SANTA BARBARA, Calif., April 6, 2022 /PRNewswire/ -- The Global Patient Initiative to Improve Eczema Care (GPIIEC), a partnership of eleven patient organizations, today released a global report card of eczema patient care in eight countries: Australia, Canada, Denmark, France, Italy, Germany, United States, and the United Kingdom. The Initiative is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients and their caregivers, and to identify opportunities for improvement.
Eczema is a chronic relapsing inflammatory skin condition that impacts approximately 15% to 20% of children and 1% to 3% of adults globally, resulting in a significant patient burden and high demand on health care systems. A global survey by the GPIIEC that received over 3,200 responses found that patients in every country, and particularly those who live with moderate-to-severe eczema, are struggling to achieve long-term control of their eczema symptoms and report limited satisfaction with current treatments.
Poorly controlled eczema that can't be fully addressed by existing treatments substantially impacts patients' health-related quality of life. Based on adult patients' descriptions of their health, they would give up between 17-36 percent of their remaining life span in order to be restored to perfect health. Key drivers of this detriment in quality of life were the pain and discomfort of eczema and the mental health impacts such as anxiety and depression.
"We have work to do to improve care for people with eczema worldwide. This data helps us see the gaps and know where to focus our attention," said Marjolaine Hering, with Association Française de l'Eczéma.
Moderate-to-severe eczema is complex and chronic, demanding a high degree of patient involvement in ongoing symptom management. However, training for this role is minimal and patient input into treatment decisions is lacking in almost every country surveyed. Interestingly, shared decision making, defined as asking patients and caregivers about their priorities during a medical visit, was predictive of symptom control. This finding suggests that such involvement may improve medical care and outcomes, and serves as a target for improvement for health systems in each country.
"Through this initiative we are discovering how patients are faring in our country and worldwide and learning from the other patient organizations how to advocate for better medical care and supports for people with eczema," said Thomas Schwennesen of the Deutscher Neurodermitis Bund in Germany.
About Global Patient Initiative to Improve Eczema Care (GPIIEC)
GPIIEC is a patient organization-led effort to measure the performance of health systems in meeting the needs of people with eczema (atopic dermatitis) and their caregivers using a common methodology to allow for direct comparisons. For more information: www.improveeczemacare.org
About Global Parents for Eczema Research (GPER)
GPER is a grassroots, non-profit organization based in California whose mission is to improve quality of life and reduce suffering for children with moderate to severe eczema and their families. For more information: www.parentsforeczemaresearch.com
View original content:
SOURCE Global Parents for Eczema Research
|
https://www.wistv.com/prnewswire/2022/04/06/global-scorecard-highlights-unmet-needs-eczema-patients-worldwide-strategies-addressing-them/
| 2022-04-06T13:02:38
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/global-scorecard-highlights-unmet-needs-eczema-patients-worldwide-strategies-addressing-them/
|
Katherine Paulson Named Partner & Head of Digital Marketing Strategies; Kevin Danaher Appointed Principal, Content Strategies; Lorene Yue Named Principal
Financial Services-Focused PR and Marketing Communications Firm Adds New Capabilities While Reinforcing Award-Winning Solutions for Clients
Launched in October 2011 as Four-Person Boutique Agency, Haven Tower Grows to 17 Professionals Across Los Angeles, Seattle, Chicago, New York
LOS ANGELES, April 6, 2022 /PRNewswire/ -- Haven Tower Group LLC ("Haven Tower"), an award-winning, full-service public relations and marketing communications agency focused on the financial services sector, today announced the addition of three senior professionals: Katherine Paulson as Partner & Head of Digital Marketing Strategies; Kevin Danaher, Principal, Content Strategies; and Lorene Yue, Principal.
The continued buildout of Haven Tower's team – which now includes 17 professionals nationwide – aligns with the firm's commitment to continuously enhancing its capabilities and talent base to benefit its clients. It also reflects Haven Tower's consistent year-over-year growth since its launch
Joseph Kuo, a veteran of LPL Financial and Kekst & Company (now Kekst CNC), started the firm in October 2011 as a four-person boutique. David Kronfeld, a fellow former Partner of Kekst, was Haven Tower's first hire.
The announcement follows the promotions earlier this year of Michael Dugan to President & Managing Partner; Mitch Manning to Partner & Head of National Media; Donald Cutler to Principal; and Eric Clapp to Principal, Operations & Administration.
Mr. Kuo, Founder & CEO of Haven Tower, said, "Bringing aboard Katherine Paulson, Lorene Yue and Kevin Danaher represents the culmination of careful planning over the past 12 months, with an emphasis on evolving our senior talent base to continue delivering the best possible client service experience. Lorene's track record as a PR strategist and business journalist is impressive, while Katherine and Kevin are both seasoned wealth management industry executives whom we have known and worked closely with for years.
"The organizational enhancements we have executed on from late last year through to completion this month fully round out our client support capabilities, while underscoring the best features of our client-driven culture: a commitment to seamless collaboration between our professionals, a team-driven approach in how we support each client relationship, and a passion for continuously embracing new ways to articulate and amplify our clients' stories."
Seasoned Experts Augment Haven Tower's Award-Winning Team
Ms. Paulson previously worked as an outsourced Chief Marketing Officer and independent brand and strategy consultant. She has more than 24 years of financial services experience, with expertise in the marketing and distribution of financial products, including mutual funds, private funds, alternative funds and fintech asset management solutions.
Earlier in her career, Ms. Paulson was Assistant Vice President and Director of Marketing Communications at MetLife, where she led the creative and digital marketing teams for their U.S. retail annuities business. During her tenure at MetLife, Ms. Paulson helped grow the company's variable annuity sales from $6 billion to $28 billion. She also served as Director of Marketing Communications at Altegris, where she led the marketing team for the wirehouse, independent and private client channels.
Ms. Paulson also has experience in developing and executing strategic marketing programs across all digital platforms for wealth management firms serving a distributed field force, as well as independent financial advisor businesses, asset managers, financial advisor recruiting firms, mortgage brokers and insurance enterprises.
Regarding her new role at Haven Tower, Ms. Paulson said, "I'm excited to join one of the most experienced, dynamic and culturally diverse teams of PR and marketing communications professionals that exists in the financial services industry today. Over the past 10-plus years, Haven Tower has distinguished itself as the agency of record for many of the most successful and fastest-growing wealth management businesses across the country. In large part, this is due to the firm's penchant for intellectual rigor, combined with a bias for action, a culture that I find very appealing."
Mr. Danaher most recently worked as a Senior Vice President with Advisor Group, where he led the firm's advisor communications, executive messaging and media relations functions. Mr. Danaher had oversight of corporate communications during the firm's spinoff from AIG to a private equity firm, and its subsequent sale.
Prior to joining Haven Tower, Ms. Yue was director of media relations for the Bulletin of the Atomic Scientists, a non-profit media organization best known for managing the Doomsday Clock. She was also the voice of the Professional Convention Management Association (PCMA) as the director of communications in charge of writing executive communications, marketing content, press releases and annual reports.
Previously, Ms. Yue was an award-winning business journalist who covered personal finance, banking, retail and consumer goods at publications including the Chicago Tribune, Detroit Free Press and Crain's Chicago Business.
Looking Forward
Michael Dugan, President & Managing Partner of Haven Tower, said, "We could not be more thrilled to welcome Katherine, Lorene and Kevin to the Haven Tower team. Their additions reflect our commitment to bringing aboard talent that can adjust to the fast-evolving PR and marketing communications landscape in a way that prioritizes thinking strategically and working together to capture opportunities and solve complex problems for our clients."
Mr. Dugan concluded, "I believe all successful businesses share many of the same traits. At the top of the list are respect, hard work and a constant focus on client service. In Katherine, Lorene and Kevin, I am confident that we have added senior professionals who understand and embrace our approach, and I look forward to partnering closely with them as we reinforce our distinctive culture and, most of all, continue to deliver great service to our clients."
Mr. Kronfeld, Partner Emeritus at Haven Tower, said, "I had the privilege of helping to create an exciting agency growth story when I became Haven Tower's first hire more than a decade ago. What makes the firm distinctive is our ability to bridge the best elements of our past with a clear vision for the future. We accomplish this by hiring, retaining and continuously inspiring talented people who are passionate about deepening our culture and providing a boutique service experience to our many clients. I look forward to seeing what the firm can accomplish in the years to come."
About Haven Tower Group LLC
Haven Tower Group LLC is an award-winning and full-service public relations and marketing communications firm focused on the financial services sector, with a particular emphasis on supporting wealth management, wealthtech, asset management and insurance clients.
Our team of dedicated professionals across Los Angeles, Seattle, Chicago and New York City develops and executes ongoing brand elevation and public visibility programs, as well as PR and communications support for transactional, regulatory, crisis and other special situations. For more information, please visit https://haventower.com/.
Media Contacts:
Elizabeth Shim
Haven Tower Group
424 317 4865
eshim@haventower.com
View original content:
SOURCE Haven Tower Group
|
https://www.wistv.com/prnewswire/2022/04/06/haven-tower-group-continues-buildout-senior-team-with-addition-former-metlife-marketing-communications-leader-advisor-group-svp-corporate-communications-chicago-tribune-business-reporter/
| 2022-04-06T13:02:45
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/haven-tower-group-continues-buildout-senior-team-with-addition-former-metlife-marketing-communications-leader-advisor-group-svp-corporate-communications-chicago-tribune-business-reporter/
|
PARAMUS, N.J., April 6, 2022 /PRNewswire/ -- Helping Hands Family (HHF) is excited to announce that they are expanding ABA therapy services into Morris and Bergen Counties of New Jersey. HHF is a leading provider of ABA therapy in New Jersey, Pennsylvania, and New York, providing services to children with autism in clinic, home, and community settings. HHF will serve these two new North Jersey markets through clinics being built in Paramus and Chatham.
HHF is committed to helping children with autism, and their families, experience behavioral growth and milestone progression through consistent, high-quality treatment. Their clinicians provide personalized care to each child through an individualized, child-led, and play-based treatment plan.
Allyson Kroneberger, New Jersey Regional Director of Operations, commented "HHF is excited to expand autism therapy services to the families of North Jersey. We are proud of our ability to take one more step to make ABA treatment available to more children diagnosed with autism. With the intensive clinical education programs our therapists must master, we are better trained and ready to serve families of those affected by autism. We will also, proudly, bring more meaningful jobs to the area."
HHF now provides ABA therapy in the following NJ counties:
- Burlington
- Ocean
- Monmouth
- Morris
- Bergen
- Middlesex
HHF is hiring RBTs and BCBAs at their new locations if you are interested in a career as a therapist! Working with children diagnosed with autism is an impactful and rewarding career. HHF provides rewarding positions, with benefits, a supportive work environment as well as mentoring for professional growth.
Any parent interested in services in New Jersey, please contact Nikki Marchetti, at (973) 967-3267.
About Helping Hands Family
Helping Hands Family (HHF) is an established provider of Applied Behavior Analysis therapy in the Northeast. We offer ABA therapy in-clinic, in-home, and in-school based on each child's unique needs. Our team is comprised of autism professionals, devoted to delivering customized treatment plans through science-based programs to help children with autism progress socially and support new ways of interacting with the world.
Media Contact:
Colleen MacDonald
colleen@hhfamily.com
View original content to download multimedia:
SOURCE Helping Hands Family
|
https://www.wistv.com/prnewswire/2022/04/06/helping-hands-family-opening-two-new-autism-therapy-centers-morris-bergen-counties/
| 2022-04-06T13:02:51
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/helping-hands-family-opening-two-new-autism-therapy-centers-morris-bergen-counties/
|
CHICAGO, April 6, 2022 /PRNewswire/ -- HUB International Limited (Hub), a leading full-service global insurance brokerage and financial services firm, announced today that it has acquired the assets of 401(k) Advisors, Inc. (401(k) Advisors). Terms of the transaction were not disclosed.
Located in Wilmette, Illinois, 401(k) Advisors provides retirement plan consulting services. With $1.3 billion in assets under advisement, 401(k) Advisors assist plan sponsors in the areas of plan design, benchmarking, investment advice, fiduciary compliance and participant outcomes. Stace Hilbrant, Managing Director of 401(k) Advisors, will join Hub Midwest West.
"Stace has an incredible background of managing diverse retirement plan clients and brings a great presence to our team in the Chicago area," said Joe DeNoyior, President of Hub Retirement and Private Wealth.
About Hub Retirement and Private Wealth
Hub Retirement and Private Wealth ("RPW") offers institutional and retirement services to for-profit and not-for-profit organizations and customized private wealth management services to individuals and families. Employees of Hub International offer securities through partner Broker Dealers not affiliated with Hub. Employees of Hub provide advisory services through both affiliated and unaffiliated Registered Investment Advisors (RIA). Global Retirement Partners, LLC, Millennium Advisory Services, Inc, TCG Advisors, Hub Investment Advisors, LLC, HUB International Investment Advisory Services, Inc., and Sheridan Road Advisors, LLC are wholly owned subsidiaries of Hub International. Learn more about Hub Retirement and Private Wealth.
About Hub's M&A Activities
Hub International Limited is committed to growing organically and through acquisitions to expand its geographic footprint and strengthen industry and product expertise. For more information on the Hub M&A experience, visit WeAreHub.com.
About Hub International
Headquartered in Chicago, Illinois, Hub International Limited is a leading full-service global insurance broker and financial services firm providing risk management, insurance, employee benefits, retirement and wealth management products and services. With more than 14,000 employees in offices located throughout North America, Hub's vast network of specialists brings clarity to a changing world with tailored solutions and unrelenting advocacy, so clients are ready for tomorrow. For more information, please visit www.hubinternational.com.
CONTACT:
Media: Jessica Wiltse
Phone: 312-596-7573
jessica.wiltse@hubinternational.com
M&A: Clark Wormer
Phone: 312.279.4848
Clark.wormer@hubinternational.com
View original content to download multimedia:
SOURCE Hub International Limited
|
https://www.wistv.com/prnewswire/2022/04/06/hub-international-bolsters-retirement-capabilities-with-acquisition-401k-advisors-inc-illinois/
| 2022-04-06T13:03:02
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/hub-international-bolsters-retirement-capabilities-with-acquisition-401k-advisors-inc-illinois/
|
Closure of Sde Avraham farm in Israel optimizes Company's organizational structure by fully leveraging global import-export supply chain
Increase in Revolving Credit Facility availability to $15 million supports increased global demand for premium cannabis
TORONTO, Canada and GLIL YAM, Israel , April 6, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, today announced new strategic imperatives designed to enhance organizational efficiency and reduce operating costs while further responding to the increased demand for premium, indoor-grown Canadian cannabis from Israeli consumers. As part of these changes, Focus Medical Herbs Ltd. ("Focus Medical") has decided to close the Sde Avraham cultivation farm in Israel that it owns and operates. Focus Medical has an exclusive commercial agreement with IM Cannabis to distribute its production under the IMC brand. Focus Medical will complete the closure of the Sde Avraham cultivation farm during the second quarter of 2022.
The closure of Sde Avraham farm will allow the Company to better leverage its fully licensed import-export supply chain and focus on importing premium and ultra-premium products from its subsidiaries in Canada and other leading Canadian suppliers. IM Cannabis will continue to support the cultivation sector in Israel by concentrating on purchasing from third-party cultivation facilities in Israel that have advanced technological greenhouses and will rely on existing inventory of proprietary genetics.
The Company also completed an amendment to increase the availability under the existing revolving credit facility with a private Canadian creditor that is maintained by Trichome JWC Acquisition Corp. ("TJAC") to $15 million (the "Revolving Credit Facility") to better support the working capital needs associated with its global supply chain and the growing demand for its premium Canadian-grown cannabis. Amounts drawn under the Revolving Credit Facility are margined against eligible accounts receivable and inventory and are secured against the assets of the Company's Canadian subsidiaries. The term of the Revolving Credit Facility was extended to May 2023. For more information on the Revolving Credit Facility, please see the Company's annual information form dated March 31, 2022, available on the Company's SEDAR profile at www.sedar.com.
"IM Cannabis is well positioned to meet the elevated demand for premium cannabis through our global supply chain and cultivation facilities in Canada," said Oren Shuster, Chief Executive Officer of IM Cannabis. "Over the last decade, Focus Medical has been the main cultivator of our products sold in the Israeli market and we are grateful for the team's hard work and dedication. Our ability to import from our Canadian facilities provides us with a high-quality and reliable source of supply for the Israeli and German medical markets as they continue to evolve. We believe this strategic transition will strengthen our operating model and ultimately support sustainable, long-term growth for our stakeholders."
In 2021, the Company established a strong presence in Canada through acquiring two indoor cultivation facilities of TJAC and MYM Nutraceuticals Inc. ("MYM"), which grow premium and ultra-premium products and have leading brands in the adult-use recreational Canadian market, WAGNERS and Highland Grow. The TJAC and MYM acquisitions enable the Company to seamlessly import these products into Israel and provide Israeli patients with premium products, some of which are already sold in pharmacies in Israel. In the first quarter of 2022, the Company launched its WAGNERS brand in Israel.
About IM Cannabis Corp.
IM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in Israel, Germany, and Canada, the three largest federally legal markets. The ecosystem created through its international operations leverages the Company's unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence, and the ability to operate within the strictest regulatory environments, the Company has quickly become one of the leading cultivators and distributors of high-quality cannabis globally.
The Company operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs through IMC Holdings Ltd. in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies to medical cannabis patients. In Canada, IM Cannabis operates through Trichome Financial Corp. and its subsidiaries TJAC and MYM, where it cultivates and processes cannabis for the adult-use market at its Ontario, Nova Scotia, and Quebec facilities under the WAGNERS and Highland Grow brands.
About Focus Medical
Focus Medical is one of eight original licensed producers of medical cannabis in Israel and has over 10 years of experience growing high quality medical cannabis in the Israeli market. According to accounting criteria in IFRS 10, the Company is viewed as effectively exercising control over Focus, and therefore, the accounts of Focus are consolidated with those of the Company. Focus Medical has an exclusive commercial agreement with IM Cannabis to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has supply agreements with other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.
Disclaimer for Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking information"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements regarding the Company's import-export supply chain and ability to import a sufficient amount of premium products from its Canadian subsidiaries and other leading Canadian suppliers, the Company's ability to meet elevated demand for premium cannabis, the ability to import cannabis from the Company's Canadian facilities, the sustainability of growth as a result of the Company's transition to an asset-light model, the savings in operating costs as a result of closing the Sde Avraham facility, the use of the Revolving Credit Facility to support working capital needs associated with the Company's global supply chain and the growing demand for its premium Canadian-grown cannabis, and the Company's business and strategic plans.
Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to the ability of the Company to execute its business plan and the continued growth of the medical and/or recreational cannabis markets in the countries in which the Company operates or intends to operate, the Company maintaining "de facto" control over Focus Medical in accordance with IFRS 10, Focus Medical maintaining its existing Israeli medical cannabis propagation and cultivation licenses and the expected decriminalization and/or legalization of adult-use recreational cannabis in Israel. The Company considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those expressed or implied in the forward-looking information. Such risks include, without limitation: the ability of the Company to comply with applicable government regulations in a highly regulated industry; the Company's reliance on third-party supply agreements; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture, import, export or use of medical and/or recreational cannabis, as applicable, in Israel, Germany and Canada; any change in the political environment which would negatively affect the decriminalization and/or legalization of recreational cannabis in Israel and Germany; conflict in Eastern Europe; and unexpected disruptions to the operations and businesses of the Company as a result of the ongoing COVID-19 global pandemic or other disease outbreaks.
Please see the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated March 31, 2022, which is available on the Company's issuer profile on SEDAR at www.sedar.com. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Maya Lustig, Director Investor & Public Relations
IM Cannabis
+972-54-677-8100
maya.l@imcannabis.com
Investor Relations:
Brooks Hamilton, Director
MZ Group – MZ North America
+1 949-546-6326
IMCC@mzgroup.us
Logo - https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:
SOURCE IM Cannabis Corp.
|
https://www.wistv.com/prnewswire/2022/04/06/im-cannabis-strengthens-focus-importing-premium-ultra-premium-products-its-canadian-subsidiaries/
| 2022-04-06T13:03:09
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/im-cannabis-strengthens-focus-importing-premium-ultra-premium-products-its-canadian-subsidiaries/
|
BOSTON , April 6, 2022 /PRNewswire/ -- IndexZoo, a decentralized, crypto asset index protocol, announced Monday that it has closed a $2 million seed round on April 4 from seasoned investors including CMS Holdings, Warburg Serres, DefinanceX, Pragma Ventures, 0xVentures, BigBrainHoldings and angel investors including Nick Tong and Yenwen Feng (co-founders of Perpetual Protocol).
"We are thrilled to take our platform to the next level," said Marshall Chang, Founder and CEO of IndexZoo. "Tokenized indexes will be key infrastructure for DeFi 3.0. Right now, index funds are the largest investment class in TradFi, and we believe passive investment will soon catch up in crypto especially with the multichain future. We will use most of this funding to expand IndexZoo's multichain index presence and the leverage token platform. Overall, our goal is to build a strong product which will better serve our community."
This funding round follows grants awarded to IndexZoo from Layer 1 and Layer 2s, including Polygon, NEAR, and Harmony. IndexZoo also won the Cronos DeFi hackathon and has been a part of the BNB Chain Most Valuable Builder (MVB) Incubation program. The project also recently announced partnerships with Acala and is planning to launch a Polkadot ecosystem index and leverage tokens.
IndexZoo also revealed that it will launch its innovative, decentralized index protocol in 2nd quarter 2022. The protocol is aiming to take DeFi indexing to the next level.
To join the community, please visit IndexZoo on Twitter, Medium, Telegram, Discord. To learn more about IndexZoo, please visit https://www.indexzoo.com/.
About IndexZoo
IndexZoo is a DeFi multi-chain ecosystem of tokenized indices built for utmost accuracy, maximum leverage and lowest cost. Every blockchain ecosystem needs its own index. With grants from NEAR, Polygon, Avalanche and more, Zoo will soon deploy its Habitat Index Protocol to multiple EVM compatible Layer 1 and Layer 2s, creating the multi-chain index standard prepared to onboard the next billion crypto investors.
View original content to download multimedia:
SOURCE Indexzoo
|
https://www.wistv.com/prnewswire/2022/04/06/indexzoo-closed-2-million-seed-round-investment/
| 2022-04-06T13:03:19
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/indexzoo-closed-2-million-seed-round-investment/
|
BOSTON and ATLANTA, April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will host a virtual KOL investor event on Wednesday, April 20, 2022 at 10:00 am ET.
The virtual event will feature presentations and an interactive Q&A session from the Company's executive leadership team as well as key opinion leaders, Dr. Robert F. Hauser, Director of Parkinson's & Movement Disorder Center and Professor, College of Medicine Neurology at University of South Florida and Dr. Werner Poewe, Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria. Presentations will highlight recently presented Phase 1 and Phase 1b data for the Company's lead candidate, IkT-148009 for the treatment of Parkinson's disease, provide an overview of the upcoming Phase 2 program, and highlight the current unmet need and competitive landscape in Parkinson's disease.
A live webcast of the Company's event will be available on the "News & Events" in the Investors section of the Company's website at www.inhibikase.com. A replay of the webcast will be available for 90 days following the presentation.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:
SOURCE Inhibikase Therapeutics, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/inhibikase-therapeutics-host-virtual-kol-investor-event-april-20-2022/
| 2022-04-06T13:03:29
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/inhibikase-therapeutics-host-virtual-kol-investor-event-april-20-2022/
|
LANCASTER, Pa., April 6, 2022 /PRNewswire/ -- Advanced Cooling Technologies, Inc. (ACT) announced today the addition of a 32,000 ft2 Constant Conductance Heat Pipe (CCHP) manufacturing facility at its Lancaster, Pennsylvania location. The facility will be the largest of its kind for the Aerospace community.
"We're excited to be ahead of the demand of the industry on this product line. Our team is gearing up, our new equipment is ordered, and construction is beginning. I don't think there could be a more exciting time to be a part of the aerospace industry," said John Hartenstine, ACT's VP of Operations.
ACT has been manufacturing its CCHP product line in Lancaster since 2007. With the dramatic increase in satellite constellations, ACT spokespeople say the company is preparing for the future. The company currently produces approximately 2,000 CCHPs per year, and it plans to drastically increase output by 2024 with projections of 22,000 heat pipes per year. An aspect that sets this project apart from ACT's competitors' CCHP production lines is that this facility is not set aside for a particular constellation or customer.
Speaking about ACT's work with the space industry, Bryan Muzyka, Manager of Sales and Marketing, commented that "satellites of all sizes need to manage their waste heat; we're in the business of not only finding innovative ways to do that, but are proud to offer our customers a proven solution with over 60 million hours of spaceflight heritage without failure that they can trust will work."
CONTACT: Megan Ulrich, megan.ulrich@1-act.com
View original content to download multimedia:
SOURCE Advanced Cooling Technologies, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/introducing-largest-dedicated-facility-space-flight-constant-conductance-heat-pipes/
| 2022-04-06T13:03:40
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/introducing-largest-dedicated-facility-space-flight-constant-conductance-heat-pipes/
|
JACKSON, Miss., April 6, 2022 /PRNewswire/ -- Jackson State University President Thomas K. Hudson, J.D., Provost Alisa Mosley, Ph.D. and College of Business Dean Fidelis M. Ikem, Ph.D. gathered with students, faculty and staff to unveil the newly named BankPlus atrium within the College of Business. BankPlus has proudly supported the institution with more than $1 million, the first company to make this level of commitment to JSU. The event also recognized The BankPlus Endowed Chair in Accounting with the Jackson State University Development Foundation, Inc. The endowment will support costs related to research, teaching and outreach by the chair-holder in the JSU College of Business.
"We are honored to acknowledge BankPlus as a corporate partner who has supported Jackson State throughout the years in the way of sponsorships, scholarships to deserving students and through the establishment of the endowed chair in accounting," said President Hudson. "This BankPlus atrium recognizes their commitment to the College of Business and the success of our university and our community as a whole."
BankPlus President and CEO William A. Ray said the company is committed to continuing its relationship with JSU, which aligns with the bank's mission to enrich lives and build stronger communities. Having honed his skills in the world of public accounting before entering banking, Ray hopes the endowed chair in accounting will facilitate more graduates to enter the world of banking and finance. The chair position is just one of several areas of support that the BankPlus has provided over the years, including event sponsorships, scholarships and support of Athletics, the Drama Club and more.
"In 2006 we made a promise to Jackson State to not only be a sponsor of the school, but to be a true corporate partner on campus and in the neighborhood. The Dalton street branch, just down the street, was a multi-million-dollar commitment to this community. One of the largest private commitments to the area in the last 30 years."
Provost Mosley thanked BankPlus for embracing JSU's mission and vision to train students who are prepared to meet the 20th century needs of Corporate America.
"This strong partnership with BankPlus allows JSU to enhance financial literacy within our local community, promote small businesses and expose our scholars to the world of commercial banking, which is an important industry for our students to immerse themselves in. Having these funds will assist us in developing an overall model of success," said Mosley.
About Jackson State University: Challenging Minds, Changing Lives
Jackson State University, founded in 1877, is a historically black, high research activity university located in Jackson, the capital city of Mississippi. Jackson State's nurturing academic environment challenges individuals to change lives through teaching, research and service. Officially designated as Mississippi's Urban University, Jackson State continues to enhance the state, nation and world through comprehensive economic development, healthcare, technological and educational initiatives. The only public university in the Jackson metropolitan area, Jackson State is located near downtown, with five satellite locations throughout the area. For more information, visit www.jsums.edu or call 601-979-2121.
About the College of Business
The College of Business at Jackson State University is fully accredited by the Association to Advance Collegiate Schools of Business (AACSB International), the highest business school accrediting body in the world. The college is also accredited by the Network of International Business Schools (NIBS). NIBS accreditation recognizes business schools that have demonstrated a commitment to internationalization in all facets of their organization.
View original content to download multimedia:
SOURCE Jackson State University
|
https://www.wistv.com/prnewswire/2022/04/06/jackson-state-university-unveils-bankplus-atrium-college-business-honor-longstanding-corporate-partnership/
| 2022-04-06T13:03:46
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/jackson-state-university-unveils-bankplus-atrium-college-business-honor-longstanding-corporate-partnership/
|
The sale of Flatiron Park represents the largest single asset sale in Colorado history
DENVER, Apr. 6, 2022 /PRNewswire/ -- JLL's Capital Markets group announced today that it has closed the record-setting sale of Flatiron Park, a 22-building life sciences and office campus totaling one million square feet in Boulder, Colorado.
JLL worked on behalf of the seller, a joint venture between Crescent Real Estate, the Real Estate business of Goldman Sachs Asset Management and Lionstone Investments. BioMed Realty, a Blackstone portfolio company and leading provider of real estate solutions to the life science and technology industries, purchased the asset. The sale represents the largest single asset sale in Colorado's history.
Flatiron Park comprises biomanufacturing, research & development and creative office space that is currently 90% leased to a mix of industry-leading technology and life sciences firms. The property also boasts in-demand tenant amenities, including an on-site gym, numerous restaurants and a food truck court.
Its location in the Boulder area and near the University of Colorado Boulder allows the property to draw from one of the most highly educated workforces in the country. In addition to the robust pipeline of skilled labor, Boulder offers companies a well-established ecosystem of best-in-class universities and public institutions and an ease of recruitment due to its renowned quality of life.
The JLL Capital Markets team representing the seller was led by Mark Katz, Peter Merrion and Hilary Barnett and supported by Phillip Anderson and Kelly Kramer.
"BioMed's acquisition of Flatiron Park will greatly benefit the rising life sciences ecosystem in Colorado," Katz said. "BioMed is one of the top life sciences and technology real estate companies in the world and we are unbelievably excited to see where they will take this project."
The JLL Capital Markets group is a full-service global provider of capital solutions for real estate investors and occupiers. The team's in-depth local market and global investor knowledge delivers the best-in-class solutions for clients — whether investment sales and advisory, debt advisory, equity advisory or a recapitalization. The firm has more than 3,000 Capital Markets specialists worldwide with offices in nearly 50 countries.
For more news, videos and research resources on JLL, please visit our newsroom.
About Crescent
Crescent Real Estate LLC (Crescent) is a real estate operating company and investment advisor, founded by Chairman John C. Goff, with assets under management, development, and investment capacity of more than $10 billion. Through the GP Invitation Fund I, GP Invitation Fund II, and GP Invitation Fund III, the company acquires, develops, and operates all real estate asset classes alongside institutional investors and high net worth clients. Crescent's premier real estate portfolio consists of Class A and creative office, life science, multifamily, hospitality, and senior living assets located throughout the U.S., including The Ritz-Carlton, Dallas, and the wellness lifestyle leader, Canyon Ranch®. For more information, visit www.crescent.com.
About Goldman Sachs Asset Management Real Estate
Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs (NYSE: GS), the company delivers investment and advisory services for the world's leading institutions, financial advisors and individuals, drawing from its deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of December 31, 2021. Driven by a passion for their clients' performance, Goldman seeks to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. Goldman Sachs Asset Management invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate and infrastructure. Established in 1991, the Real Estate business within Goldman Sachs Asset Management is one of the largest investors in real estate with over $50 billion in assets invested since 2012 across the spectrum of investment strategies from core to opportunistic. The global team invests across all sectors with deep expertise across the capital structure, in assets ranging from single properties to large portfolios, through senior mortgages, mezzanine debt and equity. Follow Goldman on LinkedIn.
About Lionstone Investments
Lionstone Investments is a data-analytics driven real estate investment firm that conceptualizes, analyzes, and executes national investment strategies using proprietary algorithms and advanced analytics to strategically pinpoint the locations where innovation, economic vitality, and productivity intersect to create sustainable and vibrant communities — Places for Productive People.® Generating smart insight via sophisticated analytic tools, Lionstone is able to identify the highest concentrations of growth and productivity in the U.S. economy. This unique approach finds durable growth and resilient income in a rapidly evolving world. Lionstone Investments is a wholly-owned subsidiary of Columbia Management Investment Advisers, LLC. Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies. Please visit: LionstoneInvestments.com.
About BioMed Realty
BioMed Realty, a Blackstone portfolio company, is a leading provider of real estate solutions to the life science and technology industries. BioMed owns and operates high quality life science real estate comprising 13.7 million square feet concentrated in leading innovation markets throughout the United States and the United Kingdom, including Boston/Cambridge, San Francisco, San Diego, Seattle and Cambridge, U.K. In addition, BioMed maintains a premier development platform with 3.5 million square feet of Class A properties in active construction in these core innovation markets to meet the growing demand of the life science and technology industries. To learn more about BioMed Realty, visit biomedrealty.com and follow the company on Twitter @biomedrealty.
About JLL
JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of $19.4 billion in 2021, operations in over 80 countries and a global workforce more than 98,000 as of December 31, 2021. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit jll.com.
Connect with us:
https://www.linkedin.com/company/jll
https://www.facebook.com/jll
https://twitter.com/jll
https://www.instagram.com/jll
Contact: Kristen Murphy, JLL Director, Public Relations
Phone: +1 617 848 1572
Email: Kristen.Murphy@am.jll.com
View original content to download multimedia:
SOURCE JLL
|
https://www.wistv.com/prnewswire/2022/04/06/jll-closes-sale-flatiron-park-boulder-colorado/
| 2022-04-06T13:03:53
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/jll-closes-sale-flatiron-park-boulder-colorado/
|
Bed Bath & Beyond® and buybuy BABY® selection now available on Kroger.com
CINCINNATI AND UNION, N.J., April 6, 2022 /PRNewswire/ -- The Kroger Co. (NYSE: KR), America's largest grocery retailer, and Bed Bath & Beyond Inc. (NASDAQ: BBBY), a leading omnichannel retailer for home, baby, and wellness products, today announced the launch of the companies' e-commerce experience.
"When our customers think of food, they think of Kroger," said Stuart Aitken, Kroger's Senior Vice President and Chief Merchant & Marketing Officer. "And we're more than just food. This collaboration expands our e-commerce selection, enabling our customers to send a new homeowner a beautiful cheese board and the cheese that goes with it. Or they can send new parents a stroller alongside diapers and a Home Chef meal – all in one digital transaction, saving our customers time and providing a positive shopping and gifting experience."
The multi-category omnichannel collaboration, which includes some of the most sought-after items from bedding and storage to baby furniture and gear, was first announced in November 2021.
"We are very pleased to expand our customer base through the extensive reach of Kroger, the largest grocer in the U.S.," said John Hartmann, Chief Operating Officer of Bed Bath & Beyond Inc. and President of buybuy BABY. "With our authoritative line of products for every room of the home, including our exclusive Owned Brands, and leading line of items that help welcome moms and dads to parenthood, we are excited to provide Kroger shoppers with a compelling one-stop shopping experience. We're also well underway with the planning and design of our Kroger in-store pilot program and look forward to its launch later this year."
The e-commerce venture enabled by Kroger's Ship marketplace has added several thousand items from Bed Bath & Beyond and buybuy BABY. The curated digital experience is divided into easily shoppable categories to help customers find exactly what they need quickly. Shoppers can browse among favorite items, including Bed Bath & Beyond's exclusive Owned Brands – NestwellTM, Haven®, Simply EssentialTM, Our TableTM, Wild SageTM, Squared AwayTM, Studio 3BTM and H for HappyTM, as well as leading national brands. Popular items now available on Kroger.com include:
From Bed Bath & Beyond:
- Our Table™ 12-inch Preseasoned Cast Iron Skillet
- Haven® Organic Cotton Flatweave Bath Towel
- Nestwell™ Washed Linen Cotton 3-Piece Full/Queen Duvet Cover Set
- Cuisinart® Power Advantage 7-Speed Hand Mixer with Storage Case
- Nespresso by Breville Vertuo Next Classic Coffee/Espresso Maker Bundle
- iRobot® Roomba® j7+ (7550) Wi-Fi® Connected Self-Emptying Robot Vacuum
- Ninja® CREAMi™ Ice Cream Maker
From buybuy BABY:
- SKIP*HOP® Silver Lining Cloud Activity Center and Exerciser
- Fridababy NoseFrida® Electric Nasal Aspirator
- Graco® 4Ever® DLX 4-in-1 Convertible Car Seat
- Boppy® Original Nursing Pillow and Positioner
- Dr. Brown's® Deluxe Bottle Warmer & Sterilizer
A branded shop-in-shop experience piloted in select stores will follow.
To download Kroger and Bed Bath & Beyond visuals, please visit here.
At The Kroger Co. (NYSE: KR), we are Fresh for Everyone™ and dedicated to our Purpose: To Feed the Human Spirit®. We are, across our family of companies, nearly half a million associates who serve over 11 million customers daily through a seamless shopping experience under a variety of banner names. We are committed to creating #ZeroHungerZeroWaste communities by 2025. To learn more about us, visit our newsroom and investor relations site.
Bed Bath & Beyond Inc. and subsidiaries (the "Company") is an omnichannel retailer that makes it easy for our customers to feel at home. The Company sells a wide assortment of merchandise in the Home, Baby, Beauty and Wellness markets. Additionally, the Company is a partner in a joint venture which operates retail stores in Mexico under the name Bed Bath & Beyond.
The Company operates websites at bedbathandbeyond.com, bedbathandbeyond.ca, buybuybaby.com, buybuybaby.ca, harmondiscount.com, facevalues.com, and decorist.com.
View original content to download multimedia:
SOURCE The Kroger Co.
|
https://www.wistv.com/prnewswire/2022/04/06/kroger-bed-bath-amp-beyond-inc-launch-national-e-commerce-experience-expanding-krogers-home-baby-offering/
| 2022-04-06T13:04:02
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/kroger-bed-bath-amp-beyond-inc-launch-national-e-commerce-experience-expanding-krogers-home-baby-offering/
|
Mr. Girand's placement expands presence in the Southeast (Florida) and positions firm for further expansion into one of the fastest growing areas in the nation.
DALLAS, April 6, 2022 /PRNewswire/ -- Lear Investment Management ("Lear"), a Dallas-based investment firm focused on portfolio management, research, and superior outcomes, today announced G. Keith Girand has joined the firm as the Director of Business Development.
Mr. Girand will be based out of Lear's Winter Park, FL office and will lead the firm's business development efforts for prospective investors, including financial advisors of both broker/dealers and registered investment advisors (RIAs).
A 26-year industry veteran, Mr. Girand joins Lear from AssetMark, where he spent the past 13 years as a Regional Consultant. During his tenure Mr. Girand partnered with many of the Southeast's top advisors by assisting with portfolio construction, manager selection and practice management.
Managing Partner Rick Lear said, "As Lear marks its 7th anniversary, we continue to see significant opportunities to partner with top Advisors around the country. To continue to build upon our impressive track record of delivering equity like returns with less than equity risk, we must attract and retain the brightest people, who also have a shared sense of purpose and passion for serving clients. Keith brings decades of experience, deep advisor relationships and a strong desire to help his clients grow their businesses. Importantly, Keith's appointment adds to our growing business development group which, will continue to enable the investment team to focus on what we do best: invest wisely and opportunistically. We welcome Keith to the Lear Investment Management team and look forward to his many contributions."
According to Mr. Girand, "The investment industry is changing rapidly. Increased market volatility will make generating strong returns more difficult in the decade ahead. With a focus on primary research, risk management and a deep commitment to the client experience, Lear is positioned well to succeed in this environment. I am honored to join the firm and look forward to sharing Lear's capabilities with the Advisors I've worked closely with for the past 26 years."
About Lear Investment Management
The Lear Investment Management team comprises research-driven experts oriented around creative intelligence-gathering and an investment process that balances quantitative analysis, rigorous fundamental research grounded in capitalizing on global economic trends, and acute attention to risk management. The research team's vast experience, coupled with its differentiated investment process, facilitates Lear's ability to develop and execute a global investment thesis. The firm's clients include select individuals, families, and foundations. Lear also serves as a sub-advisor to financial advisors and institutions seeking an investment manager with Lear's investment capabilities.
For more information, please visit www.learim.com.
Contact
Lynn Sandt lynn@learim.com
Investment Advisory Services offered through Lear Investment Management, an SEC-registered investment adviser.
Related Links
learim.com
NEWS PROVIDED BY
Lear Investment Management
April 6, 2022, 08:30 (ET)
SHARE THIS ARTICLE
View original content to download multimedia:
SOURCE Lear Investment Management
|
https://www.wistv.com/prnewswire/2022/04/06/lear-investment-management-names-industry-veteran-keith-girand-its-director-business-development-southeast-region/
| 2022-04-06T13:04:13
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/lear-investment-management-names-industry-veteran-keith-girand-its-director-business-development-southeast-region/
|
STAMFORD, Conn., April 6, 2022 /PRNewswire/ -- Industry leader, The Lockwood Group (Lockwood), a scientific medical communications agency, has been recognized by the Financial Times in their third annual ranking of The Americas' Fastest Growing Companies 2022. Lockwood is one of only 500 innovative and fast-growing companies recognized as a driving force of the economy by generating jobs and sustaining market competitiveness.
Lockwood Chief Executive Officer Matthew Schecter said of the award, "We are humbled to once again be recognized by the Financial Times for this incredible achievement. Our continued growth is possible due to the hard work, dedication, and outstanding strategic work our teams deliver every day for each other and our clients."
This prestigious award honors 500 outstanding companies among the millions of North and South American enterprises. The rating is the result of a joint project by the Financial Times and Statista. The results were achieved by conducting months of research, public calls, and intensive database research and by directly contacting tens of thousands of companies.
Lockwood collaborates with clients in the pharmaceutical, biotechnology, genetic, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical communications. With more than 160 of Lockwood's nearly 400 team members holding advanced scientific or medical degrees, Lockwood has been able to scale at size because most team members work from where they live. This flexible structure provides better work-life balance, which in turn allows Lockwood to attract the best talent who facilitate their best work and are more responsive to client needs wherever and whenever they do business.
This latest award further reinforces Lockwood's recognition for growth and workplace excellence. Lockwood is a 5-time Inc 5000 Fastest Growing Private Company, an Inc 5000 Fastest Growing Private Company in the New York Metro Region, an 8-time honoree of the Best Places to Work in Connecticut award, and a 3-time Medical, Marketing and Media (MM&M) Best Place to Work.
About Lockwood
www.thelockwoodgrp.com
Founded in 2007 and headquartered in Stamford, Connecticut, Lockwood communicates clinical and therapeutic advances to every variety of medical experts, healthcare practitioners, and decision makers. For the ultimate benefit of patients, Lockwood helps clients advance their objectives in a world of new regulations, business models, payment approaches, technologies, roles, and work practices. Lockwood teams are organized around the specific needs of each client. With experience in all major therapeutic areas and many rare diseases, along with highly specialized knowledge in biologics, devices, and diagnostics, Lockwood can quickly deploy the right scientific, business, and communications experts to address the challenges at hand.
View original content to download multimedia:
SOURCE The Lockwood Group
|
https://www.wistv.com/prnewswire/2022/04/06/lockwood-group-recognized-by-financial-times-3-time-americas-fastest-growing-company/
| 2022-04-06T13:04:20
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/lockwood-group-recognized-by-financial-times-3-time-americas-fastest-growing-company/
|
Exclusive Distribution Agreement Brings Point-of-Care (POC) Hematology Diagnostics to New Regions in the Middle East
YOKNEAM ILLIT, Israel, April 6, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced that it has signed an exclusive distribution agreement with United MakGroup Technologies L.L.C. (MakGroup Healthcare) to distribute HemoScreen™ across the United Arab Emirates. PixCell's HemoScreen delivers lab-accurate diagnostic information from a single finger-prick of blood within five minutes, facilitating rapid and reliable clinical decision-making supported by real-time diagnostic data.
Headquartered in Dubai, MakGroup Healthcare is a leading distributor of medical devices across the Middle East, providing access to advanced technological solutions for applications in laboratory, radiology and cardiology settings. With no existing reliable and efficient solutions for point-of-care (POC) diagnostic testing in the region, the company is expanding its product portfolio to distribute PixCell's HemoScreen, the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for POC use.
"Providing cost-effective and smart medical device solutions is central to our mission, and PixCell brings a unique offering to the market – an exceptionally simple, portable and miniaturized CBC analyzer that offers critical results when they are needed most," said Zahir Ali, Director of Healthcare at MakGroup Healthcare. "The importance of improving access to care has become increasingly evident. Point-of-care diagnostics allow for enhanced clinical decision-making and reduced turnaround time, and we are confident that this partnership with PixCell will support us in delivering a rapid solution for the world's most common blood test to improve access to quality healthcare in the Middle East."
Utilizing a patented, disposable cartridge preloaded with all necessary reagents, HemoScreen™ reduces reagent waste and eliminates the need for device maintenance and calibration. Designed for ease of use by non-technical operators, HemoScreen provides CBC results as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types. PixCell's goal is to increase access to CBC blood testing to improve patient care and outcomes.
"As society pivots to a wider adoption of point-of-care diagnostic testing, we are proud to be at the forefront of this healthcare revolution, adding another HemoScreen distribution deal to our growing list of partnerships," said Dr. Avishay Bransky, co-founder and CEO of PixCell Medical. "We are proud to collaborate with a leading and trusted provider of healthcare solutions, a company known for its uncompromising quality. We are confident that MakGroup Healthcare will serve as an excellent partner and help to dramatically improve the accessibility of the CBC, the most essential blood test, within the markets it serves."
About PixCell Medical
PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care use – the HemoScreen™. The portable, easy to use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. This facilitates fast diagnostic results and data-driven disease management decisions. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.
For more information: www.pixcell-medical.com
Follow PixCell Medical on LinkedIn and Twitter.
Media Contact:
FINN Partners for PixCell Medical
Lior Feigin
lior.feigin@finnpartners.com
@LiorFeigin
About MakGroup Healthcare
United MakGroup Technologies L.L.C. (MakGroup Healthcare) is the leading, trusted and well-known healthcare solutions provider in the ME region. Its core domain expertise lies in the sectors of laboratory, radiology, dental and cardiology. With a strong focus on delighting its customers, its solutions are backed with unmatched after-sales support & services which are a benchmark in the industry. The company has spent years fostering valuable partnerships with the world's leading healthcare companies and this paired with a skilled and certified team of specialist engineers has helped MakGroup Healthcare in maintaining excellent relationships with its client base. MakGroup Healthcare has a strong understanding of local needs, coupled with access to international expertise and technologies.
Contact:
Christina Thomas
Marketing Communications Manager
United MakGroup Technologies LLC
christina@makgroup.ae
+971 4 3374005
Logo - https://mma.prnewswire.com/media/1501459/PixCell_Medical_Logo.jpg
View original content:
SOURCE PixCell Medical
|
https://www.wistv.com/prnewswire/2022/04/06/makgroup-healthcare-becomes-sole-distributor-pixcell-medicals-hemoscreen-uae/
| 2022-04-06T13:04:26
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/makgroup-healthcare-becomes-sole-distributor-pixcell-medicals-hemoscreen-uae/
|
NEW YORK, April 6, 2022 /PRNewswire/ -- Mantese Honigman, P.C. is pleased to announce the opening of its New York City law office at 250 E. 54th. # 25A. The firm also has offices in the Detroit area and in St. Louis. The firm's CEO, Gerard V. Mantese, has recently been appointed co-Chair of the Committee on Corporation Law for the New York County Lawyers Association. Attorneys interested in becoming involved in the Committee are invited to contact Mr. Mantese through his assistant, Brenda Ren, at bren@manteselaw.com.
The firm focuses on complex business litigation, including shareholder disputes and business divorces. Elsewhere, the firm is counsel for public school teachers in a class action in Pennsylvania. There, the firm filed suit against investment consultants for the Pennsylvania Public School Employees' Retirement System (PSERS). The suit alleges that poor investment advice and inadequate supervision have cost the pension plan hundreds of millions of dollars and have resulted in public school teachers being forced to pay millions in extra pension contributions.
CONTACT: Gerard V. Mantese
Mantese Honigman, P.C.
212-401-4008
248-457-9200
gmantese@manteselaw.com
View original content:
SOURCE Mantese Honigman, P.C.
|
https://www.wistv.com/prnewswire/2022/04/06/mantese-honigman-pc-opens-law-office-new-york-city/
| 2022-04-06T13:04:33
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/mantese-honigman-pc-opens-law-office-new-york-city/
|
Outdoor Leader Kicks Off New Sustainability Campaign by Introducing 'ReTread' – An Exchange Program that will Preserve Nature and Keep Footwear Out of Landfills
ROCKFORD, Mich., April 6, 2022 /PRNewswire/ -- Merrell®, the leading outdoor performance and lifestyle brand, today announced This Is Home, a multi-year sustainability initiative designed to inspire consumers to protect the nature that shapes their everyday lives. The campaign will focus on digital, social, and connected TV while showcasing Merrell footwear and apparel that is made with more sustainable materials. The goal is to inspire people to get outside while minimizing their environmental impact.
To kick off the inaugural year of This Is Home, Merrell is launching a multinational product takeback and resale program called Merrell ReTreadSM, which will save 300,000 pairs of footwear from landfills in our own backyards. This first of its kind program introduces the takeback economy to the footwear industry and is a step towards a more circular economy. As part of Merrell's continuous commitment to sustainability, the company partnered with ReCircled to implement Merrell ReTreadSM. The program, which launches in April in the US and Canada, allows consumers the opportunity to give back Merrell footwear. Once received, the footwear will be repaired and refurbished for resale, broken down for use in new products, or recycled for alternative uses.
"The role of This is Home is to ignite our emotional connection to the outdoor environments around us, by encouraging people to deepen their experiences locally," says Chris Hufnagel, Global Brand President of Merrell. "We believe the outdoors is a place that people can always come home to, and that is why we are committed to preserve and protect the places we recreate. The Merrell ReTreadSM program is a firm step in our sustainable commitment, enabling us to extend the life of our Merrell footwear and giving people more options to minimize their environmental footprint."
To participate in the Merrell ReTreadSM program, consumers can visit retread.merrell.com to obtain a free return label to ship their used Merrell footwear to ReCircled. Once the shipment is collected, consumers will receive a $20 off promotion code* to either purchase new Merrell footwear or apparel. The ReTread program will continue to expand globally, with plans to launch in EMEA later this year.
The Merrell ReTreadSM program is one of the many pledges Merrell has made to deepen its commitment to sustainability through its This Is Home initiative. The company recently announced the sustainability goals they're striving to meet or exceed by 2025. This includes the following:
- 100 percent of products will contain organic, recycled, or renewable materials
- 100 percent responsibly sourced apparel materials
- Reduce shoe and apparel samples by 50 percent
- Reduce plastic packaging
- Complete 10,000 volunteer hours
- Save 300,000 pairs of footwear from ending up in landfills through ReTread program
As Merrell builds out the future of its upcoming collections, the brand is dedicated to embedding more eco-friendly and sustainable materials while balancing performance and durability. To learn more about Merrell's commitment to sustainability, please visit merrell.com/thisishome.
*Valid on a purchase of $80 or more in the US. Discount varies per region.
Merrell® exists to share the simple power of being outside and is committed to building an inclusive and sustainable environment for future generations to enjoy. As the global leader in outdoor active footwear with the Moab hiking boot and Jungle Moc, Merrell is focused on merging performance, styling, and comfort to empower all people to confidently explore the outdoors. Visit Merrell.com or follow us on social @Merrell. Merrell® is a division of Wolverine World Wide, Inc.(NYSE: WWW), one of the world's leading marketers and licensors of branded casual, active lifestyle, work, outdoor sport, athletic, children's and uniform footwear and apparel.
ReCircled is a global innovation company. Founded in 2019, their mission is to provide a novel approach to reuse of footwear and apparel. They provide process and infrastructure for clothing brands in the Circular Economy.
ReCircled has created a global process that closes the loop for circular initiatives. ReCircled works with footwear and apparel brands in North America, Europe and Asia. They have facilities in Sidney, NE and Prato, Italy.
ReCircled has built a proprietary digital process that administers take-back programs. The programs have both digital and bricks and mortar retail store applications. Consumers can return a brand's items through this portal. After assessment, items are upcycled or recycled. After cleaning, repair and photography, upcycled items are ready for resale on a brand's reCommerce site. Recycled items move on to the disassembly process. From this point, parts travel through the appropriate recycling streams.
View original content to download multimedia:
SOURCE Merrell
|
https://www.wistv.com/prnewswire/2022/04/06/merrell-announces-this-is-home-multiyear-sustainability-commttment-aimed-protecting-outdoors/
| 2022-04-06T13:04:41
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/merrell-announces-this-is-home-multiyear-sustainability-commttment-aimed-protecting-outdoors/
|
- The mileage point integration platform 'MiL.k' will enable services without boundaries among domestic and foreign customers and countries
- Ethereum-based Wrapped Milk Coin (WMLK) will be issued to globalize MiL.k, with an expectation to expand the NFT and DeFi ecosystems
- Wrapped Milk Coin has been listed on a decentralized crypto exchange called 'Uniswap,' MLK and WMLK can be swapped on the MiL.k app
SEOUL, April 6, 2022 /PRNewswire/ -- MiL.k, a leading blockchain service in South Korea, has embarked on global expansion.
Milk Partners (CEO Cho Jeong-Min), a company that operates a blockchain-based mileage point integration platform named 'MiL.k,' announced on the 6th of April that it will strengthen overseas partnerships for global expansion this year and present Wrapped Milk Coin (WMLK) based on Ethereum.
MiL.k is a service that allows users to combine and exchange mileage points acquired from different business areas using 'Milk Coin (MLK).' This service offers the benefit of increasing the utility and value of mileage points to users and an opportunity for affiliated companies to attract new customers and increase the loyalty of existing customers.
There are about 900,000 registered users on MiL.k, and many distinguished companies of Korea participate in the MiL.k ecosystem, including Yanolja (travel, leisure), Shinsegae Duty-Free (duty-free), Jin Air (airline), Megabox (multiplex theater), CU (convenience store), and Interpark (e-commerce).
Milk Partners plans to enter the Southeast Asian market during this year and expand its global service ecosystem. Southeast Asia is a popular tourist site among travelers from around the globe, including Korea. With a population that is twice as large as the United States, this region is drawing attention from the world for its fast-growing consumer market, dissemination of digital devices, advancement of technologies, and rapid growth of the digital market.
MiL.k will form partnerships with major local companies in Southeast Asia to create the same mileage point exchange ecosystem as South Korea. Through these efforts, MiL.k users will be able to receive unprecedented mileage point benefits when using the services of domestic and overseas companies.
There is additional news. Besides overseas expansion, Milk Partners has issued 'Wrapped Milk Coin (WMLK)' based on the standard blockchain network of Ethereum (ERC-20) to increase the convenience of its services. Wrapped Milk Coin is currently listed on 'Uniswap,' a leading decentralized exchange (DEX). Uniswap is an Ethereum-based, decentralized exchange that allows swapping between Ethereum and ERC-20 tokens. Unlike the conventional centralized exchanges, decentralized exchanges are characterized by individuals serving as intermediaries without an agency for peer-to-peer (P2P) transactions.
The MiL.k app allows users to exchange Milk Coin (MLK), the key currency of the MiL.k ecosystem, with Wrapped Milk Coin (WMLK). Since Wrapped Milk Coin is also available in the Ethereum ecosystem, it can apply to expanded blockchain systems like non-fungible tokens (NFT) and decentralized finance (DeFi) beyond the mileage point integration and exchange ecosystem of Milk Coin.
Cho Jeong-Min CEO of Milk Partners said, "MiL.k has become a useful daily service that offers unusual customer experience and benefits by creating a mileage point ecosystem with leading companies of Korea. He added, "This year, we will focus on forming partnerships with distinguished overseas companies and building a global ecosystem so that MiL.k can grow into a global cross-border platform removing boundaries among countries."
View original content to download multimedia:
SOURCE Milk Partners
|
https://www.wistv.com/prnewswire/2022/04/06/milk-partners-spurs-overseas-partnerships-start-global-expansion-this-year-prioritizing-entry-into-southeast-asian-market/
| 2022-04-06T13:04:48
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/milk-partners-spurs-overseas-partnerships-start-global-expansion-this-year-prioritizing-entry-into-southeast-asian-market/
|
- Patent valid through 2038
- Phase IIb ALS trial expected to commence H1 2022
CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled "Compositions comprising an anti-inflammatory drug and DICER activator for treatment of neuronal diseases" having the number 3,068,149. The patent covers NeuroSense's unique fixed-dose combination of ciprofloxacin and celecoxib, two US FDA-approved drugs that are the active ingredients in PrimeC, the Company's lead drug candidate for treating Amyotrophic Lateral Sclerosis ("ALS"). This patent has already been issued in the U.S. and Australia and is valid through 2038, subject to appropriate maintenance and renewal. The Company also received a patent allowance from the European Patent Office, and similar patent applications are pending in Japan and Israel. Additional patent applications relating to the novel formulation of PrimeC and methods for the treatment of other neurodegenerative diseases using NeuroSense's platform of combination therapies including StabiliC and CogniC are pending as well.
NeuroSense's PrimeC ALS program is headed into two clinical trials, a pharmacokinetic study to be conducted under an FDA IND which is slated to commence in the next few weeks, and a Phase IIb double-blind placebo controlled multinational study to commence Q2 2022. The Phase IIb study with PrimeC's unique formulation is expected to demonstrate results that may be superior to those already achieved in a previous Phase IIa study that met its endpoints. Concurrently, NeuroSense is investigating ALS biomarkers in conjunction with Massachusetts General Hospital with the aim of increasing the success in a future pivotal clinical study. Data from the Mass General biomarker study is expected Q2 2022.
"We are pleased to receive this most recent patent grant which adds to our growing IP portfolio at this important junction as we head into a Phase IIb study. ALS is an indication in dire need of an effective treatment, and we are determined to advance our program, backed by strong IP, toward market, fulfilling our commitment to people with ALS," stated Alon Ben-Noon, NeuroSense's CEO.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding patent applications; the company's PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.
Photo - https://mma.prnewswire.com/media/1781655/NeuroSense_Therapeutics.jpg
Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content to download multimedia:
SOURCE NeuroSense
|
https://www.wistv.com/prnewswire/2022/04/06/neurosense-therapeutics-granted-patent-canada-its-als-drug-primec/
| 2022-04-06T13:04:56
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/neurosense-therapeutics-granted-patent-canada-its-als-drug-primec/
|
Asurion Appliance Repair Provides Fast, In-Home Expert Repair of Major Appliances Including Refrigerators, Dishwashers, Washers, Dryers and More
CHARLESTON, S.C., April 6, 2022 /PRNewswire/ -- A new appliance repair company has opened in Charleston with highly trained experts providing quality, fast repairs as soon as next day. Asurion Appliance Repair experts can provide in-home repairs of major appliance brands including Whirlpool, Samsung, GE™, LG®, Electrolux® and more.
From refrigerator repair to fixing a broken dishwasher or dryer, Asurion Appliance Repair experts are able to complete many repairs in a single visit.
"Whether it's a broken ice maker, a freezer that stops freezing or a washer that leaks, our appliance repair experts can help," said Bridget Pai, Manager, Asurion Appliance Repair in Charleston. "We understand that life gets disrupted when the appliances you count on daily stop working correctly, and we're here with highly trained experts to get you back up and running quickly."
Appliance Repair Experts You Can Trust
Asurion Appliance Repair experts are highly trained in repairing Whirlpool, Samsung, GE™, LG®, Electrolux® and other major brands to provide quality repairs for today's modern appliances. Asurion Appliance Repair also has authorized service partnerships with major appliance brands which provides their repair experts with direct access to manufacturer parts to help fix customers' appliances fast. All Asurion appliance repairs are backed by a 60-day warranty on parts and labor.
"At Asurion Appliance Repair, we understand the disruption our customers experience when their appliances stop working," said Asurion Appliance Repair CEO Luke Smiley. "As we continue to build and expand our appliance repair business, we are making customer experience our top priority. The Asurion mission is about more than repairing broken refrigerators and dryers. We fix tech and appliances fast so our customers can get their lives back up and running."
Fast Repair, Because Waiting Isn't an Option
Charleston-area customers can call to schedule an appliance repair or book an appointment online. A technician will arrive at your home to complete your repair as soon as the next day. Service visits include a $99 diagnostic fee, which is waived when Asurion Appliance Repair is hired to fix your appliance.
For more information, to view a service menu, or to book a repair appointment, visit appliance-repair.asurion.com. Or contact Asurion Appliance Repair in Charleston at:
(843) 998-7084
About Asurion
Asurion is a global tech care company that provides insurance, installation, repair, replacement, and 24/7 support for a wide range of technology, from mobile phones and laptops to major household appliances. Our 12,000 experts are available online, on the phone, in store, or can even come to you. Asurion eliminates the fears and frustrations associated with technology to ensure its 300 million customers get the most out of their devices and connections.
View original content to download multimedia:
SOURCE Asurion
|
https://www.wistv.com/prnewswire/2022/04/06/new-appliance-repair-company-opens-charleston-amid-growing-demand/
| 2022-04-06T13:05:03
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/new-appliance-repair-company-opens-charleston-amid-growing-demand/
|
WASHINGTON and LOS ANGELES, April 6, 2022 /PRNewswire/ -- Women Business Collaborative (WBC) and 50/50 Women on Boards™ (50/50WOB) today released "Women Leading Boards," a new benchmark report for tracking board diversity.
"Women Leading Boards'' contains collective data and insight from 23 organizations focused on advancing women and diversity boards and is the only industry tracker for appointees across the Fortune 500, S&P 500, Russell 3000 and private companies. The report shows that 2021 was a watershed year for board diversity, with women representing 42.5% of all new appointees for public companies in the U.S. in 2021. Women hold 27% of all board seats in 2021, up from 24% in 2020—the largest year-over-year increase among the Russell 3000 and far above the Russell 3000's average annual increase of 2.14% for women on boards.
The report also shows the need for achieving greater diversity on boards. Based on those who chose to self-disclose their race, only 6% women of color and 9% men of color hold board seats.
Additionally, at the current rate of change women are not expected to hold 50% of corporate board seats for at least another eight years. To cut the timeline in half and reach this goal by 2026, the percentage of women appointees needs to increase by 5.8% year-over-year.
"This new report shows that while gender diversity is increasing in U.S. boardrooms, bold change still needs to occur," said Edie Fraser, CEO of WBC. "Additionally, with more women exiting the workforce due to the effect of the pandemic, organizations need to ensure a robust pipeline of qualified women board candidates."
"This report highlights the work that remains to continue to drive the movement for diversity on corporate boards," said Betsy Berkhemer-Credaire, CEO of 50/50 Women on Boards. "The more organizations shed light on this issue, the more women and women of color will be encouraged to find their path to a corporate board earlier in their careers."
The report also features six insight pieces from 50/50 WOB, Bolster, Diligent Institute, Digital Directors Network & Emerald Growth Partners LLC, the Latino Corporate Directors Association (LCDA) and The Lodis Forum.
Using data provided by WBC key partner organizations, key findings include:
- As of February 2022, 114 women were appointed to public company boards, with 58% of those women being appointed to a board for the first time.
- 42.3% of all public board appointments for the year 2021 were women.
- As of December 31, 2021, women hold 26.7% of the Russell 3000 company board seats, a 10.7% increase over the last five years.
- 61.6% of women appointments in 2021 were first-time appointments.
- The share of newly appointed directors who come from nontraditional backgrounds has increased from 13.0% to 18.9% since 2019.
To read the full report, please visit here.
About 50/50 Women on Boards (50/50WOB)
50/50 Women on Boards™ (50/50WOB), a nonprofit 501(c)3, is a leading education and advocacy campaign driving the movement toward gender balance and diversity on corporate boards. For more information visit: www.5050wob.com.
About Women Business Collaborative (WBC)
The Women Business Collaborative (WBC) is an unprecedented alliance of 65+ women's business organizations and hundreds of business leaders building a movement to achieve equal position, pay, and power for all women in business.
View original content:
SOURCE Women Business Collaborative
|
https://www.wistv.com/prnewswire/2022/04/06/new-report-women-business-collaborative-5050-women-boards-finds-2021-was-watershed-year-board-diversity-with-women-now-holding-27-all-board-seats/
| 2022-04-06T13:05:12
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/new-report-women-business-collaborative-5050-women-boards-finds-2021-was-watershed-year-board-diversity-with-women-now-holding-27-all-board-seats/
|
RICHMOND, Va., April 6, 2022 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) today announced its donation of the complete collection of historical documents and archives from predecessor company Norfolk and Western Railway to the Virginia Museum of History & Culture (VMHC).
The collection dates to the 1840s and includes thousands of photographs and glass plate negatives, as well as business records, annual reports, blueprints, plans, bridge drawings, advertisements, portraits, and three-dimensional artifacts from predecessor railroads that together provide a fascinating look into the growth of rail transportation across the eastern United States. The company will also donate $750,000 to support the collection in perpetuity.
"The Commonwealth of Virginia has played a pivotal role in our history, and we are incredibly proud of the contributions it has made to our success," said Jim Squires, Chairman and CEO of Norfolk Southern. "This important piece of history belongs in Virginia, and we're confident that our archives will be in excellent hands with the Virginia Museum of History & Culture."
Norfolk and Western originated as a nine-mile single-track line in 1838 to connect Petersburg and City Point (now Hopewell), Virginia. In the years to follow, more than 200 railroad companies were built, merged, reorganized, and consolidated until the company merged with Southern Railway in 1982 to create Norfolk Southern. Since then, Norfolk Southern has grown to become one of the nation's largest freight railroads and premier transportation companies. In total, the archives represent the history of Norfolk and Western and its predecessor companies.
"Railroads have played a critical role in the expansion of both passenger travel and commercial transportation in the United States," said VMHC President & CEO Jamie Bosket. "With the addition of the Norfolk and Western collection, the VMHC now houses one of the most significant railroad archives in the U.S. We're thrilled to preserve this iconic history and to make it publicly available to students and teachers, researchers, and railroad enthusiasts."
The $750,000 grant will allow the VMHC to digitize, catalog and preserve the collection. As part of the donation, Norfolk Southern has created a special fund to allow the VHMC to hire interns from underrepresented communities to support the museum's work annually for the next five years, beginning this coming fall academic semester.
Among the historic materials in the archives are publicity materials including radio program scripts and posters, timetables, and rolling stock records as well as advertisements, contracts, an extensive collection of photographs, and construction plans for rail stations and yards.
About Norfolk Southern
Norfolk Southern Corporation (NYSE: NSC) is one of the nation's premier transportation companies, moving the goods and materials that drive the U.S. economy. Norfolk Southern connects customers to markets and communities to economic opportunity, with safe, reliable, and sustainable shipping solutions. The company's service area includes 22 states and the District of Columbia, every major container port in the eastern United States, and a majority of the U.S. population and manufacturing base.
About the Virginia Museum of History & Culture
The Virginia Museum of History & Culture is owned and operated by the Virginia Historical Society — a private, non-profit organization established in 1831. The historical society is the oldest cultural organization in Virginia, and one of the oldest and most distinguished history organizations in the nation. For use in its state history museum and its renowned research library, the historical society cares for a collection of nearly nine million items representing the ever-evolving story of Virginia.
View original content to download multimedia:
SOURCE Norfolk Southern Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/norfolk-southern-donates-norfolk-western-railway-archives-750000-virginia-museum-history-amp-culture/
| 2022-04-06T13:05:19
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/norfolk-southern-donates-norfolk-western-railway-archives-750000-virginia-museum-history-amp-culture/
|
— Dr. Rajesh is a veteran stem cell biologist, cancer immunologist, and innovator in the directed differentiation of human pluripotent stem cells (iPSCs) —
VANCOUVER, BC , April 6, 2022 /PRNewswire/ -- Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, is pleased to announce the appointment of Deepika Rajesh as VP, Stem Cell Biology and Developmental Immunology. Dr. Rajesh joins Notch from FUJIFILM Cellular Dynamics, Inc. (FCDI), where she was most recently Senior Director, Research & Development. Dr. Rajesh will be based in Notch's new research and development facility in Vancouver.
"The people who work at Notch are some of the most innovative minds in biotech today—a balance of seasoned industry veterans and emerging young talent—and we are pleased to welcome Deepika to the team," said David Main, President and Chief Executive Officer of Notch. "Deepika's career has focused on the complex biology we're developing to commercial standards, and we are grateful for her leadership and experience as we apply our proprietary technology to maximize the benefits of cell therapies."
Dr. Rajesh is a stem cell biologist and cancer immunologist with more than 20 years of experience leading teams developing innovative stem cell products. She brings to Notch a record of technical innovation that includes more than 20 granted and pending patent applications worldwide. Her research has focused primarily on reprogramming various somatic cell types into human pluripotent stem cells (iPSCs) and their subsequent differentiation into hematopoietic, cardiovascular, neural, hepatic, and pancreatic lineages. Over the course of her career, she has managed multidisciplinary teams in research, intellectual property, manufacturing, and quality control to launch a variety of iPSC-derived cell types for disease modeling and drug discovery markets. Dr. Rajesh received a Ph.D. in Applied Biology from the University of Mumbai, India, and completed her postdoctoral fellowship at the University of Wisconsin–Madison.
"I've spent more than 25 years investigating the immune system's response to cancer and understand the transformational benefits cell therapies offer over existing standards of care," said Dr. Rajesh. "Notch's technology platform unlocks the ability to generate T cells and other immune cells from renewable stem cell lines, and I am excited to be playing a part in developing future-generation cell therapies that will change the way we treat and cure cancer."
About Notch Therapeutics
Notch is an early-stage biotech company working to maximize the benefit of cell therapies through a proprietary T cell-production platform that combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch's iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells. www.notchtx.com.
Media Contact:
Megan Helmer
Puzzlewood Communication Inc.
1.604.240.5223
megan@puzzlewood.ca
View original content:
SOURCE Notch Therapeutics
|
https://www.wistv.com/prnewswire/2022/04/06/notch-therapeutics-welcomes-deepika-rajesh-vp-stem-cell-biology-amp-developmental-immunology/
| 2022-04-06T13:05:29
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/notch-therapeutics-welcomes-deepika-rajesh-vp-stem-cell-biology-amp-developmental-immunology/
|
Increases ARR Over 300%, Launches Two Groundbreaking New Products, Announces Major Partnership
SUNNYVALE, Calif., April 6, 2022 /PRNewswire/ -- OpsMx, provider of an Intelligent Continuous Delivery Platform, today announced strong momentum for the most recently completed fiscal year ended in January. Total Annual Recurring Revenue (ARR) increased over 300% compared to the prior fiscal year, with half of new customers having over $1 billion in revenue. The company delivered two new critical capabilities for its Intelligent Continuous Delivery Platform, along with a new partnership with Google Cloud. OpsMx also continued its thought leadership efforts, conducting 23 webinars that provided in-depth information and best practices related to automating, accelerating, and securing Continuous Delivery (CD) pipelines to enhance moving software into production.
"The need to deliver better quality software faster, more reliably and with minimal human involvement continues to drive demand for OpsMx. We take a comprehensive, data-driven approach to accelerating Continuous Delivery pipelines, reducing release risk, and increasing the productivity of DevOps teams by leveraging deep integrations with popular CI/CD tools and applying AI and machine learning," said Gopal Dommety, CEO of OpsMx. "The most recently completed fiscal year ended in January 2022 was an excellent year as we continued to deliver the solutions our customers need to automate their workflows, centralize policy management, and implement the latest CD best practices. In the coming fiscal year, we will be releasing more new capabilities designed to further improve time-to-value and enhance control over the CD process."
Growth vs. Prior Fiscal Year
- Over 300% increase in Annual Recurring Revenue
- More than doubled bookings from new customers
- Nearly doubled employee headcount
Products, Services, Partnerships
- Announced a new partnership with Google Cloud to deliver OpsMx and expert Spinnaker support for Google Cloud customers.
- Released Autopilot, an intelligent, data-driven software solution for continuous delivery, providing automated self-governing and self-healing for CI/CD pipelines containing popular DevOps tools such as Spinnaker, Argo and Jenkins.
- Released OpsMx Intelligent Cloud, a SaaS solution that leverages AI/ML to deliver intelligent software delivery at cloud scale.
Industry Thought Leadership
The 23 webinars offered by OpsMx in 2021 included the following topics and more:
- Exploring Progressive Delivery – The Cutting Edge of CD
- SaaS Spinnaker: Modernizing Jenkins CI/CD Pipelines
- Jenkins to Spinnaker – Shift Your Continuous Delivery to the Left
- Faster, Safer, and Happier Deployments to Kubernetes
- GitOps and Continuous Delivery Best Practices
- Deploy Kubernetes Applications Safely Using Argo and Autopilot
- Accelerate Release Velocity with Spinnaker While Reducing Risk
- Secure Your Continuous Delivery Using Machine Learning
- Accelerate Your Continuous Delivery Journey in One Hour
- 5G, Cloud, and the Edge: Mastering Software Delivery
- Four Steps to Secure Your CI/CD Pipelines with Vault
- SaaS Spinnaker: Secrets of Successful Software Delivery
About OpsMX
OpsMx helps companies achieve their Digital Transformation goals around modernizing their software delivery processes and moving their systems to the cloud. The OpsMx Intelligent Continuous Delivery Platform provides end-to-end insights and control over the software delivery process through a single pane of glass. The solution dramatically increases the productivity of development, DevOps, and operations personnel by intelligently increasing the velocity and accuracy of releases, enhancing security and compliance for development teams and their workflows, and automating the Continuous Delivery process. Native integration with more than 50 common CI/CD tools – such as Spinnaker, Argo and Jenkins – helps slash time-to-value. The open design allows development teams to continue using the tools they love, while DevOps, security and compliance teams gain the end-to-end visibility, control, and audit capabilities they require. OpsMx is trusted by leading enterprises worldwide. For more information, visit opsmx.com.
All product and company names herein may be trademarks of their registered owners.
View original content to download multimedia:
SOURCE OpsMx Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/opsmx-continues-strong-momentum-most-recent-fiscal-year/
| 2022-04-06T13:05:36
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/opsmx-continues-strong-momentum-most-recent-fiscal-year/
|
PeriWatch Vigilance recognized for applying AI to revolutionize clinicians' ability to protect expectant mothers and their babies
CARY, N.C., April 6, 2022 /PRNewswire/ -- PeriGen Inc., the market leader in computerized maternal-fetal early warning systems, has been awarded 'Best AI Product in Health' for its PeriWatch Vigilance solution at the 2022 CogX Awards in London. The award is given annually to a product that harnesses AI to take on new challenges within the health sector. Vigilance uses FDA-cleared AI pattern recognition to consistently identify and visualize troubling trends in childbirth.
Now in its sixth year, the CogX Awards have championed some of the finest practitioners of innovation across the world. The awards celebrate those innovators, visionaries, and change-makers who are impacting the world, helping us get the next ten years right. The Best AI Product categories recognize products and people who bring AI to life and by shaping our future will revolutionize our approach to real world problems.
"A substantial percentage of injuries in childbirth stem from delayed and inconsistent recognition of troubling trends, and this is one area where a continuous computerized assessment is more effective and frankly more scalable than human observation," said Matthew Sappern, CEO of PeriGen. "The status quo of relying solely on training perpetuates the incidence of preventable bad outcomes whereas applying AI tools judiciously to support and augment the bedside clinician can be transformational across geography, race, or socioeconomic status."
An automated Early Warning System and Clinical Decision Support tool for obstetrics, PeriWatch Vigilance® is designed to enhance clinical efficiency, timely intervention, and standardization of care. It adds an artificial intelligence-based approach to patient safety initiatives. It can track hundreds of patients across multiple sites continuously sorting and color-coding them according to defined parameters and notifying clinicians based on degree and duration of abnormality. Using artificial intelligence and other analytical techniques, it continuously analyzes maternal vital signs, fetal heart rate, contractions, and labor progression.
In November, PeriGen introduced PeriWatch Vigilance® Mobile, which empowers obstetricians and nursing leaders to actively monitor multiple patients from anywhere they can access the hospital network.
The CogX Awards celebrate the innovators and change makers impacting our world. Over the last five years the awards have become synonymous with innovation and the positive impact that technology can have. The award's multiple categories cover everything from the best AI products by sector to recognizing the individuals who are leading their industries into the next decade.
PeriGen Inc., a Halma company, offers innovative perinatal software solutions that incorporate advanced statistical analysis features to enhance clinical efficiency and standardization of care during childbirth. Led by skilled OB practitioners and IT visionaries, PeriGen has created the PeriWatch® platform to provide consistent analysis and efficient display of complex data to promote better human recognition and communication about impending problems during labor. With PeriWatch®, clinicians can spend more time on direct patient care and less time on manual calculations and data manipulation. To learn more, visit www.perigen.com; visit us on Twitter, LinkedIn, YouTube, and Facebook; or email info@perigen.com.
Media Contacts:
Amendola Communications for PeriGen Inc.
Grant Evans
gevans@acmarketingpr.com
(215) 582-8146
View original content to download multimedia:
SOURCE PeriGen
|
https://www.wistv.com/prnewswire/2022/04/06/perigen-wins-best-ai-product-health-2022-cogx-awards/
| 2022-04-06T13:05:43
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/perigen-wins-best-ai-product-health-2022-cogx-awards/
|
NASHVILLE, Tenn., April 6, 2022 /PRNewswire/ -- Phosphorus Cybersecurity™, the leading provider of full scope security for Internet of Things devices, is pleased to announce the appointment of security industry luminary Art Coviello Jr. as Chairman of its Board of Directors.
Coviello's appointment reflects his belief in Phosphorus Cybersecurity™ as the only company with a robust and proven security solution for protecting the Internet of Things from malicious cyber attacks and insider attacks. Coviello will provide strategic guidance to Phosphorus Cybersecurity™'s executive leadership team, as the company gears up for significant growth, following a $38 million Series A earlier this year led by SYN Ventures and MassMutual Ventures. The company is led by co-founders Chris Rouland (CEO), Rebecca Rouland (CFO) and Earle Ady (CTO).
"We are honored to have Art's commitment and support, and he will play an important role in helping us solidify our position as the leading IoT security company in the global market," said Chris Rouland, CEO of Phosphorus Cybersecurity™. "While there are many companies that can find IoT vulnerabilities, we are the only company that can actually secure these devices from attack. We anticipate a large growth period ahead of us, as the size of the IoT market is already 10X the traditional endpoint market and approaching $1 trillion in overall value."
"Art is a legend in the industry and a visionary who understands how the cybersecurity market is changing and where the greatest needs are," said Earle Ady, CTO of Phosphorus Cybersecurity™. "We look forward to his insights while working with him to drive more awareness about these important security risks."
Coviello has been a central figure in the information security industry for more than 25 years. He served as President and CEO of RSA Security, one of the most iconic brands in cybersecurity. He is frequently a featured presenter at conferences and forums around the world, and he has played key roles in several national cybersecurity initiatives.
"Phosphorus is a once-in-a-decade company, as it has created the only robust technology platform capable of remediating enterprise IoT risks at scale," said Coviello. "IoT-based attacks are already the next big cyber threat companies are facing, and they need advanced, reliable IoT security solutions in the same way they've relied on traditional endpoint security solutions for the last 30 years. With Phosphorus's innovative technology platform and strong executive team, they are the only company ready to deliver on those challenges. "
Coviello serves on the Boards of Directors of several public companies, including Synchrony Financial (NYSE: SYF), Tenable (NASDAQ: TENB), and Mandiant (NASDAQ: MNDT). He is also the Investment Committee Chairman at SYN Ventures.
Phosphorus Cybersecurity™ provides unprecedented IoT defense solutions for enterprise customers. Through its automated security solutions against IoT's most critical vulnerabilities, Phosphorus Cybersecurity™ enables organizations to scale IoT technologies without adding additional employees to secure them.
Phosphorus Cybersecurity™ has found that 20% to 30% of today's corporate networks consist of IoT devices, with little to no security programs in place. Across the enterprise, as high as 25-30% of all IoT devices are end-of-life and no longer supported with firmware updates by their manufacturer; and as many as 50% have known vulnerabilities or default passwords, with 20% of those vulnerabilities being critical CVEs (CVSS score of 9 or above). As an example of these current risks, Phosphorus Cybersecurity™ has recently observed hackers exploiting vulnerable IoT systems, including door controllers and camera systems, in order to launch ransomware attacks inside US company networks.
ABOUT PHOSPHORUS CYBERSECURITY™
Phosphorus Cybersecurity™ is a leading provider of full scope, automated Security of Things™ device protection solutions for enterprise and government customers. Founded in 2017 by Chris Rouland, Rebecca Rouland and Earle Ady, the company is a trusted partner of large financial institutions, Fortune 500s and government agencies. Phosphorus Cybersecurity™'s investors include SYN Ventures, MassMutual Ventures, General Advance and Atypical Ventures. Website: www.phosphorus.io
Media contact:
Michael Sias
Firm 19 for Phosphorus Cybersecurity
inquiry@firm19.com
(954) 361-3963
View original content to download multimedia:
SOURCE Phosphorus Cybersecurity
|
https://www.wistv.com/prnewswire/2022/04/06/phosphorus-cybersecurity-appoints-art-coviello-chairman-board/
| 2022-04-06T13:05:50
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/phosphorus-cybersecurity-appoints-art-coviello-chairman-board/
|
Bank's Diverse Business Banking Segment to accelerate support of minority-owned businesses
PITTSBURGH, April 6, 2022 /PRNewswire/ -- PNC Bank has launched a new Minority Business Development Group, intended to deliver products, solutions and resources focused on advancing the financial wellness of emerging minority businesses.
Comprised of bankers and advocacy partners, the Minority Business Development Group will help prepare minority-owned businesses for effective growth, development and sustainability. The group will invest in and leverage innovative technology and financial solutions in order to empower, educate and accelerate entrepreneurial success.
"By making this investment, we are further reinforcing our local market commitment to small businesses, and ensuring we are doing all that we can to help minority-owned businesses succeed and grow," said Alex Overstrom, head of Small Business at PNC. "PNC is dedicated to being an advocate and champion in this space, so I'm excited to see the team bring this commitment to life in communities across the country."
With 33 years of banking experience, Marshalynn Odneal, national sales executive for Minority Business, will lead this national effort. She and her team of bankers will work in close collaboration with PNC's dedicated Minority Business Development Officers (MBDOs) and Community Development Banking and Corporate Responsibility Groups, as well as the bank's Regional Presidents across the country to establish and deepen relationships with minority-owned business clients and prospects. These teams will work together to enhance the capacity-building of minority-owned businesses through strategic alliances with external organizations that support business development and offer technical support to foster business growth opportunities.
"Small businesses are the fabric of our communities, and it's our privilege to help and support them." said Odneal. "Through this work, we hope to become a true partner to minority business owners and arm them with the tools and support they need to be successful. Our team will be a part of these communities, fulfilling our mission of financial wellness for all by ensuring equitable access to products and solutions that will help these businesses thrive."
The efforts of PNC's Minority Business Development Group will help support a portion of the bank's $88 billion Community Benefits Plan, which will provide $26.5 billion in small business loans, investments, and other financial support to bolster economic opportunity for low- and moderate-income (LMI) individuals and neighborhoods through 2025.
"PNC's Community Benefits Plan will have a direct impact on the work we're able to do in these communities, including our ability to leverage and expand upon alternative lending options through external partners for Black and Brown business owners in LMI communities," said Odneal.
To intentionally expand the focus on minority-owned businesses and the unique challenges they face, the bank also is launching a PNC Certified Minority Business Advocate (cMBA) program, a voluntary advocacy training program available to PNC employees interested in providing enhanced support for minority business decision makers. The new certificate program focuses on helping PNC employees understand the unique challenges facing diverse businesses, ultimately supporting PNC's brand purpose of leveraging the power of our resources to help all move forward financially.
cMBAs will have the opportunity to serve as PNC ambassadors in their communities, strengthening community engagement through volunteerism, mentorship and technical support. cMBAs also will be empowered to educate and guide these business owners toward valuable community resources. More information about the Minority Business Development Group and the tools and resources it offers are available here.
PNC Small Business serves approximately one million clients across PNC's coast-to-coast franchise, offering a comprehensive set of advice and solutions designed to help small businesses grow and thrive. The Small Business team includes all of the bank's sales platforms focused on small business clients, including Business Banking, Merchant Services and Treasury Management, as well as dedicated product, digital and solution teams focused on solving the unique challenges that small businesses face.
PNC Bank, National Association, is a member of The PNC Financial Services Group, Inc. (NYSE: PNC). PNC is one of the largest diversified financial services institutions in the United States, organized around its customers and communities for strong relationships and local delivery of retail and business banking including a full range of lending products; specialized services for corporations and government entities, including corporate banking, real estate finance and asset-based lending; wealth management and asset management. For information about PNC, visit www.pnc.com.
CONTACT:
Katie Kirby
(216) 222-8725
katie.kirby@pnc.com
View original content to download multimedia:
SOURCE PNC Financial Services Group, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/pnc-bank-introduces-minority-business-development-group/
| 2022-04-06T13:05:57
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/pnc-bank-introduces-minority-business-development-group/
|
SHENZHEN, China and LEIDEN, Netherlands, April 6, 2022 /PRNewswire/ -- Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care (POC), today announce an exclusive license agreement for the development and commercialization of PRG-1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T cell (CAR-T) program, for the treatment of hematological indications in Europe and the United States.
PRG-1801 is a single domain antibody anti-BCMA CAR-T cell therapy in development for the treatment of relapsed/refractory multiple myeloma that has demonstrated strong signs of efficacy and an excellent safety profile in its initial investigator-initiated trial and Phase I/II clinical trials.
Under the terms of the collaboration, Pregene will receive over €20 million of upfront and near-term consideration, and is eligible to receive additional development, commercial milestone and royalty payments. CellPoint will be responsible for the development and commercialization of the anti-BCMA CAR-T therapy in Europe and the US. As part of this partnership, Pregene will also provide translational and lentivirus manufacturing services to be reimbursed by Cellpoint.
"We are excited to partner with Cellpoint to develop CAR-T cell therapies via a POC platform," said Jishuai Zhang, Chief Technology Officer and Co-founder of Pregene. "The potential of our single domain antibody fully human BCMA CAR-T to treat patients with relapsed/refractory multiple myeloma has been validated in clinical trials of our BCMA autologous CAR-T product candidate. We expect the POC modality to enable faster treatment for broader patients using our differentiated CAR-T therapy, and we look forward to working with the team at CellPoint as they seek to develop and commercialize PRG-1801."
Tol Trimborn, Chief Executive Officer of CellPoint, said: "We are very pleased to add Pregene's novel anti-BCMA CAR-T therapy to our CAR-T portfolio and look forward to develop it using our decentralised, POC manufacturing model. This is our second clinical stage program and we have demonstrated we can provide cell therapy to cancer patients in only 6 days vein-to-vein, from apheresis to infusion. We are excited to work closely alongside Pregene to bring this to patients with a convenient, readily available treatment alternative."
About PRG-1801 (anti-BCMA CAR-T)
PRG-1801 is an anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. The lentivirus vectors are produced by Pregene using a proprietary serum free suspension production system with gene-therapy-grade quality and a high transduction unit yield. This CAR-T therapy has already demonstrated strong signs of efficacy and an excellent safety profile in an investigator initiated trial and Phase I/II clinical trials. In addition to multiple myeloma, Pregene is investigating PRG-1801 in patients with autoimmune diseases. In May of 2021, Pregene and Dr. Reddy's Laboratories announced a license agreement whereby Dr Reddy's acquired the exclusive rights in India for PRG-1801.
Clinical trials of PRG-1801 include:
- Phase I trial to evaluate the safety and tolerance of patients with relapsed/ refractory multiple myeloma after anti-BCMA CAR-T infusion, and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of anti-BCMA CAR-T for relapsed/refractory multiple myeloma. Available clinical data showed overall response rate (ORR) of 100%. A Phase II clinical trial is now ongoing.
- Investigator-initiated trial in China to evaluate the safety and efficacy of PRG-1801 (NCT03661554). Among 34 patients treated, 30 (88.2%) patients achieved best objective response and 19 (55.8%) patients achieved complete response. No neurotoxicity was observed among treated patients. Grade 3 CRS occurred in only one patient (2.9%), and all the other patients had lower grade or no CRS.
About Pregene
Pregene is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies with industry-leading cell and lentivirus manufacturing processes and technology. Leveraging its proprietary fully human single domain antibody discovery platform, high-throughput CAR-T drug priority platform, and proprietary cell and lentivirus manufacturing processes, Pregene is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T, CAR-NK, TCR-T, stem cell and biologics product candidates, including Pregene's leading asset, PRG-1801, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory multiple myeloma (RRMM)., has obtained NMPA IND clearance as the Class I new drug, and Phase I/II clinical trials are now ongoing. Find more at www.pregene.com.
About CellPoint
CellPoint B.V. is a Dutch (EU) company founded to provide affordable and readily available CAR-T therapies for all patients in need. CellPoint has initiated 2 clinical trials with CD19 CAR in NHL and CLL. The CellPoint CAR-T treatment workflow is designed for quality and patient safety, while driving down the time-to-treatment and costs by automation at the POC. Clinical centers of excellence have been selected that have experienced hematology teams and a local cell processing facility. These centers are equipped with a device, Cocoon (by Lonza), that allows automated manufacturing and receive full training and support to manufacture CAR-T therapies and to treat patients. Clinicians are enabled to schedule and perform CAR-T treatments within 1 week, without complex logistics. CellPoint's secure online xCellit platform is used to facilitate scheduling and monitoring of the CAR-T treatment workflow for the various stakeholders. In 2020, CellPoint raised series A funding from +ND Capital, the Dutch government (RVO) and has an exclusive license from Lonza to use the Cocoon at the point of care. Find out more at www.cellpoint.bio.
For further information
Pregene:
Xueying Fan, Media/Investor Contact
fanxy@pregene.com
CellPoint:
Maarten Zandvliet, CDO
maarten.zandvliet@cellpoint.bio
View original content:
SOURCE Shenzhen Pregene Biopharma Co. Ltd
|
https://www.wistv.com/prnewswire/2022/04/06/pregene-enters-into-innovative-partnership-with-cellpoint-develop-anti-bcma-car-t-cell-therapy-europe-us/
| 2022-04-06T13:06:04
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/pregene-enters-into-innovative-partnership-with-cellpoint-develop-anti-bcma-car-t-cell-therapy-europe-us/
|
NEW YORK, April 6, 2022 /PRNewswire/ -- Pretium, a specialized investment firm with over $40 billion in assets, today announced that it has closed its second residential credit fund, Pretium Residential Credit Fund II, with $1.7 billion in capital commitments, which exceeded its target and is nearly twice the size of its predecessor residential credit fund. The Fund received strong support from a broad range of investors and institutional consultants globally, including insurance companies, pension plans, and wealth managers.
The Fund invests in U.S. residential mortgage loans that fall outside the traditional mortgage system and are less able to be serviced by traditional banks. Through its integrated residential ecosystem, which includes industry-leading specialized mortgage servicing and loan origination platforms and loan-level analytics, Pretium is able to maximize value creation for investors.
"Our investment strategy reflects the decades of experience our team has across all aspects of mortgage investing and through multiple economic cycles," said Jonathan Babkow, Senior Managing Director and Co-Head of Residential Credit at Pretium. "We are pleased to have closed our largest residential credit fund to date, and we are grateful for the support from our partners as we identify new opportunities in an unprecedented residential credit market, defined by strong demand for housing and record levels of home equity."
"This record fundraise is a testament to the strength of our team, platform, and long-term vision, and we look forward to building on our momentum to date," said Matt Nichols, Senior Managing Director and Co-Head of Residential Credit at Pretium. "Our returns are driven by our ability to successfully restructure loans to help borrowers find sustainable payment structures that keep them in their homes and maximize the value of the loans for our investors."
Pretium has continued to invest in building its leading Residential Credit platform with recent hires, including Managing Directors Sarah Kong from Goldman Sachs, Andrew Miller from Fortress, and Peter Morreale from Cadwalader. These seasoned professionals expand Pretium's ability to source, originate and invest in a broader range of mortgage products.
Simpson Thacher & Bartlett LLP served as fund counsel.
About Pretium
Pretium is a specialized investment firm focused on U.S. residential real estate, residential credit, and corporate credit. Pretium was founded in 2012 to capitalize on secular investment and lending opportunities arising as a result of structural changes, disruptions, and inefficiencies within the economy. Pretium has built an integrated analytical and operational ecosystem within the U.S. housing, residential credit, and corporate credit markets, and believes that its insight and experience within these markets create a strategic advantage over other investment managers. Pretium's platform has over $40 billion of assets under management and employs approximately 3,000 people across 30 offices, including London and Dubai. Please visit www.pretium.com for additional information.
Contacts
Jon Keehner / Kate Thompson / Lyle Weston
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
View original content to download multimedia:
SOURCE Pretium
|
https://www.wistv.com/prnewswire/2022/04/06/pretium-closes-second-residential-credit-fund-with-17-billion-capital-commitments/
| 2022-04-06T13:06:10
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/pretium-closes-second-residential-credit-fund-with-17-billion-capital-commitments/
|
SAN JOSE, Calif., April 6, 2022 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of ultra-low power multi-core voice-enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, today announced that Owen Bateman has been appointed Vice President of Worldwide Sales. The appointment is effective immediately.
Mr. Bateman brings a unique breadth of experience to his new role, with more than 30 years in various semiconductor sales positions including strategic accounts, direct sales, and channel sales. He also has deep experience in the programmable logic industry and international sales. Prior to joining QuickLogic, Mr. Bateman served in a variety of sales and field application engineer positions at Intel, Abacus Polar, and others.
"Owen has been a tremendous asset to QuickLogic, securing multiple, large design wins that have been contributing to our strong revenue growth over the past several quarters," said Brian Faith, QuickLogic's president and chief executive officer. "He has been particularly successful at driving QuickLogic's eFPGA and SensiML efforts – key strategic initiatives for the company. We are pleased to appoint him to this role and look forward to his continued success."
"QuickLogic has a fantastic team and very exciting new products that are being widely adopted, especially in the eFPGA space," said Mr. Bateman. "I am grateful to Brian and the leadership team for putting their trust in me to lead the worldwide sales organization at this important point in QuickLogic's history."
Mr. Bateman will oversee the worldwide corporate direct and field sales representative channels. He will lead the company's efforts to drive new sales strategies across a growing and diverse set of customers. Mr. Bateman will report directly to Mr. Faith.
QuickLogic Corporation (NASDAQ: QUIK) is a fabless semiconductor company that develops low power, multi-core semiconductor platforms and Intellectual Property (IP) for Artificial Intelligence (AI), voice and sensor processing. The solutions include embedded FPGA IP (eFPGA) for hardware acceleration and pre-processing, and heterogeneous multi-core SoCs that integrate eFPGA with other processors and peripherals. The Analytics Toolkit from our recently acquired wholly owned subsidiary, SensiML Corporation, completes the end-to-end solution with accurate sensor algorithms using AI technology. The full range of platforms, software tools and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across mobile, wearable, hearable, consumer, industrial, edge and endpoint IoT. For more information, visit www.quicklogic.com and https://www.quicklogic.com/blog.
The QuickLogic logo and QuickLogic are registered trademarks of QuickLogic Corporation. All other brands or trademarks are the property of their respective holders and should be treated as such.
View original content to download multimedia:
SOURCE QuickLogic Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/quicklogic-appoints-owen-bateman-vice-president-worldwide-sales/
| 2022-04-06T13:06:11
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/quicklogic-appoints-owen-bateman-vice-president-worldwide-sales/
|
SEATTLE, April 6, 2022 /PRNewswire/ -- RealNetworks, Inc. (NASDAQ: RNWK) today announced the appointment of Mike Cooley to the newly created position of President for KONTXT, Messaging, and Telecom. This new role is recognition of both the significant progress Real has made in developing KONTXT® into a core platform for Real's future, and the large opportunities available to turn KONTXT into a very significant business at Real.
"In just a few short years, KONTXT has become one of the most widely used NLP platforms in the U.S. Telecom industry, blocking millions of pernicious spam and phishing text messages every day," said Rob Glaser, Chairman and CEO, RealNetworks, Inc. "To take KONTXT's business to the next level, we're delighted that Mike Cooley is joining us and will be leading the charge. Our goal is to deploy KONTXT and our other messaging products even more widely to enable our partners to deliver the best mobile experience for consumers worldwide."
Cooley's mission is to drive KONTXT's strategy, sales, and business operations; to lead Real's worldwide efforts in the telecom industry for KONTXT and our other communications products; and to partner with our world class product team to continue to drive forward the development of world class technology, products, and services based on Machine Learning-based Natural Language Processing (NLP).
"RealNetworks has developed best in class, innovative platforms and products to strengthen and protect the telecom industry," said Mike Cooley. "I am very excited to leverage Real's strong technology and mobile product development, and lead the team to find new ways to bring its great products like KONTXT to communication service providers around the world."
Well known and highly respected in the mobile industry, Mike Cooley joins the executive team at RealNetworks with more than 20 years of experience leading mobile and digital growth and strategy operations in the telecom marketplace. He spent most of his career at Sprint Nextel where he held executive roles leading the digital and new ventures group. He co-founded and led digital/ad tech startups including Sundial.com and Pinsight Media, a subsidiary of Sprint. Most recently, he was the SVP/GM Enterprise IOT at Kajeet. Mike has also served as VP of Business Development for Neustar with additional management roles at Fortune 500 companies like Motorola and Deloitte Consulting. Mike was awarded his MBA from the University of Michigan and earned his Bachelor of Arts degree in Economics from Tufts University.
Today, RealNetworks enables global mobile operators to secure and maximize their messaging capabilities through its leading edge interoperability, AI machine learning and value-added messaging services. RealNetworks' Metcalf® Inter-Carrier Messaging (ICM) platform powers SMS Inter-connect solutions for mobile operators worldwide. KONTXT is Real's patented NLP platform which categorizes and blocks over 20 million fraudulent text messages, images, and voice calls per day, to help carriers build customer loyalty and drive new revenue through text/voice message classification and antispam activity.
Building on a 25+ year legacy of digital media expertise and innovation, RealNetworks® has created a new generation of products that employ best-in-class artificial intelligence and machine learning to enhance and secure our daily lives. KONTXT® (KONTXT.com) is Real's patented NLP (Natural Language Processing) platform for categorizing and blocking fraudulent text messages, images, and voice calls, to help carriers build customer loyalty and drive new revenue through text message classification and antispam. For information about our other products, visit www.realnetworks.com.
RealNetworks, Metcalf, and KONTXT are registered trademarks of RealNetworks, Inc. All other trademarks, names of actual companies and products mentioned herein are the property of their respective owners.
Media Contact:
Lisa Amore, Amore PR for RealNetworks. Mobile: 206-954-8006. lisa@amorepr.com
View original content to download multimedia:
SOURCE RealNetworks, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/realnetworks-appoints-mike-cooley-president-kontxt-messaging-telecom/
| 2022-04-06T13:06:17
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/realnetworks-appoints-mike-cooley-president-kontxt-messaging-telecom/
|
DENVER, April 6, 2022 /PRNewswire/ -- RE/MAX Holdings, Inc. (NYSE:RMAX), parent company of RE/MAX, one of the world's leading franchisors of real estate brokerage services, and Motto Mortgage, the first and only national mortgage brokerage franchise brand in the U.S., will release financial results for the quarter ended March 31, 2022, after market close on Thursday, April 28, 2022, and will host a conference call and webcast for interested parties on Friday, April 29, 2022, at 8:30 a.m. Eastern Time.
RE/MAX Holdings, Inc. First Quarter Earnings Conference Call
Date: April 29, 2022
Time: 8:30 a.m. Eastern Time
Webcast: https://investors.remaxholdings.com
Please join the webcast 10 minutes before the start of the conference call. Following the call, an archive of the webcast will be available on the Investor Relations website for a limited time as well.
Investors and participants can register for the telephonic version of the conference call in advance by visiting https://conferencingportals.com/event/tTSuEepd. After registering, instructions will be shared on how to join the call including dial-in information as well as a unique passcode and registrant ID. At the time of the call, registered participants will dial in using the numbers from the confirmation email, and upon entering their unique passcode and ID, will be entered directly into the conference.
About RE/MAX Holdings, Inc.
RE/MAX Holdings, Inc. (NYSE: RMAX) is one of the world's leading franchisors in the real estate industry, franchising real estate brokerages globally under the RE/MAX® brand, and mortgage brokerages within the U.S. under the Motto® Mortgage brand. RE/MAX was founded in 1973 by Dave and Gail Liniger, with an innovative, entrepreneurial culture affording its agents and franchisees the flexibility to operate their businesses with great independence. Now with more than 140,000 agents in almost 9,000 offices across more than 110 countries and territories, nobody in the world sells more real estate than RE/MAX, as measured by total residential transaction sides. Dedicated to innovation and change in the real estate industry, RE/MAX launched Motto Franchising, LLC, a ground-breaking mortgage brokerage franchisor, in 2016. Motto Mortgage has grown to over 175 offices across almost 40 states.
View original content to download multimedia:
SOURCE RE/MAX Holdings, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/remax-holdings-inc-release-first-quarter-results-april-28-2022/
| 2022-04-06T13:06:24
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/remax-holdings-inc-release-first-quarter-results-april-28-2022/
|
Higher upfront costs add to the challenge faced by renters of color searching for a new home in today's tight rental market
- Renters of color pay security deposits more often than white renters, and the deposits they pay are typically $150 higher.
- Black and Latinx renters report submitting more applications than white and Asian American and Pacific Islander renters. The typical white or Asian American and Pacific Islander renter submits two applications, while the typical Black or Latinx renter submits three.
SEATTLE, April 6, 2022 /PRNewswire/ -- Results from Zillow's Consumer Housing Trends Report show renters of color typically submit more applications — and pay more in application fees — before they secure a place to live than white renters do. Renters of color also typically pay a higher security deposit when they move in.i
The U.S. rental market is as competitive as it's been in decades, with the national vacancy rate lower than at any time since 1984.ii Rent prices have skyrocketed, up a record 17% in just the past year, prompting some priced-out renters to look for a more affordable home when their lease expires. About 9 in 10 renters paid a security deposit last year, with the typical deposit coming in at $700. A higher share of renters of color paid a deposit (93%) than white renters (85%), and the median amount paid by renters of color was higher, too — $750, compared to $600.
"Rents grew more last year than any year on record, forcing many renters to look for a more affordable option. About 2 in 5 renters who moved in the past year said a rent hike influenced their decision to move," said Manny Garcia, population scientist at Zillow. "Renters typically do not have much of a financial cushion, and the cost of finding a new place to live can be an expensive burden. Regrettably, renters of color are especially likely to experience rising rents, and when they shop for a new rental, generally report higher upfront costs, restricting the mobility that is often held up as a benefit of renting."
A $750 security deposit represents a significant amount of a typical renter's wealth. Zillow's research indicates a typical renter holds $3,400 total across savings, checking, retirement and investment accounts. More than one-third (38%) of renters surveyed say they couldn't cover an unexpected expense of $1,000.
In addition to facing higher and more frequent security deposits, renters of color report submitting more applications and paying higher fees for those applications than white renters. In 2021, 61% of all renters applied for two or more properties — an 11-point increase from 2019 and five points higher than in 2020, likely owing to the tight rental market. The typical white or Asian American and Pacific Islander renter submits two applications, while a Black or Latinx renter typically submits three. More than one-third of renters of color submit five or more applications during their home search: that's true of 38% of Black and Latinx renters, 33% of Asian American and Pacific Islander renters, and only 21% of white renters.
With a median rental application fee of $50, the cost can add up quickly if renters need to apply for several properties. The burden is often greater for renters of color, who report paying a higher median application fee than white renters, on top of usually needing to apply to more rentals. Among renters who paid an application fee for the home they rent, the typical white renter reports paying $50, while a typical Black renter paid $65, a typical Latinx renter paid $80 and a typical Asian American and Pacific Islander renter paid $100.
The higher fees and number of applications for renters of color are likely partially attributable to their age, income and geography. The typical renter of color is two years younger than the median white renter, meaning two fewer years of potential income growth. White renters are also more likely to rent in rural markets and the Midwest, both of which are generally less expensive. Asian American and Pacific Islander and Latinx renters, in particular, are more likely to rent in the West, which includes many of the country's most expensive and competitive rental markets.
Expanding access to credit could help improve outcomes for Black and Latinx renters. Nearly half of white renters (46%) say they were completely certain they would qualify for a rental, compared to 38% of Latinx renters and 34% of Black renters. Credit checks are part of many rental applications, and Black and Latinx adults are more prone to being credit invisible and more often live in counties with higher levels of credit insecurity.
Renters looking to reign in application fees may have options. For a flat $29 fee, renters can use Zillow's online rental application to apply through Zillow for an unlimited number of participating properties within 30 days. The online application includes a credit report and background check, which saves landlords time while screening prospective tenants and provides them with the information needed to feel confident about each applicant. Renters can also offer additional context and explain any negative items on their rental and credit history.
*Of renters who paid a security deposit
**Of renters who paid an application fee
About Zillow Group
Zillow Group, Inc. (NASDAQ: Z and ZG) is reimagining real estate to make it easier to unlock life's next chapter. As the most visited real estate website in the United States, Zillow® and its affiliates offer customers an on-demand experience for selling, buying, renting or financing with transparency and ease.
Zillow Group's affiliates and subsidiaries include Zillow®, Zillow Offers®, Zillow Premier Agent®, Zillow Home Loans™, Zillow Closing Services™, Zillow Homes, Inc., Trulia®, Out East®, ShowingTime®, Bridge Interactive®, dotloop®, StreetEasy® and HotPads®. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org).
i 2021 Zillow Consumer Housing Trends Report. Zillow Group Population Science conducted a nationally representative survey of more than 2,000 renters. The study was fielded between March and August 2021. For the purpose of this study, "renters" refers to household decision-makers who moved in the past year to a primary residence that they rent.
ii Source: U.S. Census Bureau, Current Population Survey/Housing Vacancy Survey, February 2, 2022.
View original content to download multimedia:
SOURCE Zillow
|
https://www.wistv.com/prnewswire/2022/04/06/renters-color-pay-higher-security-deposits-more-application-fees/
| 2022-04-06T13:06:38
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/renters-color-pay-higher-security-deposits-more-application-fees/
|
DETROIT, April 6, 2022 /PRNewswire/ -- U.S. representative Nancy Mace (R-SC), will be participating in the Benzinga Cannabis Capital Conference, which will take place on April 20 and April 21, 2022, at the Fontainebleau Miami Beach hotel, in Miami, Florida.
Mace, who introduced to Congress the biggest cannabis legalization bill, the States Reform Act, will be speaking about the state of the industry and legalization in the U.S. As Mace explained, the bill "seeks to remove cannabis from Schedule I in a manner consistent with the rights of states to determine what level of cannabis reform each state already has, or not."
"This bill supports veterans, law enforcement, farmers, businesses, those with serious illnesses, and it is good for criminal justice reform… The States Reform Act takes special care to keep Americans and their children safe while ending federal interference with state cannabis laws," Mace added.
Interested parties can register to attend here.
"We've been looking forward to speaking at the Benzinga Cannabis Capital Conference and sharing valuable insights into the lawmaking process with the top business leaders in cannabis," said Mace.
"It's a real honor to count on the presence of a speaker of the level of Rep. Mace at our Miami event," said Chief Zinger Jason Raznick. "The Benzinga Cannabis Capital Conference in Miami will bring together the top movers and shakers in the cannabis industry, fostering dialogue between businesses and lawmakers."
To register and access please follow this link.
Why Attend The Benzinga Cannabis Capital Conference
Enjoy exclusive opportunities for curated networking and unparalleled access to private deal flow at an event hosted by Benzinga, a financial news and data company recently acquired at a $300 million valuation. Hear directly from the executives of top-performing cannabis companies and get priceless insights from the world's leading cannabis investors, all in one place.
The upgraded version of the Benzinga Cannabis Capital Conference, the biggest and best yet, will not only feature the traditional keynotes, panel discussions, fireside chats, networking, company presentations, and investor and celebrity appearances, but also a larger exhibit floor and enhanced industry networking opportunities.
Among the top new features of the Miami Benzinga Cannabis Capital Conference are:
- An expo floor like you've never seen before, with bigger booths and a lot of additional branding opportunities for your company.
- A private, VIP area for select companies and investors.
- An upgraded system for 1:1 meetings.
- More networking opportunities and higher profile attendees than ever before.
"Adding an expo floor is extremely exciting for us. We were waiting for the right time to do this; now that we've had many years to curate the best of the best companies in the cannabis space, we feel confident that the offering will be like no other. This, on top of the already impressive speaker lineup and investment opportunities Benzinga always brings to the table," concluded Patrick Lane, Executive Vice President of Partnerships at Benzinga.
A Proven Model
After 13 extremely successful editions in Toronto, Chicago, Detroit, New York and Miami, the Benzinga Cannabis Capital Conference is going bigger than ever.
The April 20 and April 21 Benzinga Cannabis Capital Conference will include, for the first time ever, an expo floor to give more visibility to the brands that are shaping this space. In addition, attendees will enjoy private meeting areas, comfortable seating and premium food options.
"We've seen cannabis businesses raise tens of millions of dollars at our events and this year's meeting will be even larger, with a record level of investment capital and top-notch operators," said Chief Zinger Jason Raznick.
"We'll also dive into key issues related to cannabis and capital markets with incredible speakers and, for the first time ever, a slew of new features we cannot share publicly just yet."
About Nancy Mace
Congresswoman Nancy Mace grew up in the Lowcountry. She is the daughter of a retired Army General and retired school teacher.
Before being sworn into Congress, Nancy earned accolades as one of the most fiscally conservative members of the South Carolina General Assembly; she's also one of the most pro-conservation lawmakers in the state of South Carolina.
Nancy grew up in Goose Creek, S.C. And when she dropped out of high school at the age of 17, her parents said, "If you're going to stop going to school, you got to start going to work." She immediately became a waitress at the Waffle House on College Park Road in Ladson (exit 203).
Nancy earned her high school diploma a few months later by taking college classes at Trident Technical College in North Charleston.
She graduated magna cum laude from The Citadel, the Military College of South Carolina, where she was the school's first female to graduate from its Corps of Cadets in 1999. In 2004 Nancy earned a masters degree from The University of Georgia. Go dogs!
She is the author of In The Company of Men: A Woman at The Citadel, published by Simon & Schuster in 2001.
In 2008 Nancy started her own company. Her background in business is in technology, PR & marketing and more recently commercial real estate before coming to Congress.
Nancy is the recipient of the 2019 Taxpayer Hero Award from the South Carolina Club for Growth; she has a 100% record of voting to lower taxes. Nancy is also the recipient of the Champion Award from Palmetto Goodwill in her efforts in education and in helping those most in need receive job training; she has a 100 percent rating with Conservation Voters of South Carolina.
Nancy is a single mom of two children ages 12 and 14. She also has two cats, Tyler and Tiger, and a puppy named Liberty.
About The Benzinga Cannabis Capital Conference
The Benzinga Cannabis Capital Conference, renowned for being the premier gathering of cannabis entrepreneurs and investors in North America, returns for another edition, recharged with an impressive list of speakers.
Check out the full lineup here.
View original content:
SOURCE Benzinga
|
https://www.wistv.com/prnewswire/2022/04/06/rep-nancy-mace-speak-leading-cannabis-investment-event-benzinga-cannabis-capital-conference-april-20-21-miami/
| 2022-04-06T13:06:45
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/rep-nancy-mace-speak-leading-cannabis-investment-event-benzinga-cannabis-capital-conference-april-20-21-miami/
|
HERNDON, Va., April 6, 2022 /PRNewswire/ -- SOC Telemed, Inc. (NASDAQ: TLMD) (the "Company" or "SOC Telemed"), the largest national provider of acute care telemedicine, today announced the completion of its previously announced transaction to be acquired by Patient Square Capital, a leading dedicated health care investment firm, in an all-cash transaction. The acquisition was previously announced on February 3, 2022, and SOC Telemed's stockholders approved the transaction at the Special Meeting of Stockholders held on April 4, 2022.
Upon completion of the acquisition, SOC Telemed stockholders received $3.00 in cash per share of Class A common stock. SOC Telemed's Class A common stock and warrants to purchase shares of Class A common stock have ceased trading and are no longer listed on Nasdaq.
With the closing of the transaction, SOC Telemed will now be a private company with the flexibility and resources to continue investing in its unique clinical capabilities, innovating its offering, and expanding its footprint.
SOC Telemed will continue to be led by Dr. Chris Gallagher, Chief Executive Officer, who assumed the role of CEO in September of 2021. Dr. Gallagher said, "We are excited about this next chapter in our company's journey. I am extremely grateful to our team members whose dedication and hard work have contributed to SOC Telemed's success and made this possible. We believe that with the support and expertise of Patient Square Capital, SOC Telemed will be well positioned to meet the growing needs of patients, physicians and our hospital partners."
Additional details can be found in a Current Report on Form 8-K filed by SOC Telemed this morning with the Securities and Exchange Commission (the "SEC").
About SOC Telemed
SOC Telemed ("SOC") is the leading national provider of acute telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations since 2004. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC's technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry, teleCritical Care, telePulmonology, teleCardiology, teleInfectious Disease, teleNephrology, teleMaternal-Fetal Medicine and other service lines, enabling healthcare organizations to build sustainable telemedicine programs across clinical specialties. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission's Gold Seal of Approval and has maintained that accreditation every year since inception. For more information, visit www.soctelemed.com.
About Patient Square Capital
Patient Square Capital is a dedicated health care investment firm that partners with best-in-class management teams whose products, services and technologies improve health. We utilize our deep industry expertise, our broad network of relationships and a true partnership approach to make investments in companies that will grow and thrive. We believe in the power these companies have to improve patient lives, strengthen communities and create a healthier world. Patient Square Capital is purpose built by a team of industry-leading executives, differentiated by the depth of our focus in health care, the breadth of our health care investing experience, and the network we can activate to drive differentiated outcomes. Most importantly, patients are squarely at the center of all that we do. For more information, visit www.patientsquarecapital.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on SOC Telemed's current expectations, estimates and projections about the potential benefits of the transaction, its business and industry, management's beliefs and certain assumptions made by SOC Telemed and Patient Square Capital, all of which are subject to change. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "could," "seek," "see," "will," "may," "would," "might," "potentially," "estimate," "continue," "expect," "target," similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control, and are not guarantees of future results, such as statements about the anticipated benefits of the transaction. These and other forward-looking statements, including statements about the parties' ability to realize the anticipated benefits of the transaction are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the impact of the COVID-19 pandemic on SOC Telemed's business and general economic conditions; (ii) SOC Telemed's ability to implement its business strategy; (iii) significant transaction costs associated with the transaction; (iv) potential litigation relating to the transaction; (v) the risk that disruptions from the transaction will harm SOC Telemed's business, including current plans and operations; (vi) the ability of SOC Telemed to retain and hire key personnel; (vii) potential adverse reactions or changes to business relationships resulting from the completion of the transaction; (viii) legislative, regulatory and economic developments affecting SOC Telemed's business; (ix) general economic and market developments and conditions; (x) the evolving legal, regulatory and tax regimes under which SOC Telemed operates; (xi) potential business uncertainty, including changes to existing business relationships, following the completion of the transaction that could affect SOC Telemed's financial performance; (xii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities, or pandemics; (xiii) other factors as set forth from time to time in SOC Telemed's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2021, as may be updated or supplemented by any subsequent filings that SOC Telemed may file with the SEC, as well as SOC Telemed's response to any of the aforementioned factors. These risks, as well as other risks associated with the transaction, are more fully discussed in the Proxy Statement filed with the SEC in connection with the transaction. Investors are cautioned not to place undue reliance on such statements which speak only as of the date they are made. While the list of factors presented here is, and the list of factors presented in the Proxy Statement is, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and other similar risks, any of which could have a material adverse effect on SOC Telemed's financial condition, results of operations, or liquidity. SOC Telemed does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Media Contact
Doug Allen/Zach Kouwe
Dukas Linden Public Relations
646-722-6530
PatientSquare@DLPR.com
Investor Relations
Steve Rubis
Vice President, Investor Relations
SOC Telemed
(214) 681-7991
srubis@soctelemed.com
View original content:
SOURCE SOC Telemed
|
https://www.wistv.com/prnewswire/2022/04/06/soc-telemed-completes-acquisition-by-patient-square-capital/
| 2022-04-06T13:06:56
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/soc-telemed-completes-acquisition-by-patient-square-capital/
|
Hunzeker brings extensive public and private expertise to global AI company's distinguished Board of government and commercial leaders
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- SparkCognition Government Systems (SGS), developing trusted artificial intelligence (AI) solutions for defense and national security, is pleased to announce it has named three-star Lieutenant General Ken Hunzeker (Ret.) to its Board of Directors. Hunzeker will bring his extensive leadership experience from a 35-year career in the Department of Defense (DoD) and across nearly a decade of commercial federal sector roles to the company's distinguished Board, helping guide SGS' strategy and growth over the coming years.
"The challenges facing the defense and intelligence communities today are complex and require leading-edge technologies and deep domain expertise that can be delivered in a rapidly configurable, highly reliable, and scalable manner," said Hunzeker. "SGS has a proven track record of building AI-enabled solutions to solve the government's most challenging problems, and I am excited to join my fellow Board members to help guide the business as it continues to grow."
Hunzeker served in the Army for 35 years before retiring in 2010 in the assignment as Deputy Commander, United States Forces–Iraq. He also commanded the 1st Infantry Division and the 5th U.S. Corps, both in U.S. Army Europe. Following his retirement from the Army, Hunzeker joined ITT Corporation as the Vice President of Government Relations for ITT Defense and Information Solutions. In April 2011, he was appointed president of Exelis Mission Systems, a business division of the ITT Corporate subsidiary, Exelis. In 2014, Mission Systems was established as a publicly-traded company, Vectrus, where Hunzeker served as Chief Executive Officer and President until his retirement in December 2016.
Following his highly decorated military and commercial career, Hunzeker brings a wealth of experience and understanding of the unique challenges facing industry and governments alike, and how the private sector is integral to solving these issues. He joins some of the most experienced and decorated leaders at the helm of SGS, including:
- General John R. Allen (Ret.)
- Admiral John M. Richardson (Ret.)
- Robert O. Work, former Deputy Secretary of Defense
- Amir Husain, Founder and CEO of SparkCognition
"Lt. Gen. Hunzeker brings deep leadership experience in the public and private sectors and a pragmatic approach to technology adoption, all of which will be instrumental to winning new business and accelerating the growth of the company," said Logan Jones, President & General Manager, SGS. "I look forward to him helping us deliver next-generation AI solutions in order to ensure mission readiness, optimize decision making, and enhance operational effectiveness."
To learn more about SparkCognition Government Systems, visit www.sparkgov.ai.
About SparkCognition Government Systems
SparkCognition Government Systems (SGS), a wholly-owned subsidiary of SparkCognition, is the first artificial intelligence (AI) company devoted entirely to government and national defense. By developing and operationalizing next-generation AI-powered systems, SGS enables government organizations to meet the needs of their most pressing national security missions. SGS advances government operations by analyzing complex data to inform and accelerate intelligent decisions, applying predictive and prescriptive analytics to improve logistics, deploying autonomy technology for power projection systems, using AI and machine learning for large-scale processing of unstructured data, and more. For in-depth information about SGS and its offerings, visit www.sparkgov.ai.
Contact Info
Cara Schwartzkopf
Communications Manager
cschwartzkopf@sparkcognition.com
251-501-6121
View original content to download multimedia:
SOURCE SparkCognition Government Systems
|
https://www.wistv.com/prnewswire/2022/04/06/sparkcognition-government-systems-appoints-lieutenant-general-ken-hunzeker-ret-board-directors/
| 2022-04-06T13:07:03
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/sparkcognition-government-systems-appoints-lieutenant-general-ken-hunzeker-ret-board-directors/
|
Spectra7's GC1122 GaugeChangerTM Chips now Sampling
SANTA CLARA, Calif., April 6, 2022 /PRNewswire/ -- (TSXV: SEV) (OTCQB: SPVNF) Spectra7 Microsystems Inc. ("Spectra7" or the "Company"), a leading provider of high-performance analog semiconductor products for broadband connectivity markets, today announced that it will partnering with Volex plc ("Volex") to demonstrate Spectra7's new 112G PAM4 GaugeChangerTM chip intended for next generation 800Gbps data center interconnects at this year's annual DesignCon Conference and Exhibition being held in Santa Clara, CA from April 6-7, 2022. The demonstration will highlight the performance of Spectra7's new GC1122 chip compensating for 112Gbps PAM4 signal loss over 4m of Volex 28AWG high-speed twin-ax cable.
"Customers continue to demand copper as they move to next-generation 25.6 and 51.2 Tbps platforms and 800G switching solutions," said Alan Weckel, Founder and Technology Analyst with 650 Group. "We see the 800G and above Ethernet switch market growing at over 150% CAGR over the next 5 years to over $10 billion, and Spectra7 and cable partners such as Volex are sure to benefit from this CAPEX spending growth."
"We are excited to have Volex as a partner for this impressive demonstration of what is achievable with our GaugeChanger™ technology and their cable technology," said Spectra7 CEO Raouf Halim. "We look forward to bringing 800G cables to market with them later this year."
The GC1122 is the latest addition to the GaugeChanger™ product line and extends the data rate from 56 to 112Gbps per lane. Since the GC1122 is analog and highly linear, dynamics such as line rate adjustment, multi-level signaling, intermittent line silence, transmit pre-emphasis or amplitude adjustment and receiver adaptivity are fully preserved. GC1122 chips are now sampling to leading cable partners and end customers.
GaugeChanger™ is an innovative technology that allows copper to extend much longer lengths without the cost and power penalty of optics or DSP based retimed copper solutions. It works equally well at 25 Gbps NRZ, 50 Gbps PAM-4 and 100 Gbps PAM-4 enabling new connector standards of 100, 200, 400 and 800 Gbps.
DesignCon is the premier high-speed interconnect and system design conference attended by engineers from around the world. Spectra7 will be exhibiting in booth #1158.
ABOUT VOLEX
Volex plc (AIM: VLX) is a global leader in integrated manufacturing for performance-critical applications and a supplier of power products. We serve a diverse range of markets and customers, with particular expertise in cable assemblies, higher-level assemblies, data center power and connectivity, electric vehicles, and consumer electricals. We are headquartered in the UK and operate from 19 manufacturing locations with a global workforce of over 7,000 employees across 22 countries. Our products are sold through our own locally based sales teams and through authorized distributor partners to Original Equipment Manufacturers ('OEMs') and Electronic Manufacturing Services ('EMS') companies worldwide. All of the products and services that we offer are integral to the increasingly complex digital world in which we live, providing power and connectivity from the most common household items to the most complex medical equipment. For more information, please visit www.volex.com.
ABOUT SPECTRA7 MICROSYSTEMS INC.
Spectra7 Microsystems Inc. is a high-performance analog semiconductor company delivering unprecedented bandwidth, speed and resolution to enable disruptive industrial design for leading electronics manufacturers in data centers, virtual reality, augmented reality, mixed reality and other connectivity markets. Spectra7 is based in San Jose, California with a design center in Cork, Ireland and technical support location in Dongguan, China. For more information, please visit www.spectra7.com.
Neither the TSX Venture Exchange nor its regulation services provided (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY NOTES
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the anticipated demonstrations of the Company's products at DesignCon 2022, the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's Management's Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.
For more information, please contact:
Matt Kreps/Jim Fanucchi
Darrow Associates
214-597-8200
ir@spectra7.com
Spectra7 Microsystems Inc.
Bonnie Tomei
Chief Financial Officer
669-212-1089
ir@spectra7.com
Spectra7 Microsystems Inc.
John Mitchell
Public Relations
650-269-3043
pr@spectra7.com
View original content to download multimedia:
SOURCE Spectra7 Microsystems Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/spectra7-volex-demonstrate-112g-pam4-signaling-over-4-meters-28awg-copper-cable-designcon/
| 2022-04-06T13:07:10
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/spectra7-volex-demonstrate-112g-pam4-signaling-over-4-meters-28awg-copper-cable-designcon/
|
Company to streamline medical waste collection with new portfolio of innovative containers to better serve customers and help protect communities
BANNOCKBURN, Ill., April 6, 2022 /PRNewswire/ -- Stericycle, Inc. (Nasdaq: SRCL), a leading provider of medical waste management, secure information destruction and patient engagement solutions, today announced its new SafeShield™ antimicrobial medical waste containers, a line of high-quality, standardized containers specifically designed for the storage and transport of regulated medical waste (RMW). Compared to Stericycle's current containers, this new line of containers provides customers with an improved design, better storage options and an additional level of protection to help combat the growth of microorganisms on RMW containers. Stericycle previously began rolling out the containers to select U.S. markets and has planned a phased national rollout.
"Our SafeShield™ medical waste containers are designed to meet our customers' needs as RMW generators," commented Cory White, chief commercial officer at Stericycle. "The safe and efficient management of RMW helps hospitals and healthcare systems run more effectively. Through continued innovation and investment, Stericycle aims to provide safe, responsible and sustainable products and services that help healthcare organizations protect the health and well-being of the people and communities they serve, so they can focus on what matters most– patients."
The new SafeShield™ containers include features such as:
- Antimicrobial Properties: SafeShield™ containers are exclusively equipped with Cupron®, a copper-based antimicrobial additive to help prevent the growth of bacteria, fungi, mold and mildew, which can reduce odors and increase cleanliness. The containers also have a smooth interior finish with built-in drainage ports for easy cleaning.
- Improved Design: These new, reusable RMW containers have an integrated lid that closes securely and eliminates lid misplacement. These containers are also nestable and stackable, enabling Stericycle drivers to load and transport more containers at one time.
- Durability: SafeShield™ containers have reinforced handles to help withstand heavy loads. The split lid also securely locks and includes a tie area for added security during storage and transport.
Over the next several years, Stericycle will simplify its container portfolio and work with customers to transition from their current containers to the new models, ultimately aiming to reduce its line of more than 150 containers to less than 20. In 2021, approximately 75,000 new SafeShield™ containers were delivered to customers. In 2022, Stericycle plans to ship approximately 290,000 SafeShield™ containers to customers across the U.S. with an additional phased roll-out to follow. As the new containers are introduced in the marketplace, Stericycle will recycle as many of the decommissioned containers as possible to help reduce landfill waste.
For more information about the SafeShield™ containers or to speak with a Stericycle representative, visit the Stericycle website: https://www.stericycle.com/en-us/solutions/regulated-waste-disposal/SafeShield.
Stericycle, Inc., is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people and brands, promotes health and well-being and safeguards the environment. Stericycle serves customers in the U.S. and 16 countries with solutions for regulated waste and compliance services, secure information destruction and patient engagement. For more information about Stericycle, please visit stericycle.com.
Media Contact:
Media Relations
Stericycle, Inc.
media@stericycle.com
View original content to download multimedia:
SOURCE Stericycle
|
https://www.wistv.com/prnewswire/2022/04/06/stericycle-announces-new-safeshield-medical-waste-containers/
| 2022-04-06T13:07:17
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/stericycle-announces-new-safeshield-medical-waste-containers/
|
PHILADELPHIA, April 6, 2022 /PRNewswire/ -- Decision Research Corporation (DRC), an industry-leading provider of cloud-optimized, enterprise solutions in Insurtech (insurance technology), is proud to announce Steven Blaire as a new addition to the executive leadership team as Vice President of Platform and Cloud Services.
Steven has been with DRC for the past 5 years as Director of Quality Assurance and Release Management. During this time, he has led all aspects of software testing, automation and release engineering. His experienced perspective and collaborative nature has resulted in elevating existing quality standards and release protocols as well as leading DRC's transition to a DevOps culture while introducing modern software management tools (Azure DevOps Services). Steven also leads DRC's internship program that has contributed to the growth of the DRC family in Hawai'i.
As DRC's Vice President of Platform and Cloud Services, Steven will be using his proven expertise to oversee DRC's cloud services and security, software quality, testing, and automation capabilities. He understands the complex capabilities of the DRC Insurance Platform and is committed to delivering proven and reliable services.
On being promoted to his new position, Blaire states "I am excited about the next chapter in my career with DRC. DRC has strong company culture and unwavering commitment to clients. I am looking forward to building on that strong foundation with a focus on security, quality, efficiency and operational excellence. I have the pleasure of working with a talented group of engineers who are motivated to take DRC to the next level."
"Having worked with Steven the past several years, I am confident that DRC will continue to grow our cloud capabilities in a scalable and sustainable manner under Steven's leadership," says Les McElhaney, Vice President of Product and Technology. "He has a clear vision of where we want to be and knows how to facilitate action to get us there. It is exciting to welcome Steven to this new and important role."
About DRC
DRC provides innovative, cloud-based, enterprise solutions to P&C insurance companies looking to boost their business development efforts, reduce administrative overhead, and accelerate speed-to-market for their products through automation. RS X Rating, DRC's no-code rating solution, gives actuaries the ability to configure powerful automation functions without IT assistance, and to price risks and model products, no matter how complex, all through a familiar Microsoft Excel® interface. DRC's flagship product is the DRC Insurance Platform, a full-service policy administration system, including portals, quoting, billing, claims, and advanced analytics, powered by RS X Rating, and engineered to streamline internal processes and empower business users within a secure and robust enterprise ecosystem. DRC has remained committed to total customer satisfaction throughout its 50-year history, and its clients, running the gamut of size and scope from large global carriers to regional start-ups, continue to rely on DRC's trusted solutions to manage over $7 billion in written premium. To learn more about DRC, visit www.decisionresearch.com.
View original content to download multimedia:
SOURCE Decision Research Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/steven-blaire-joins-drc-executive-leadership-vice-president-platform-cloud-services/
| 2022-04-06T13:07:23
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/steven-blaire-joins-drc-executive-leadership-vice-president-platform-cloud-services/
|
CHANTILLY, Va. , April 6, 2022 /PRNewswire/ -- SuccessKPI, Inc., a SaaS Contact Center Insight and Action Platform provider, is pleased to announce the hiring of two new vice presidents. David McAbee as Vice President of Sales and Kathleen Atkins as Vice President of Marketing.
David's responsibilities are sales team leadership, accelerating SuccessKPI's revenue by expanding the company's presence in new geographies, expanding new partners and channels, and contributing to the company's business strategies.
David brings over 20 years of sales and leadership experience to SuccessKPI, with over six of those years in the NICE inContact ecosystem and earning President's Club multiple years during his time there. Before joining SuccessKPI, David grew enterprise and SMB market share in North America at Genesys, Oracle, and T-Mobile. He is a graduate of George Mason University and holds a bachelor's degree in economics.
Kathleen Atkins joins as SuccessKPI's first Vice President of Marketing responsible for go-to-market strategy, corporate marketing, growth and channel marketing, public and analyst relations globally.
Recently, she served as Director of Corporate Marketing at Digital Realty, the world's largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions. Before Digital Realty, Kathleen led marketing and customer success for Akoonu.
"Kathleen and David are outstanding additions to our team, as both bring a deep blend of growth experience and track records of results that it takes to deliver client success," said Dave Rennyson, President and Co-Founder of SuccessKPI. "As SuccessKPI continues its rapid growth and focuses across the United States, Europe, Latin America and Asia Pacific, their leadership and strong backgrounds in building top-performing teams will accelerate our growth.
Two Directors were also hired as part of the company's investment in functions critical to its growth and customer success, worldwide.
Jessica Grupposo joined as Senior Director of People and Culture. Certified in Human Resources from Becker College, Jessica has a Master of Business Administration and a Master of Science in Organizational Leadership from Nichols College. She is responsible for ensuring the company's values, culture, and focus on diversity, equity and inclusion are reflected in its actions and its culture. SuccessKPI's values are grounded in five attributes:
- We solve problems for our customers.
- We care for our partners and teammates.
- We work hard but we don't take ourselves too seriously.
- We make simple things easy and complex things possible.
- We are creative and innovative.
Erin Stewart, Executive Director of Emerging Markets, leads the company's market expansion efforts. She was named "Best Woman in Software and Technology Sales" by Women in Sales, North America, and was a judge for the 2021 Awards. In 2020, Erin was awarded the Top Receivables Product of the Year in the January/February issue of Receivables Advisor magazine. She holds a degree from Indiana University–Purdue University Indianapolis and completed coursework at the M.I.T Sloan School of Management concentrating on Artificial Intelligence Implications for Business Strategy
Social Networks
Web: https://www.successkpi.com
Blog: https://successkpi.com/blog/
LinkedIn: https://www.linkedin.com/company/successkpi/
About SuccessKPI:
SuccessKPI's Insight and Action Platform is an AI-driven Experience Analytics SaaS Platform. The platform unifies data from the multi-channel customer experience journey and integrates insights and action recommendations with popular CCaaS solutions, including Amazon, Genesys, Twilio, UJet, and Talkdesk. SuccessKPI serves a global enterprise market with operations in the US, Europe, and Latin America. Some of the largest contact centers in the world leverage SuccessKPI including government, BPO, financial, and global retail enterprises. Learn more at www.successkpi.com.
View original content to download multimedia:
SOURCE SuccessKPIs
|
https://www.wistv.com/prnewswire/2022/04/06/successkpi-welcomes-vice-presidents-sales-marketing-accelerate-expansion-plans/
| 2022-04-06T13:07:30
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/successkpi-welcomes-vice-presidents-sales-marketing-accelerate-expansion-plans/
|
Program connects talented entry-level professionals with leading VC firms as part of effort to build a more diverse, equitable and accessible innovation economy
SANTA CLARA, Calif., April 6, 2022 /PRNewswire/ -- SVB Financial Group (SVB), financial partner of the innovation economy and parent company of Silicon Valley Bank, today announced the SVB Fellows Program, a fellowship program for Black, Latinx and women professionals looking to launch their careers in venture capital. The SVB Fellows Program is powered by the Black Venture Capital Consortium (BVCC), an organization working to increase diversity within the venture capital and entrepreneurship ecosystem, and the largest provider of specialized venture capital programming for Historically Black College and University (HBCU) students.
The SVB Fellows Program connects talented emerging professionals with distinguished VC firms, where they will serve in entry-level investment roles. Fellowships are a one- to two- year commitment and participants are salaried and receive benefits or a stipend to offset the cost of benefits.
"SVB and our partners designed the Fellows Program to create pathways for a new generation of investors to succeed in the VC industry and benefit VC firms by helping them find talent with diverse backgrounds, experiences and ideas," said Courtney Karnes, Managing Director of SVB's Access to Innovation program. "Our aspiration is that this program will accelerate the flywheel effect of innovation investing while increasing representation in the industry."
Leading VC firms General Catalyst, Collab Capital, Material Impact and 3x5 Partners have already signed on to host fellows. In addition to connections with SVB's extensive network of VC partners and career opportunities, SVB Fellows will receive mentorship from SVB leaders, and access to training and networking opportunities designed to propel their success in venture capital for years to come.
"The SVB Fellows Program is connecting us with talented young professionals who not only have strong foundational VC training, but also bring much-needed diversity of thought and experience to a fairly homogenous industry," said Arum Lansel, VP of Learning & Development at General Catalyst.
SVB plans to support twenty fellows throughout 2022, identified in partnership with BVCC on a rolling basis. At launch, candidates will be selected from professionals who have previously participated in BVCC's career development programming. As the program expands, SVB will leverage additional recruitment channels to identify additional Latinx and women fellows.
"We are excited to be a founding partner in the SVB Fellows Program, connecting our network of talented young professionals with some of the top VC firms in the country and setting them on a path toward personal success and a more equitable venture capital ecosystem," said Malcolm Robinson, Executive Director of BVCC.
SVB is committed to building a more diverse, equitable and accessible innovation economy for all. Through its Access to Innovation program, SVB addresses the innovation sector's biggest diversity opportunities by creating and amplifying new and existing educational, employment and funding pathways for Black, Latinx and women VC investors. The SVB Fellows Program is part of this goal.
About SVB Financial Group
SVB Financial Group (NASDAQ: SIVB) and its subsidiaries help innovative companies and their investors move bold ideas forward, fast. SVB Financial Group's businesses, including Silicon Valley Bank, offer commercial, investment and private banking, asset management, private wealth management, brokerage and investment services and funds management services to companies in the technology, life science and healthcare, private equity and venture capital, and premium wine industries. Headquartered in Santa Clara, California, SVB Financial Group operates in centers of innovation around the world. Learn more at svb.com.
SVB Financial Group is the holding company for all business units and groups © 2022 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group. [SIVB-F]
View original content to download multimedia:
SOURCE Silicon Valley Bank
|
https://www.wistv.com/prnewswire/2022/04/06/svb-financial-group-debuts-fellowship-program-foster-next-generation-black-latinx-women-venture-capital-leaders/
| 2022-04-06T13:07:37
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/svb-financial-group-debuts-fellowship-program-foster-next-generation-black-latinx-women-venture-capital-leaders/
|
BALTIMORE, April 6, 2022 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), a global leader in asset management, announced today that Kimberly Johnson has been named chief operating officer (COO), effective April 29. Johnson will report to Rob Sharps, CEO and president, and will serve on the Management Committee.
As COO, Johnson will lead Global Technology, Global Investment Operations, Global Client Account Services, Enterprise Change, Real Estate & Workplace Services, Enterprise Risk, and the regional operating teams.
"Operations and technology are essential to enabling our strategic priorities," says Rob Sharps. "I am confident that with her deep experience and strategic vision, Kimberly will quickly become an integral part of our leadership team."
Johnson joins T. Rowe Price from Fannie Mae, where she served as executive vice president, chief operating officer, and a member of Fannie Mae's Management Committee. As Fannie Mae's COO, Johnson managed a team of 3,600 and a $1.4 billion operating budget and was responsible for the company's technology, operations, data, modeling, analytics, information security, resiliency, innovation, and corporate strategy. She also led Fannie Mae's digital transformation, establishing a four-year enterprise modernization plan and an operational roadmap for redesigning business processes and reengineering core technology.
Additional key roles Johnson held during her tenure at Fannie Mae include executive vice president and chief risk officer, senior vice president of multifamily capital markets and credit pricing, and head of multifamily trading.
Johnson holds a B.A. in economics from Princeton University and an M.B.A. from Columbia University. She serves as a board member for Eli Lilly and many nonprofits. Additionally, Johnson serves as a member of the board of trustees for Princeton University.
ABOUT T. ROWE PRICE
Founded in 1937, Baltimore-based T. Rowe Price Group, Inc. (NASDAQ-GS: TROW), is a global investment management organization with $1.54 trillion in assets under management as of February 28, 2022. The organization provides a broad array of mutual funds, subadvisory services, and separate account management for individual and institutional investors, retirement plans, and financial intermediaries. The company also offers a variety of sophisticated investment planning and guidance tools. T. Rowe Price's disciplined, risk-aware investment approach focuses on diversification, style consistency, and fundamental research.
View original content to download multimedia:
SOURCE T. Rowe Price Group, Inc.
|
https://www.wistv.com/prnewswire/2022/04/06/t-rowe-price-names-kimberly-johnson-chief-operating-officer/
| 2022-04-06T13:07:44
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/t-rowe-price-names-kimberly-johnson-chief-operating-officer/
|
- 6-month shelf-life milestone achieved
- Successful thaw of highly activated Gamma delta cells
EDINBURGH, Scotland, April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today that it has successfully registered the UK trademark "CryoTC®", for the Company's proprietary process for freezing and thawing of its lead oncology product, OmnImmune®.
CryoTR® is TC BioPharm's unique process of cryopreservation, which is performed in a controlled rate freezer using an optimized protocol. OmnImmune® is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. OmnImmune® comprises GDT cells sourced from healthy donors, activated and expanded in large numbers before being purified formulated, and cryopreserved for subsequent thawing and infusion into patients.
"Being the first gamma delta cell therapy company with a frozen/thawed product in the clinic is yet another milestone achieved by TCBP," said Bryan Kobel, CEO of TC BioPharm. "This novel freeze-thaw process truly establishes OmnImmune® an 'off the shelf' cell therapy, allowing us to campaign manufacture, ship and store the product around the world for the potential treatment of AML and other blood cancers. Given the multiple development trials and programs we are advancing with OmnImmune®, we are pleased to have this trademark contribute to our brand protection and continue to validate our position at the forefront of innovation in the gamma delta vertical."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer and viral infections with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company's proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and other aggressive viral infections as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
Contact:
Chris Camarra
EVP Communications
c.camarra@tcbiopharm.com
View original content to download multimedia:
SOURCE TC BioPharm
|
https://www.wistv.com/prnewswire/2022/04/06/tc-biopharm-receives-cryotc-trademark-proprietary-cell-freezing-process/
| 2022-04-06T13:07:55
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/tc-biopharm-receives-cryotc-trademark-proprietary-cell-freezing-process/
|
WASHINGTON, D.C. -- Six oil company executives are set to testify Wednesday on Capitol Hill about skyrocketing gas prices amid a political messaging battle over pain at the pump.
BP America, Chevron and ExxonMobil executives are among the "Big Oil" leaders who will face questions from lawmakers on the House Energy and Commerce Subcommittee on Oversight and Investigations.
The hearing comes as costs for gas rose following Russia's invasion of Ukraine, which prompted the U.S. to put a ban on imports of Russian oil and gas. Though the price of gas has dropped slightly in recent days, Americans were still paying an average $4.17 as of Tuesday, according to American Automobile Association data.
SEE RELATED STORY: Biden taps oil reserve for 6 months to control gas prices
Politicians on both sides of the aisle continue to fight over who's to blame.
Democrats have worked hard to pinpoint Russia's invasion of Ukraine as the source of the rise in gas prices, with President Joe Biden coining it "Putin's price hike."
Republicans, on the other hand, are quick to argue that the higher costs kicked in long before the war began and that Biden's energy policies are what's hurting Americans' pocketbooks. Others are accusing oil companies of taking advantage of consumers by not lowering gas prices even though the price of oil has dropped.
SEE RELATED STORY: Energy officer says we will see gas prices drop at least 30 cents by end of the week
Patrick De Haan, head of Petroleum Analysis at GasBuddy, told ABC News the reasons behind the cost of gas are more complex than any one of those narratives suggests.
"There's too many political games being played in too many political points trying to be won. Neither side is portraying it accurately," he said. "There's a lot of factors that go into this and the politicians on both sides of the aisle are, you know, just using buzzwords and phrases and they're using regurgitated, establishment talking points by their own parties ... "
De Haan also noted the "extremely volatile" situation gas companies are in with regard to fluctuating oil prices.
"Stations are not eager to lower prices right now. Not necessarily because of, you know, they're greedy or something but because the market is extremely volatile," De Haan said, adding that "if they were to pass along a decrease one day, they may have to raise prices another 25 to 50 cents the day after if the market goes back up."
Instead, he said the "stations are essentially smoothing out the incredible volatility and they're cautiously passing along decreases once they are kind of certain that they're not going to have to raise prices again."
PolitiFact also noted that "experts who study the price of oil and gas said it can take weeks for gasoline prices to respond to changes in crude oil costs" and that "Russia's invasion of Ukraine, increased labor costs, the pandemic and additional taxes and inflation have all contributed to rising gasoline prices."
Richard Wiles, president of the Center for Climate Integrity, a nonprofit focused on climate policy and holding corporations accountable, says Democrats aren't wrong to shift the blame onto Russian President Vladimir Putin.
"The Democrats aren't making something up to point out how this is a really acute example of what dependency on oil and gas would get you. That's exactly right. And the oil companies, they don't care at all," he said.
But Wiles noted the rising cost of gas started long before the Russian invasion of Ukraine.
"Oil companies are bad in war and peace," he said.
ABC News reached out to all six oil companies expected to testify Wednesday but none provided a comment.
As the oil company executives face members of the House, lawmakers are also scrambling to pass legislation to provide immediate relief as a consequential midterm season quickly approaches.
Most recently, Biden announced the release of 1 million barrels of oil per day from oil reserves to combat high gas prices; though, senior White House administration officials couldn't say how quickly Americans will start to feel relief from it.
At her weekly press conference last week, House Speaker Nancy Pelosi said Congress is looking to help as long as the benefit goes directly to consumers, likely in the form of a rebate card or a direct payment.
And some progressive Democrats are renewing their push toward more long-term investments in renewable energy to end oil dependency.
For their part, House Republicans on the Natural Resources Committee introduced a package of bills last week reversing the Biden administration's moratorium on federal onshore and offshore lease sales.
Energy expert says Dems aren't wrong to blame Russia : 'Oil companies are bad in war and peace'
GAS PRICES
|
https://abc11.com/bp-america-chevron-exxonmobil-oil-executives-testify-before-congress/11716112/
| 2022-04-06T13:08:01
| 0
|
https://abc11.com/bp-america-chevron-exxonmobil-oil-executives-testify-before-congress/11716112/
|
Daviyonne Dawson, 31, was arrested after police said he was seen carrying a weapon following the mass shooting. He was charged with being a prohibited person in possession of a firearm.
Dawson was not charged for the shooting specifically, police said.
During Dawson's arrest, they seized a gun, but they do not believe the weapon was used in Sunday night's shooting.
Authorities have also arrested Dandrae Martin, 26, for charges of assault with a firearm and being a prohibited person in possession of a firearm, and Smiley Martin, 27, for possession of a firearm by a prohibited person and possession of a machine gun, in connection to the shooting.
THIS IS A BREAKING NEWS UPDATE. PREVIOUS STORY BELOW.
A second suspect was arrested Tuesday in connection to the mass shooting in Sacramento that killed six people in California's capital, and police said he is the brother of the first suspect.
Smiley Martin, 27, was arrested while hospitalized with serious injuries from the gunfire. When his condition improves enough for him to be jailed, he will be booked for possession of a firearm by a prohibited person and possession of a machine gun, a police statement said.
More than 100 shots were fired early Sunday in downtown Sacramento, creating a chaotic scene with hundreds of people trying desperately to get to safety. In addition to the dead, 11 people were wounded along with Smiley Martin.
A day later police announced the arrest of Dandrae Martin, 26, as a "related suspect" on charges of assault with a deadly weapon and being a convict carrying a loaded gun. His first court appearance was set for Tuesday.
Detectives and SWAT team members found one handgun during searches of three area homes. Smiley Martin was located at the scene and taken to a hospital, police said.
VIDEO: Sacramento Mayor Darrell Steinberg discusses 'senseless' tragedy following mass shooting
"Smiley Martin was quickly identified as a person of interest and has remained under the supervision of an officer at the hospital while his treatment continues. Based on information developed during this investigation, Smiley Martin was taken into custody by Sacramento Police Department detectives on April 5, 2022," the statement said.
The arrests came as the three women and three men killed were identified. The shooting occurred at about 2 a.m. Sunday as bars were closing and patrons filled the streets near the state Capitol. The fallen included a father of four, a young woman who wanted to be a social worker, a man described as the life of the party, and a woman who lived on the streets nearby and was looking for housing.
The Sacramento County coroner identified the women killed as Johntaya Alexander, 21; Melinda Davis, 57; and Yamile Martinez-Andrade, 21. The three men were Sergio Harris, 38; Joshua Hoye-Lucchesi, 32; and De'vazia Turner, 29.
Sacramento Mayor Darrell Steinberg read their names during a vigil Monday evening attended by grieving relatives, friends and community members.
"So we gather here to remember the victims and to commit ourselves to doing all we can to ending the stain of violence, not only in our community but throughout the state, throughout the country, and throughout the world," Steinberg said.
Turner, who had three daughters and a son, was a "protector" who worked as the night manager at an inventory company, his mother, Penelope Scott, told The Associated Press. He rarely went out, and she had no reason to believe he would be in harm's way when he left her house after he visited Saturday night.
"My son was walking down the street and somebody started shooting, and he got shot. Why is that to happen?" Scott said. "I feel like I've got a hole in my heart."
The burst of gunshots sent people running in terror in the neighborhood just a few blocks from the arena where the NBA's Sacramento Kings play.
Police were investigating whether the shooting was connected with a street fight that broke out just before gunfire erupted. Several people could be seen in videos scrapping on a street lined with an upscale hotel, nightclubs and bars when gunshots sent people scattering.
Detectives also were trying to determine if a stolen handgun found at the crime scene was connected to the shooting, Police Chief Kathy Lester said. Witnesses answered her plea for help by providing more than 100 videos and photos of evidence.
District Attorney Anne Marie Schubert noted that Dandrae Martin was not arrested on suspicion of homicide, but suggested investigators were making progress.
"The investigation is highly complex involving many witnesses, videos of numerous types and significant physical evidence," Schubert said in a statement. "This is an ongoing investigation and we anticipate more arrests in this case."
Dandrae Martin, who was held without bail, was freed from an Arizona prison in 2020 after serving just over 1 1/2 years for violating probation in separate cases involving a felony conviction for aggravated assault in 2016 and a conviction on a marijuana charge in 2018. Court records show he pleaded guilty to punching, kicking and choking a woman in a hotel room when she refused to work for him as a prostitute.
It was not immediately clear Tuesday whether the Martins had attorneys who could speak on their behalf.
Four of those wounded suffered critical injuries, the Sacramento Fire Department has said. At least seven of the victims had been released from hospitals by Monday and two patients were still hospitalized at UC Davis Medical Center on Tuesday, according to spokesperson Tricia Tomiyoshi. She did not disclose their conditions.
At the scene where the chaos erupted, memorials with candles and flowers grew on the same sidewalks where video showed people screaming and running for shelter as others lay on the ground writhing in pain.
A small bouquet of purple roses was dedicated to Melinda Davis, who lived on the streets for years, with a note saying "Melinda Rest In Peace."
Politicians decried the shooting, and some Democrats, including President Joe Biden, called for tougher action against gun violence.
RELATED: Witnesses describe chaos as gunshots ring out on Sacramento downtown street
California has some of the nation's toughest restrictions on firearms, requiring background checks to buy guns and ammunition, limiting magazines to 10 bullets, and banning firearms that fall into its definition of assault weapons.
But state lawmakers plan to go further. A bill getting its first hearing Tuesday would allow citizens to sue those who possess illegal weapons, a measure patterned after a controversial Texas bill aimed at abortions.
Other proposed California legislation this year would make it easier for people to sue gun companies and target unregistered "ghost guns," firearms made from build-it-yourself kits.
The California Assembly held a moment of silence Monday in honor of the victims. Assemblymember Kevin McCarty, a Democrat who represents Sacramento, noted lawmakers could see the crime scene from the building's balcony.
"Tragic is too small of a word to describe what occurred just two nights ago as a devastating loss for our city," McCarty said.
___
Associated Press writers Stefanie Dazio, Brian Melley and Christopher Weber in Los Angeles, Don Thompson in Sacramento, Jacques Billeaud in Phoenix and News Researcher Rhonda Shafner in New York City contributed to this story.
___
This story has corrected the spelling of suspects' first names to Dandrae, not Dandre; and De'vazia , not Devazia.
|
https://abc11.com/sacramento-mass-shooting-downtown-california-victims/11715882/
| 2022-04-06T13:08:07
| 1
|
https://abc11.com/sacramento-mass-shooting-downtown-california-victims/11715882/
|
SCHAFFHAUSEN, Switzerland, April 6, 2022 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) will report financial results for the second quarter of fiscal 2022 before trading begins on April 27, 2022. The company will hold a conference call for investors at 8:30 a.m. ET. The conference call may be accessed in the following ways:
- At TE Connectivity's website: investors.te.com
- By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the United States is (888) 330-3417 and for international callers, the dial-in number is (646) 960-0804
- A replay of the conference call will be available on TE Connectivity's investor website at investors.te.com at 11:30 a.m. ET on April 27, 2022.
ABOUT TE CONNECTIVITY
TE Connectivity Ltd. (NYSE: TEL) is a global industrial technology leader creating a safer, sustainable, productive, and connected future. Our broad range of connectivity and sensor solutions, proven in the harshest environments, enable advancements in transportation, industrial applications, medical technology, energy, data communications, and the home. With more than 85,000 employees, including over 8,000 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.
View original content to download multimedia:
SOURCE TE Connectivity Ltd.
|
https://www.wistv.com/prnewswire/2022/04/06/te-connectivity-report-second-quarter-financial-results-april-27-2022/
| 2022-04-06T13:08:06
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/te-connectivity-report-second-quarter-financial-results-april-27-2022/
|
Best-Of-Breed AI-Based Providers Collaborate to Deliver
an Integrated Saas Solution for the Fintech Market
NEW YORK and TEL AVIV and LUXEMBOURG, April 6, 2022 /PRNewswire/ -- ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced it is partnering with next-gen sanctions screening company Screena. Through the alliance, Screena's cloud-based AI-driven screening system will be fully integrated into ThetaRay's SONAR SaaS transaction monitoring solution, providing fintechs and banks with a holistic view of transactional and sanctions list risks.
ThetaRay's SONAR is the industry's most advanced financial crime prevention solution for global payments. Screena's real-time, AI-powered solution uses proprietary algorithms and risk analysis to screen transactions against financial sanctions watchlists with a high degree of precision. The combined transaction monitoring and integrated screening solution can be deployed within weeks.
"The financial world is facing the unprecedented challenge of implementing sanctions that require high-level automation and accuracy, yet ensure the smooth flow of transactions," said Cédric Iggiotti, CEO of Screena. "Screening is the first line of defense against sanctioned countries, individuals, groups, and companies, which are being added around the clock by various global authorities. However, speed and precision are major necessities today. Financial institutions cannot afford 2-5 days for the compliance department to investigate; customers will not stand for it."
SONAR uses an advanced form of AI called "artificial intelligence intuition" to analyze transactions, risk indicators and client data to detect suspicious activities across complex, cross-border transaction paths -- including the use of shell people and companies.
"The only way to accurately monitor the financial activities of sanctioned entities without causing pain to ordinary people is by leveraging advanced AI-powered capabilities," said Mark Gazit, ThetaRay CEO. "ThetaRay and Screena are partnering to help establish a new level of trust in the global financial system. We are committed to enabling unimpeded business and the flow of currencies while preventing money launderers and sanctioned parties from exploiting banks and payments fintechs for illegal activities. We know that the bad guys are using AI, so it is our responsibility to use the most advanced machine learning capabilities available to defend our banking system against them."
The ThetaRay system can identify sophisticated attempts to circumvent economic and trade sanctions and helps governments and financial institutions maintain smooth and uninterrupted global banking activities.
"ThetaRay has teamed up with Screena as the perfect partner to deliver value to our customers through one effective platform that accelerates the investigation process into suspected financial crimes and sanctions violations," said Dagan Osovlansky, Chief Product Officer, ThetaRay. "Cloud-based AML and screening enables fintechs especially to ramp up quickly and grow business opportunities in the financial ecosystem while instilling a new level of trust for global payments."
For more information, visit thetaray.com.
For more information on Screena, please visit https://screena.ai/.
About Screena
Screena empowers banks, fintechs, and digital businesses to quickly and easily integrate name screening and entity resolution with any customer onboarding or payment platform. Screena's innovative technology stops wrongdoers without afflicting legitimate parties, allowing smooth customer registration and fast payment operations. Screena's AI-driven algorithms surface true positives with unrivaled precision and de-risk financial organizations from regulatory fines, personal liability, and reputational damage. Screena can be integrated with third-party systems in a matter of days. Its API-first solution combines extreme configurability and scalability to keep ahead of changing regulation while drastically reducing the cost of financial crime compliance.
About ThetaRay
ThetaRay's AI-powered SONAR transaction monitoring solution, based on "artificial intelligence intuition," allows banks and fintechs to expand their business opportunities through safe and reliable cross-border payments. The groundbreaking solution also improves customer satisfaction, reduces compliance costs, and increases risk coverage. ThetaRay's technology is the only SaaS offering that analyzes SWIFT traffic, risk indicators and client/payer/payee data to detect anomalies indicating money laundering activity across complex, cross-border transaction paths in a single unified platform. Financial organizations that rely on highly heterogeneous and complex ecosystems benefit greatly from ThetaRay's unmatchable low false positive and high detection rates.
View original content:
SOURCE ThetaRay
|
https://www.wistv.com/prnewswire/2022/04/06/thetaray-chooses-screena-sanctions-list-screening-solutions-partner/
| 2022-04-06T13:08:13
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/thetaray-chooses-screena-sanctions-list-screening-solutions-partner/
|
NEW YORK, April 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, BTAI, ARRY, GOGO, and CLVS.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- CTXR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=CTXR&prnumber=040620221
- BTAI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BTAI&prnumber=040620221
- ARRY: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=ARRY&prnumber=040620221
- GOGO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=GOGO&prnumber=040620221
- CLVS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=CLVS&prnumber=040620221
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver
|
https://www.wistv.com/prnewswire/2022/04/06/thinking-about-buying-stock-citius-pharmaceuticals-bioxcel-therapeutics-array-technologies-gogo-or-clovis-oncology/
| 2022-04-06T13:08:21
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/thinking-about-buying-stock-citius-pharmaceuticals-bioxcel-therapeutics-array-technologies-gogo-or-clovis-oncology/
|
Social Worker Was the Leading Telehealth Specialty Nationally in January 2022
FAIR Health's Monthly Telehealth Regional Tracker Introduces New Features in Its Third Year, including Telehealth Cost Corner
NEW YORK, April 6, 2022 /PRNewswire/ -- For the third straight month, national telehealth utilization, measured as a percentage of all medical claim lines, grew in January 2022, according to FAIR Health's Monthly Telehealth Regional Tracker.1 As the wave of cases related to the Omicron variant of COVID-19 continued, telehealth utilization increased 10.2 percent, from 4.9 percent of all medical claim lines in December 2021 to 5.4 percent in January 2022. Telehealth utilization also increased in January in every US census region (Midwest, Northeast, South and West), with the greatest increase (17.5 percent) in the West. The data represent the privately insured population, including Medicare Advantage and excluding Medicare Fee-for-Service and Medicaid.
With January 2022, FAIR Health's Monthly Telehealth Regional Tracker enters its third year of reporting on the evolution of telehealth from month to month. As before, a free, interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions.
This third year brings notable changes to the Tracker. In the first year, to study the impact of the COVID-19 pandemic on telehealth, each month in 2020 was compared to the corresponding month in 2019. In the second year, the focus turned to monthly rather than year-over-year changes. The third year adds new features: the top five telehealth specialties and the Telehealth Cost Corner, which presents a specific telehealth procedure code with its median charge amount and median allowed amount.2 Continuing from previous years are the percent change in telehealth's percentage of medical claim lines, the top five telehealth procedure codes and the top five telehealth diagnoses.
In January 2022, social worker was the leading telehealth specialty nationally and in every region but the West, where primary care physician was the leading telehealth specialty, 0.1 percent ahead of social worker. In every other region and nationally, primary care physician was in second place behind social worker. Nationally, psychiatrist, psychologist and primary care nonphysician were in third, fourth and fifth place, respectively.
For January 2022, the Telehealth Cost Corner spotlighted the cost of CPT®3 92507, treatment of speech, language, voice, communication and/or hearing processing disorder. Nationally, the median charge amount for this service when rendered via telehealth was $129.92, and the median allowed amount was $77.64. The costs varied by region. For example, the highest median allowed amount was $88.47 in the Midwest, and the lowest $69.50 in the South.
In January 2022, COVID-19 continued to rank at number two or three among the top five telehealth diagnoses nationally and in all regions. Its share of telehealth claim lines, however, fell in all locations but the West, where the share remained the same. Mental health conditions remained in first place nationally and in all regions, but certain other diagnoses changed. Developmental disorders, for example, rejoined the top five diagnoses in the Northeast after a month off the list, and encounter for examination rejoined the top five in the South after a month off that list.
In January 2022, CPT 90837, one hour of psychotherapy, was in first place among telehealth procedure codes nationally and in every region. CPT 90833, psychotherapy with evaluation and management visit, 30 minutes, rejoined the top five procedure codes nationally and in the Midwest after a month off those lists. It remained in the top five in the Northeast and West but was not on the list in the South in either December or January.
FAIR Health President Robin Gelburd stated: "As the COVID-19 pandemic enters its third year, FAIR Health begins our third year of tracking the evolution of telehealth. Once again, we have modified our Monthly Telehealth Regional Tracker to keep pace with the changing needs of stakeholders for current information about this venue of care."
For the Monthly Telehealth Regional Tracker, click here.
Follow us on Twitter @FAIRHealth
FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of private healthcare claims data, which includes over 36 billion claim records and is growing at a rate of over 2 billion claim records a year. FAIR Health licenses its privately billed data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D; FAIR Health includes among the private claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. FAIR Health also is named a top resource for patients in Dr. Marty Makary's book The Price We Pay: What Broke American Health Care—and How to Fix It and Dr. Elisabeth Rosenthal's book An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. For more information on FAIR Health, visit fairhealth.org.
1 A claim line is an individual service or procedure listed on an insurance claim.
2 A charge amount is the provider's undiscounted fee, which a patient may have to pay when the patient is uninsured, or when the patient chooses to go to a provider who does not belong to the patient's plan's network. An allowed amount is the total fee paid to the provider under an insurance plan. It includes the amount that the health plan pays and the part the patient pays under the plan's in-network cost-sharing provisions (e.g., copay or coinsurance if the patient has met the deductible).
3 CPT © 2021 American Medical Association (AMA). All rights reserved.
Contact:
Rachel Kent
Senior Director of Marketing
FAIR Health
646-396-0795
rkent@fairhealth.org
View original content to download multimedia:
SOURCE FAIR Health
|
https://www.wistv.com/prnewswire/2022/04/06/third-straight-month-telehealth-utilization-increased-nationally-january-2022/
| 2022-04-06T13:08:27
| 0
|
https://www.wistv.com/prnewswire/2022/04/06/third-straight-month-telehealth-utilization-increased-nationally-january-2022/
|
Third dispensary in Massachusetts to open offers an elevated in-store experience; Celebration on April 9 includes celebrity appearances, giveaways and deals
TALLAHASSEE, Fla., April 6, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, is pleased to announce the opening of a dispensary in Framingham, Massachusetts on Sunday, April 3. Located in New England's Golden Triangle retail district at 85 Worcester Rd., the new dispensary provides an elevated in-store experience. This is Trulieve's third and largest retail location in Massachusetts.
At more than 5,000 square feet, the Trulieve Framingham showroom will offer a fresh, spacious, contemporary look with elegant finishes. The updated configuration allows customers to browse and explore in an interactive space. The dispensary will open as an adult-use dispensary and expand to include medical cannabis later this Spring.
The grand opening celebration on Saturday, April 9 will include several dignitary and celebrity appearances, executive meet & greets, live brand activations, giveaways, food trucks, all day in-store promotional offers, and more. Register for exclusive Framingham updates and events at enrollnow.vip/join/3542.
"We are thrilled to offer a more elevated experience for Trulieve customers and patients," said Kim Rivers, Chief Executive Officer of Trulieve. "This is a tremendous milestone in Trulieve's Northeast growth, and we look forward to providing exceptional customer service to a variety of patients and customers with our high-quality products."
Trulieve focuses on growing safe, quality cannabis and continually works to provide a wide variety of innovative products for adult use customers and medical patients in Massachusetts. Trulieve will offer a wide selection of cannabis products and in-house brands such as:
- Momenta – Trulieve's staple cannabis line for everyday wellness and overall well-being. The product lineup includes tinctures, nano tinctures, capsules, RSO and a topical muscle gel.
- Sweet Talk – Trulieve's line of tasty edibles, including craveable chocolates and gummies infused with premium quality cannabis.
- Muse – Trulieve's line of premium, cannabis concentrates and cartridges.
- Cultivar Collection – Premium group of small-batch, top-shelf cannabis. Each unique strain is carefully bred to deliver undeniably rich flavor and potent terpenes.
In addition to Trulieve's proprietary brands, customers and patients will have access to beloved partner brands such as Bhang, Binske, Blue River, O.pen, Puffco, and Slang. Trulieve is also the exclusive provider of clones in the Massachusetts market.
Trulieve is partnering with Dr. Marion McNabb's team at the Cannabis Center of Excellence (CCOE) to support the non-profit's ongoing medical cannabis research. The CCOE's study was first approved in March 2021 by the University of Massachusetts Dartmouth to collect information from healthcare providers in both the U.S. and Canada about their knowledge, attitude, and practices related to medical cannabis.
Additional Trulieve dispensaries in Massachusetts are located in Northampton and Worcester. For more information on store activations, promotions and locations, please visit trulieve.com/dispensaries/massachusetts.
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
MATTIO Communications
Trulieve@Mattio.com
View original content to download multimedia:
SOURCE Trulieve Cannabis Corp.
|
https://www.wistv.com/prnewswire/2022/04/06/trulieve-hosts-framingham-massachusetts-grand-opening-celebration/
| 2022-04-06T13:08:34
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/trulieve-hosts-framingham-massachusetts-grand-opening-celebration/
|
ORLANDO, Fla., April 6, 2022 /PRNewswire/ -- Tupperware Brands Corporation (NYSE: TUP), a leading global consumer products company, is scheduled to release its first quarter 2022 financial results on Wednesday, May 4, 2022, before the market opens. The company will host a conference call at 8:30a.m. ET that day to discuss its financial results.
Call Information
To access the live webcast, visit https://ir.tupperwarebrands.com. To listen to the conference call via telephone, dial (855) 982-8102 and enter conference ID number 8463622 when prompted. Participants outside the U.S. who are not able to access the webcast should dial +1 (209) 940-8021 and enter the conference ID number provided above.
Replay
A replay of the conference call will be available at https://ir.tupperwarebrands.com approximately two hours after the live call has ended. An audio replay of the conference call will be available via telephone starting at 11:30am ET on Wednesday, May 4, 2022, through 11:30am ET on Wednesday, May 18, 2022. To listen to the recorded conference call via telephone, dial (855) 859-2056 and enter the conference ID provided above. Outside the U.S., dial +1 (404) 537-3406 and enter the conference ID number provided above.
About Tupperware Brands Corporation
Tupperware Brands Corporation (NYSE: TUP) is a leading global consumer products company that designs innovative, functional and environmentally responsible products that people love and trust. Founded in 1946, Tupperware's signature container created the modern food storage category that revolutionized the way the world stores, serves and prepares food. Today, this iconic brand has more than 8,500 functional design and utility patents for solution-oriented kitchen and home products. With a purpose to nurture a better future, Tupperware® products are an alternative to single-use items. The company distributes its products into nearly 70 countries primarily through independent representatives around the world. For more information, visit Tupperwarebrands.com or follow Tupperware on Facebook, Instagram, LinkedIn and Twitter.
Investors: Alexis Callahan, alexiscallahan@tupperware.com 321.588.5129
Media: Cameron Klaus, cameronklaus@tupperware.com, 407.371.9784
View original content to download multimedia:
SOURCE Tupperware Brands Corporation
|
https://www.wistv.com/prnewswire/2022/04/06/tupperware-brands-corporation-schedules-release-first-quarter-2022-financial-results-may-4/
| 2022-04-06T13:08:41
| 1
|
https://www.wistv.com/prnewswire/2022/04/06/tupperware-brands-corporation-schedules-release-first-quarter-2022-financial-results-may-4/
|